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Surgery
EAST Early treatment of Atrial fibrillation for Stroke
prevention Trial
ECG electrocardiogram/electrocardiography
EHRA European Heart Rhythm Association
ENGAGE AF-TIMI
48
Effective Anticoagulation with Factor Xa
Next Generation in Atrial Fibrillation–
Thrombolysis in Myocardial Infarction 48
EORP EURObservational Research Programme
ESC European Society of Cardiology
ESO European stroke Organisation
FAST Atrial Fibrillation Catheter Ablation vs. Surgi-
cal Ablation Treatment
FEV1 forced expiratory volume in 1 s
FFP four-factor prothrombin complex concentrates
FXII factor XII
GDF-15 growth differentiation factor 15
GFR glomerular filtration rate
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GUCH grown-up congenital heart disease
HARMONY A Study to Evaluate the Effect of Ranolazine
and Dronedarone When Given Alone and
in Combination in Patients With Paroxysmal
Atrial Fibrillation
HAS-BLED hypertension, abnormal renal/liver function
(1 point each), stroke, bleeding history or
predisposition, labile INR, elderly (.65
years), drugs/alcohol concomitantly (1 point
each)
HEMORR2HAGES Hepatic or renal disease, ethanol abuse,
malignancy history, older age .75, reduced
platelet count/function/antiplatelet, rebleed-
ing risk (scores double), hypertension
(uncontrolled), anaemia, genetic factors, ex-
cessive fall risk, stroke history
HF heart failure
HFmrEF heart failure with mid-range ejection fraction
HFpEF heart failure with preserved ejection fraction
HFrEF heart failure with reduced ejection fraction
HR hazard ratio
ICD implantable cardioverter defibrillator
IHD ischaemic heart disease
IL-6 interleukin 6
INR international normalized ratio
i.v. intravenous
LA left atrium/atrial
LAA left atrial appendage
LAAOS Left Atrial Appendage Occlusion Study
LV left ventricular
LVEF left ventricular ejection fraction
LVH left ventricular hypertrophy
MANTRA-PAF Medical ANtiarrhythmic Treatment or Radio-
frequency Ablation in Paroxysmal Atrial
Fibrillation
MERLIN Metabolic Efficiency With Ranolazine for Less
Ischemia in Non ST-Elevation Acute Coron-
ary Syndromes
MRA Mineralocorticoid receptor antagonist
MRI magnetic resonance imaging
NIHSS National Institutes of Health stroke severity
scale
NOAC non-vitamin K antagonist oral anticoagulant
NOAH Non vitamin K antagonist Oral anticoagulants
in patients with Atrial High rate episodes
(NOAH)
NYHA New York Heart Association
OAC oral anticoagulation/oral anticoagulant
OR odds ratio
ORBIT Outcomes Registry for Better Informed
Treatment of Atrial Fibrillation
PAFAC Prevention of Atrial Fibrillation After Cardio-
version trial
PAI-1 plasminogen activator inhibitor 1
PCI percutaneous coronary intervention
PCC prothrombin complex concentrates
PICOT Population, Intervention, Comparison, Out-
come, Time
PREVAIL Prospective Randomized Evaluation of the
Watchman LAA Closure Device In Patients
with AF Versus Long Term Warfarin Therapy
trial
PROTECT AF Watchman Left Atrial Appendage System for
Embolic Protection in Patients With AF trial
PUFA polyunsaturated fatty acid
PVI pulmonary vein isolation
QoL quality of life
RACE Rate Control Efficacy in Permanent Atrial
Fibrillation
RATE-AF Rate Control Therapy Evaluation in Perman-
ent Atrial Fibrillation
RCT randomized controlled trial
RE-CIRCUIT Randomized Evaluation of Dabigatran Etexi-
late Compared to warfarIn in pulmonaRy
Vein Ablation: Assessment of an Uninterrupt-
ed periproCedUral antIcoagulation sTrategy
RE-LY Randomized Evaluation of Long-Term Antic-
oagulation Therapy
RF radiofrequency
ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation
RR risk ratio
rtPA recombinant tissue plasminogen activator
SAMe-TT2R2 Sex (female), age (,60 years), medical history
(two of the following: hypertension, diabetes,
mi, pad, congestive heart failure, history of
stroke, pulmonary disease, hepatic or renal dis-
ease), treatment (interacting medications e.g.
amiodarone), tobacco use (within 2 years; scores
double), race (non-Caucasian; scores double)
SD standard deviation
SPAF Stroke Prevention in Atrial Fibrillation
SR sinus rhythm
TF tissue factor
TIA transient ischaemic attack
TIMI Thrombolysis in Myocardial Infarction
TOE transoesophageal echocardiography
TTR time in therapeutic range
UFH unfractionated heparin
VKA vitamin K antagonist
VT Ventricular tachycardia
VVI Ventricular pacing, ventricular sensing, inhib-
ited response pacemaker
WOEST What is the Optimal antiplatElet and anti-
coagulant therapy in patients with oral anti-
coagulation and coronary StenTing
WPW Wolff-Parkinson-White syndrome
1. Preamble
Guidelines summarize and evaluate all available evidence on a par-
ticular issue at the time of the writing process, with the aim of assist-
ing health professionals in selecting the best management strategies
ESC Guidelines 1613





for an individual patient with a given condition, taking into account
the impact on outcome, as well as the risk–benefit ratio of particular
diagnostic or therapeutic means. Guidelines and recommendations
should help health professionals to make decisions in their daily prac-
tice. However, the final decisions concerning an individual patient
must be made by the responsible health professional(s) in consult-
ation with the patient and caregiver as appropriate.
A great number of Guidelines have been issued in recent years by
the European Society of Cardiology (ESC) and by the European As-
sociation for Cardio-Thoracic Surgery (EACTS), as well as by other
societies and organisations. Because of the impact on clinical prac-
tice, quality criteria for the development of guidelines have been es-
tablished in order to make all decisions transparent to the user. The
recommendations for formulating and issuing ESC Guidelines can be
found on the ESC website (http://www.escardio.org/Guidelines-
&-Education/Clinical-Practice-Guidelines/Guidelines-development/
Writing-ESC-Guidelines). ESC Guidelines represent the official pos-
ition of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC, including
representation from the European Heart Rhythm Association
(EHRA), and EACTS as well as by the European Stroke Organisa-
tion (ESO) to represent professionals involved with the medical
care of patients with this pathology. Selected experts in the field
undertook a comprehensive review of the published evidence
for management (including diagnosis, treatment, prevention and
rehabilitation) of a given condition according to ESC Committee
for Practice Guidelines (CPG) policy and approved by the EACTS
and ESO. A critical evaluation of diagnostic and therapeutic proce-
dures was performed, including assessment of the risk–benefit ra-
tio. Estimates of expected health outcomes for larger populations
were included, where data exist. The level of evidence and the
strength of the recommendation of particular management op-
tions were weighed and graded according to predefined scales,
as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided declar-
ation of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http
://www.escardio.org/guidelines). Any changes in declarations of
interest that arise during the writing period must be notified to
the ESC and EACTS and updated. The Task Force received its entire
financial support from the ESC and EACTS without any involvement
from the healthcare industry.
The ESC CPG supervises and co-ordinates the preparation of
new Guidelines produced by task forces, expert groups or consen-
sus panels. The Committee is also responsible for the endorsement
process of these Guidelines. The ESC Guidelines undergo extensive
review by the CPG and external experts, and in this case by EACTS
and ESO-appointed experts. After appropriate revisions the Guide-
lines are approved by all the experts involved in the Task Force. The
finalized document is approved by the CPG, EACTS and ESO for
publication in the European Heart Journal, Europace, and in the
European Journal of Cardio-Thoracic Surgery. The Guidelines
were developed after careful consideration of the scientific and
medical knowledge and the evidence available at the time of their
dating.
The task of developing ESC and EACTS Guidelines covers not
only integration of the most recent research, but also the creation
Table 1 Classes of recommendations
Classes of 
recommendations
Suggested wording to 
use
Class I Evidence and/or general agreement 
that a given treatment or 





divergence of opinion about the 
usefulness/efficacy of the given
Conflicting evidence and/or a 
treatment or procedure. 
    Class IIa Weight of evidence/opinion is in 
favour of usefulness/efficacy.
Should be considered
    Class IIb
established by evidence/opinion. 
Usefulness/efficacy is less well May be considered
Class III Evidence or general agreement that 
the given treatment or procedure 
is not useful/effective, and in some 
cases may be harmful. 
Is not recommended
Definition
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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of educational tools and implementation programmes for the re-
commendations. To implement the guidelines, condensed pocket
guideline versions, summary slides, booklets with essential mes-
sages, summary cards for non-specialists and an electronic version
for digital applications (smartphones, etc.) are produced. These ver-
sions are abridged and thus, if needed, one should always refer to
the full text version, which is freely available on the ESC website.
The National Societies of the ESC are encouraged to endorse,
translate and implement all ESC Guidelines. Implementation pro-
grammes are needed because it has been shown that the outcome
of disease may be favourably influenced by the thorough application
of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC and EACTS
Guidelines fully into account when exercising their clinical judgment,
as well as in the determination and the implementation of prevent-
ive, diagnostic or therapeutic medical strategies. However, the ESC
and EACTS Guidelines do not override in any way whatsoever the
individual responsibility of health professionals to make appropriate
and accurate decisions in consideration of each patient’s health con-
dition and in consultation with that patient and the patient’s care-
giver where appropriate and/or necessary. It is also the health
professional’s responsibility to verify the rules and regulations
applicable to drugs and devices at the time of prescription.
2. Introduction
Despite good progress in the management of patients with atrial fib-
rillation (AF), this arrhythmia remains one of the major causes of
stroke, heart failure, sudden death, and cardiovascular morbidity
in the world. Furthermore, the number of patients with AF is pre-
dicted to rise steeply in the coming years. To meet the growing de-
mand for effective care of patients with AF, new information is
continually generated and published, and the last few years have
seen substantial progress. Therefore, it seems timely to publish
this 2nd edition of the ESC guidelines on AF.
Reflecting the multidisciplinary input into the management of
patients with AF, the Task Force includes cardiologists with varying sub-
specialty expertise, cardiac surgeons, stroke neurologists, and specialist
nurses amongst its members. Supplementing the evidence review
as outlined in the preamble, this Task Force defined three Population,
Intervention, Comparison, Outcome, Time (PICOT) questions on
relevant topics for the guidelines. The ESC commissioned external sys-
tematic reviews to answer these questions, and these reviews have
informed specific recommendations.
Further to adhering to the standards for generating recommenda-
tions that are common to all ESC guidelines (see preamble), this
Task Force discussed each draft recommendation during web-based
conference calls dedicated to specific chapters, followed by consen-
sus modifications and an online vote on each recommendation.
Only recommendations that were supported by at least 75% of
the Task Force members were included in the guidelines.
We hope that these guidelines will help to deliver good care to
all patients with AF based on the current state-of-the-art evidence
in 2016.
3. Epidemiology and impact for
patients
3.1 Incidence and prevalence of atrial
fibrillation
In 2010, the estimated numbers of men and women with AF world-
wide were 20.9 million and 12.6 million, respectively, with higher in-
cidence and prevalence rates in developed countries.1,2 One in four
middle-aged adults in Europe and the US will develop AF.3–5 By 2030,
14–17 million AF patients are anticipated in the European Union,
with 120 000–215 000 newly diagnosed patients per year.2,6,7 Esti-
mates suggest an AF prevalence of approximately 3% in adults aged
20 years or older,8,9 with greater prevalence in older persons1 and
in patients with conditions such as hypertension, heart failure, coron-
ary artery disease (CAD), valvular heart disease, obesity, diabetes
mellitus, or chronic kidney disease (CKD).7,10 – 15 The increase
in AF prevalence can be attributed both to better detection of
silent AF16–18, alongside increasing age and conditions predisposing
to AF.19
3.2 Morbidity, mortality, and healthcare
burden of atrial fibrillation
AF is independently associated with a two-fold increased risk of
all-cause mortality in women and a 1.5-fold increase in men20 – 22
(Table 3). Death due to stroke can largely be mitigated by anticoa-
gulation, while other cardiovascular deaths, for example due to
heart failure and sudden death, remain common even in AF pa-
tients treated according to the current evidence base.23 AF is
also associated with increased morbidity, such as heart failure
and stroke.21,24,25 Contemporary studies show that 20–30% of pa-
tients with an ischaemic stroke have AF diagnosed before, during,
Table 3 Cardiovascular morbidity and mortality
associated with atrial fibrillation
Event Association with AF
Death Increased mortality, especially cardiovascular 
mortality due to sudden death, heart failure or 
stroke. 
Stroke 20–30% of all strokes are due to AF.  A growing 
number of patients with stroke are diagnosed with 
‘silent’, paroxysmal AF.
Hospitalizations 10–40% of AF patients are hospitalized every year.
Quality of life Quality of life is impaired in AF patients independent 




Left ventricular dysfunction is found in 20–30% of all 
AF patients.  AF causes or aggravates LV dysfunction 
in many AF patients, while others have completely 




Cognitive decline and vascular dementia can 
develop even in anticoagulated AF patients. 
Brain white matter lesions are more common in 
AF patients than in patients without AF.
AF ¼ atrial fibrillation; LV ¼ left ventricular.
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or after the initial event.17,26,27 White matter lesions in the brain,
cognitive impairment,28 – 30 decreased quality of life,31,32 and
depressed mood33 are common in AF patients, and between
10–40% of AF patients are hospitalized each year.23,34,35
The direct costs of AF already amount to approximately 1% of to-
tal healthcare spending in the UK, and between 6.0–26.0 billion US
dollars in the US for 2008,36,37 driven by AF-related complications
(e.g. stroke) and treatment costs (e.g. hospitalizations). These costs
will increase dramatically unless AF is prevented and treated in a
timely and effective manner.
3.3 Impact of evidence-based
management on outcomes in atrial
fibrillation patients
Figure 1 depicts the major milestones in the management of AF.
Despite these advances, substantial morbidity remains. Oral
anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-
VKA oral anticoagulants (NOACs) markedly reduces stroke and
mortality in AF patients.38,39 Other interventions such as rhythm
control and rate control improve AF-related symptoms and may
preserve cardiac function, but have not demonstrated a reduction
in long-term morbidity or mortality.40,41
In contemporary, well-controlled, randomized clinical trials
in AF, the average annual stroke rate is about 1.5% and the
annualized death rate is around 3% in anticoagulated AF patients.40
In real life, the annual mortality can be different (both higher and
lower).42 A minority of these deaths are related to stroke, while
sudden cardiac death and death from progressive heart failure
are more frequent, emphasizing the need for interventions beyond
anticoagulation.43,44 Furthermore, AF is also associated with high
rates of hospitalization, commonly for AF management, but often
also for heart failure, myocardial infarction, and treatment-
associated complications.34,45

































VKA superior to aspirin
for stroke prevention in
AF
Dabigatran at least as
effective as VKA in AF
Rixaroxaban and
Apixaban at least as
effective as VKA in AF
Edoxaban at least as





















AF in heart failure
ARBs prevent AF in 
hypertension & LVH









prevent AF in HFrEF
patients pre-treated
with ACE-I


















but increases risk of
permanent pacemaker
LVH = left ventricular hypertrophy; NOAC = non-vitamin K antagonist oral anticoagulant; PUFA = polyunsaturated fatty acid; PVI = pulmonary vein isolation; 
QoL = quality of life; RF = radiofrequency; SR = sinus rhythm; VKA = vitamin K antagonist.
Figure 1 Timeline of findings from landmark trials in atrial fibrillation management, including treatment of concomitant conditions and preven-
tion (green), anticoagulation (blue), rate control therapy (orange), rhythm control therapy (red), and atrial fibrillation surgery (purple).
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In both developed and developing countries, the age-adjusted inci-
dence and prevalence of AF are lower in women, while the risk of
death in women with AF is similar to or higher than that in men with
AF.1,46,47 Female AF patients who have additional stroke risk factors
(particularly older age) are also at greater risk than men of having a
stroke,48,49 even those anticoagulated with warfarin50 (see Chapter
9 for details). Women with diagnosed AF can be more symptomatic
than men and are typically older with more comorbidities.51,52
Bleeding risk on anticoagulation is similar in both sexes,49,50,53 but
women appear less likely to receive specialist care and rhythm con-
trol therapy,54 while the outcomes of catheter ablation or AF sur-
gery are comparable to those in men.55,56 These observations
highlight the need to offer effective diagnostic tools and therapeutic
management equally to women and men.
Recommendations relating to gender
Recommendations Classa Levelb Ref C
AF clinicians must offer effective 
diagnostic tools and therapeutic 
management to women and men 
equally to prevent stroke and death.
I A 39, 46, 57
Catheter or surgical ablation 
techniques should be regarded as 
equally effective in women and men.
IIa B 55, 56




4. Pathophysiological and genetic
aspects that guide management
4.1 Genetic predisposition
AF, especially early-onset AF, has a strong heritable component that
is independent of concomitant cardiovascular conditions.58,59 A few
young AF patients suffer from inherited cardiomyopathies or chan-
nelopathies mediated by disease-causing mutations. These mono-
genic diseases also convey a risk for sudden death (see Chapter
6). Up to one-third of AF patients carry common genetic variants
that predispose to AF, albeit with a relatively low added risk. At least
14 of these common variants, often single nucleotide polymorphisms,
are known to increase the risk of prevalent AF in populations.60–62
The most important variants are located close to the paired-like home-
odomain transcription factor 2 (Pitx2) gene on chromosome 4q25.63,64
These variants modify the risk of AF up to seven-fold.64 Several of the
AF risk variants are also associated with cardioembolic or ischaemic
stroke, possibly due to silent AF (see chapter 5 and 5.2).62,65,66
Changes in atrial action potential characteristics,67–70 atrial remodel-
ling, and modified penetration of rare gene defects61 have been
suggested as potential mechanisms mediating increased AF risk in car-
riers of common gene variants. Genetic variants could, in the future,
become useful for patient selection of rhythm or rate control.71–74
While genomic analysis may provide an opportunity to improve the
diagnosis and management of AF in the future,75,76 routine genetic
testing for common gene variants associated with AF cannot be re-
commended at present.77
4.2 Mechanisms leading to atrial
fibrillation
4.2.1 Remodelling of atrial structure and ion channel
function
External stressors such as structural heart disease, hypertension,
possibly diabetes, but also AF itself induce a slow but progressive
process of structural remodelling in the atria (Figure 2). Activation
of fibroblasts, enhanced connective tissue deposition, and fibrosis
are the hallmarks of this process.78–80 In addition, atrial fatty infiltra-
tion, inflammatory infiltrates, myocyte hypertrophy, necrosis, and
amyloidosis are found in AF patients with concomitant conditions
predisposing to AF.81– 84 Structural remodelling results in electrical
dissociation between muscle bundles and local conduction hetero-
geneities,85 favouring re-entry and perpetuation of the arrhythmia.86
In many patients, the structural remodelling process occurs before
the onset of AF.78 As some of the structural remodelling will be ir-
reversible, early initiation of treatment seems desirable.87 Table 4
gives an overview of the most relevant pathophysiological altera-
tions in atrial tissue associated with AF, and lists corresponding clin-
ical conditions that can contribute to these changes.
The functional and structural changes in atrial myocardium and
stasis of blood, especially in the left atrial appendage (LAA), generate
a prothrombotic milieu. Furthermore, even short episodes of AF
lead to atrial myocardial damage and the expression of prothrom-
botic factors on the atrial endothelial surface, alongside activation
of platelets and inflammatory cells, and contribute to a generalized
prothrombotic state.88,89 The atrial and systemic activation of the
coagulation system can partially explain why short episodes of AF
convey a long-term stroke risk.
4.2.2 Electrophysiological mechanisms of atrial fibrillation
AF provokes a shortening of the atrial refractory period and AF cy-
cle length during the first days of the arrhythmia, largely due to
downregulation of the Ca2+-inward current and upregulation of
inward rectifier K+ currents.94,95 Structural heart disease, in con-
trast, tends to prolong the atrial refractory period, illustrating the
heterogeneous nature of mechanisms that cause AF in different pa-
tients.96 Hyperphosphorylation of various Ca2+-handling proteins
may contribute to enhanced spontaneous Ca2+ release events and
triggered activity,97,98 thus causing ectopy and promoting AF. Al-
though the concept of Ca2+-handling instability has been chal-
lenged recently,106,107 it may mediate AF in structurally
remodelled atria and explain how altered autonomic tone can gen-
erate AF.80,105
4.2.2.1 Focal initiation and maintenance of atrial fibrillation
The seminal observation by Haissaguerre et al.108 was that a
focal source in the pulmonary veins can trigger AF, and ablation
of this source can suppress recurrent AF. The mechanism of
focal activity might involve both triggered activity and localized
reentry.109,110 Hierarchic organization of AF with rapidly activated
areas driving the arrhythmia has been documented in patients
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with paroxysmal AF,111,112 but is less obvious in unselected patients
with persistent AF.113
4.2.2.2 The multiple wavelet hypothesis and rotors as sources of atrial
fibrillation
Moe and Abildskov114 proposed that AF can be perpetuated by
continuous conduction of several independent wavelets propagat-
ing through the atrial musculature in a seemingly chaotic manner.
As long as the number of wavefronts does not decline below a crit-
ical level, they will be capable of sustaining the arrhythmia. Numer-
ous experimental and clinical observations can be reconciled with
the multiple wavelet hypothesis.115 All localized sources of AF (ec-
topic foci, rotors, or other stable re-entry circuits) cause fibrillatory
conduction remote from the source, which is difficult to distinguish
from propagation sustaining AF by multiple wavelets, and either of
these phenomena may generate ‘rotors’ picked up by intracar-
diac116,117 or body surface117 recordings.
5. Diagnosis and timely detection
of atrial fibrillation
5.1 Overt and silent atrial fibrillation
The diagnosis of AF requires rhythm documentation using an elec-
trocardiogram (ECG) showing the typical pattern of AF: Absolutely
irregular RR intervals and no discernible, distinct P waves. ECG-
documented AF was the entry criterion in trials forming the evi-
dence for these guidelines. By accepted convention, an episode last-
ing at least 30 s is diagnostic. Individuals with AF may be















Figure 2 Major mechanisms causing atrial fibrillation that can be considered when choosing therapy. The various aetiological factors (left) cause
a complex array of pathophysiological changes in the atria, including stretch-induced atrial fibrosis, hypocontractility, fatty infiltration, inflamma-
tion, vascular remodelling, ischaemia, ion channel dysfunction, and Ca2+-instability. These changes enhance both ectopy and conduction distur-
bances, increasing the propensity of the atria to develop or maintain AF. At the same time, some of these alterations are involved in the occurrence
of the hypercoagulable state associated with AF. For example, hypocontractility reduces local endothelial shear stress, which increases PAI-1 ex-
pression, and ischaemia-induced inflammation enhances the expression of endothelial adhesion molecules or promotes shedding of endothelial
cells, resulting in tissue factor exposure to the blood stream. These changes contribute to the thrombogenic milieu in the atria of AF patients. AF in
itself can aggravate many of the mechanisms shown, which may explain the progressive nature of the arrhythmia.
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symptomatic or asymptomatic (‘silent AF’). Many AF patients have
both symptomatic and asymptomatic episodes of AF.118 – 121
Silent, undetected AF is common,120,122 with severe consequences
such as stroke and death.123–125 Prompt recording of an ECG is an ef-
fective and cost-effective method to document chronic forms of
AF.126 The technology to detect paroxysmal, self-terminating AF epi-
sodes is rapidly evolving (see Chapter 6.1 for a definition of AF pat-
terns). There is good evidence that prolonged ECG monitoring
enhances the detection of undiagnosed AF, e.g. monitoring for 72 h
after a stroke,27,127 or even longer periods.18,128 Daily short-term
ECG recordings increase AF detection in populations over 75 years
of age129 (Web Figure 1). Ongoing studies will determine whether
such early detection alters management (e.g. initiation of anticoagu-
lation) and improves outcomes.
Once the ECG diagnosis of AF has been established, further ECG
monitoring can inform management in the context of: (1) a change
in symptoms or new symptoms; (2) suspected progression of AF; (3)
monitoring of drug effects on ventricular rate; and (4) monitoring of
antiarrhythmic drug effects or catheter ablation for rhythm control.
5.2 Screening for silent atrial fibrillation
5.2.1 Screening for atrial fibrillation by electrocardiogram
in the community
Undiagnosed AF is common, especially in older populations and
in patients with heart failure.130 Opportunistic screening for silent AF
seems cost-effective in elderly populations (e.g.. 65 years),131 and simi-
lar effects have been reported using single-lead ECG screening in other
at-risk populations.132,133 Screening of older populations (mean age 64
years) yielded a prevalence of 2.3% for chronic forms of AF in 122,571
participants using either short-term ECG or pulse palpation (followed
by ECG in those with an irregular pulse).134 Previously undiagnosed
AF was found in 1.4% of those aged .65 years, suggesting a number
needed to screen of 70. These findings encourage the further evaluation
of systematic AF screening programmes in at-risk populations.
Table 4 Pathophysiological alterations in atrial tissue associated with atrial fibrillation and clinical conditions that could
contribute to such alterations
Pathophysiological 
alteration
Changes of the extracellular matrix, fibroblast function and fat cells









AF (especially forms with a high AF burden), 
hypertension, heart failure, valvular heart disease (via 
pressure and volume overload).
Electrical dissociation, conduction block, 
enhanced AF complexity.
78, 79, 90, 91
complexity.
Profibrotic responses, enhanced AF 81
Obesity.
localized conduction block.
Profibrotic / proinflammatory responses, 82, 92
Amyloid deposition Aging, heart failure, coronary artery disease (via atrial 
scarring), genetic factors.
Conduction disturbances. 83, 93
Ion channel alterations
Ion channel remodelling AF (especially forms with a high AF burden), genetic 
predisposition to AF.
AF cycle shortening (if due to atrial 
tachycardia),  AF cycle length prolongation (if 
due to heart failure), enhanced heterogeneity 
of atrial repolarization.
94–96
Ca2+ handling instability AF (especially forms with a high AF burden), heart 
failure and hypertension (possibly through increased 
sympathetic activation).
Enhanced propensity to ectopy. 97, 98
Gap-junction redistribution AF Conduction disturbances.
May induce replacement fibrosis.
99
Myocyte alterations
Apoptosis and necrosis Coronary artery disease, heart failure (through 
cardiomyocyte death and atrial scarring).
100
Myocyte hypertrophy Atrial dilatation,  AF. Aggravates conduction disturbances. 84, 101
Endothelial and vascular alterations
Microvascular changes Atherosclerosis, coronary and peripheral artery disease, 
possibly atrial fibrillation.
Aggravation of atrial ischaemia, heterogeneity 
of electrical function, structural remodelling.
102
Endocardial remodelling Enhanced risk for thrombus formation. 103,104
Changes of the autonomic nervous system
Sympathetic 
hyperinnervation
Heart failure, hypertension. Enhanced propensity to ectopy. 80, 105
AF ¼ atrial fibrillation; CAD ¼ coronary artery disease.
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5.2.2 Prolonged monitoring for paroxysmal atrial
fibrillation
Paroxysmal AF is often missed.120 Repeated daily ECG recordings
increased the detection of silent, asymptomatic paroxysmal AF in
an unselected Swedish population aged .75 years.120,135 Several
patient-operated devices136,137 and extended continuous ECG
monitoring using skin patch recorders138 have been validated for
the detection of paroxysmal AF (Web Figure 1).139 The detection
of asymptomatic AF by new technologies, such as smartphone cases
with ECG electrodes, smart watches, and blood pressure machines
with AF detection algorithms, has not yet been formally evaluated
against an established arrhythmia detection method.140
5.2.3 Patients with pacemakers and implanted devices
Implanted pacemakers or defibrillators with an atrial lead allow
continuous monitoring of atrial rhythm. Using this technology, pa-
tients with atrial high rate episodes (AHRE) can be identified. De-
pending on the risk profile of the population studied, such AHRE are
detected in 10–15% of pacemaker patients.141 AHRE are associated
with an increased risk of overt AF [hazard ratio (HR) 5.56; 95% con-
fidence interval (CI) 3.78–8.17; P, 0.001] and ischaemic stroke or
systemic embolism (HR 2.49; 95% CI 1.28–4.85; P ¼ 0.007). The
stroke risk in AHRE patients seems lower than the stroke risk in pa-
tients with diagnosed AF, and not all AHRE represent AF.142 Strokes
often occur without AHRE detected within 30 days before the
event.143 –147 Consequently, it is unclear whether AHRE imply the
same therapeutic requirements as overt AF,148 and the benefit of
OAC in patients with AHRE is tested in ongoing clinical trials [e.g.
Apixaban for the Reduction of Thrombo-Embolism in Patients With
Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)
(NCT01938248) and Non vitamin K antagonist Oral anticoagulants
in patients with Atrial High rate episodes (NOAH – AFNET 6)
(NCT02618577)]. At present, pacemakers and implanted devices
should be interrogated on a regular basis for AHRE, and patients
with AHRE should undergo further assessment of stroke risk factors











Patient without known AF presenting with atrial high rate episode
(AHRE, >5–6 min and >180 bpm) detected by an implanted device
Assess eligibility for oral anticoagulation using CHA2DS2-VASc score




Review device electrograms (if available) to determine whether it is AF
Consider patient characteristics




2DS2-VASc = Congestive 
Heart failure, hypertension,  Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); ECG = electrocardiogram; EHRA = European Heart 
Rhythm Association.
*In rare individual circumstances, oral anticoagulation may be considered in patients with AHRE, but without diagnosed AF.  This clearly needs discussion with the patient and careful 
aAdapted from the report of the 3rd AFNET/EHRA consensus conference.150
No antithrombotic
therapy (IB)
Figure 3 Management of AHRE detected by an implanted device.
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5.2.4 Detection of atrial fibrillation in stroke survivors
Sequential stratified ECG monitoring detected AF in 24% (95% CI
17–31) of stroke survivors,151 and in 11.5% (95% CI 8.9%–14.3%)
in another meta-analysis,17 with large variations depending on the
timing, duration, and method of monitoring. AF detection is not
uncommon in unselected stroke patients (6.2%, 95% CI 4.4 –
8.3),128 but is more likely in patients with cryptogenic stroke im-
planted with loop recorders or who have had ECG monitors
for several weeks.18,128,152 Cryptogenic stroke is defined as a
stroke in which the cause could not be identified after extensive
investigations.153 A broader definition is embolic stroke of un-
determined source.154 Several studies have also found AF in pa-
tients in whom another competing cause for stroke has been
identified clinically (e.g. hypertension or carotid artery sten-
osis).27,127 Hence, prolonged ECG monitoring seems reasonable
in all survivors of an ischaemic stroke without an established diag-
nosis of AF.
Recommendations for screening for atrial fibrillation
Recommendations Classa Levelb Ref C
Opportunistic screening for AF is 
recommended by pulse taking or 
ECG rhythm strip in patients 




In patients with TIA or ischaemic 
stroke, screening for AF is 
recommended by short-term ECG 
recording followed by continuous 
ECG monitoring for at least 72 hours.
I B 27, 127 
It is recommended to interrogate 
pacemakers and ICDs on a regular 
basis for atrial high rate episodes 
(AHRE). Patients with AHRE should 
undergo further ECG monitoring to 
document AF before initiating AF 
therapy.
I B 141, 156
In stroke patients, additional ECG 
monitoring by long-term non-
invasive ECG monitors or implanted 
loop recorders should be considered 
to document silent atrial fibrillation.
IIa B 18, 128
Systematic ECG screening may be 
considered to detect AF in patients 





AF ¼ atrial fibrillation; AHRE ¼ atrial high rate episodes;
ECG ¼ electrocardiogram; ICD ¼ implantable cardioverter defibrillator;




5.3 Electrocardiogram detection of atrial
flutter
Right atrial isthmus-dependent flutter has a typical ECG pattern and
ventricular rate.158 The prevalence of atrial flutter is less than one-
tenth of the prevalence of AF.159 Atrial flutter often coexists with or
precedes AF.160 In typical, isthmus-dependent flutter, P waves will
often show a ‘saw tooth’ morphology, especially in the inferior leads
(II, III, aVF). The ventricular rate can be variable (usual ratio of atrial
to ventricular contraction 4:1 to 2:1, in rare cases 1:1) and
macro-re-entrant tachycardias may be missed in stable 2:1 conduc-
tion. Vagal stimulation or intravenous adenosine can therefore
be helpful to unmask atrial flutter. The management of atrial flutter
is discussed in chapter 13.7. Left or right atrial macro re-entrant
tachycardia is mainly found in patients after catheter ablation for
AF, AF surgery, or after open heart surgery.158
6. Classification of atrial fibrillation
6.1 Atrial fibrillation pattern
In many patients, AF progresses from short, infrequent episodes to
longer and more frequent attacks. Over time, many patients will de-
velop sustained forms of AF. In a small proportion of patients, AF
will remain paroxysmal over several decades (2–3% of AF pa-
tients).161 The distribution of paroxysmal AF recurrences is not ran-
dom, but clustered.162 AF may also regress from persistent to
paroxysmal AF. Furthermore, asymptomatic recurrences of AF
are common in patients with symptomatic AF.120
Based on the presentation, duration, and spontaneous termin-
ation of AF episodes, five types of AF are traditionally distin-
guished: first diagnosed, paroxysmal, persistent, long-standing
persistent, and permanent AF (Table 5). If patients suffer from
both paroxysmal and persistent AF episodes, the more common
type should be used for classification. Clinically determined AF
patterns do not correspond well to the AF burden measured




AF that has not been diagnosed before, irrespective 
of the duration of the arrhythmia or the presence 
and severity of AF-related symptoms.
Paroxysmal AF Self-terminating, in most cases within 48 hours. 
Some AF paroxysms may continue for up to 7 days.a
AF episodes that are cardioverted within 
7 days should be considered paroxysmal.a
Persistent AF AF that lasts longer than 7 days, including episodes 
that are terminated by cardioversion, either with 
drugs or by direct current cardioversion, after
7 days or more. 
Long-standing 
persistent AF
Continuous AF lasting for ≥1 year when it is decided 
to adopt a rhythm control strategy.
Permanent AF AF that is accepted by the patient (and physician). 
Hence, rhythm control interventions are, by 
AF.  Should a rhythm control strategy be adopted, the 
arrhythmia would be re-classified as ‘long-standing
definition, not pursued in patients with permanent
persistent AF’.
AF ¼ atrial fibrillation.
aThe distinction between paroxysmal and persistent AF is often not made correctly
without access to long-term monitoring.163 Hence, this classification alone is often
insufficient to select specific therapies. If both persistent and paroxysmal episodes
are present, the predominant pattern should guide the classification.
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by long-term ECG monitoring.163 Even less is known about the
response to therapy in patients with long-standing persistent
AF or long-standing paroxysmal AF. Despite these inaccuracies,
the distinction between paroxysmal and persistent AF has been
used in many trials and therefore still forms the basis of some
recommendations.
There is some evidence suggesting that AF burden may influence
stroke risk44,124,164 and could modify the response to rhythm con-
trol therapy.76,165 The evidence for this is weak. Therefore, AF bur-
den should not be a major factor in deciding on the usefulness of an
intervention that is deemed suitable for other reasons.
6.2 Atrial fibrillation types reflecting
different causes of the arrhythmia
The risk of developing AF is increased in a variety of physiological
and disease states (Figure 2), and the historic term ‘lone AF’ is prob-
ably misleading and should be avoided.166 Although the pattern of
AF may be the same, the mechanisms underpinning AF vary substan-
tially between patients167 (Table 6). This suggests that stratifying AF
patients by underlying drivers of AF could inform management,
for example, considering cardiac and systemic comorbidity (e.g.
diabetes and obesity168), lifestyle factors (e.g. activity level, smoking,
alcohol intake169,170), markers of cardiac structural remodelling (e.g.
fibrosis171 –173 or electrocardiographic parameters of AF complex-
ity174), or genetic background. Table 6 provides such a taxonomy,
informed by expert consensus,76,120,175 but without much evidence
to underpin its clinical use.176 Systematic research defining the
major drivers of AF is clearly needed to better define different types
of AF.176
6.3 Symptom burden in atrial fibrillation
Patients with AF have significantly poorer quality of life than
healthy controls, experiencing a variety of symptoms including
lethargy, palpitations, dyspnoea, chest tightness, sleeping difficul-
ties, and psychosocial distress.32,177 – 180 Improved quality of life
Table 6 Clinical types of atrial fibrillationa
AF type Clinical presentation Possible pathophysiology
AF secondary to 
structural heart 
disease
AF in patients with LV systolic or diastolic dysfunction, long-standing 
hypertension with LVH, and/or other structural heart disease.  
The onset of AF in these patients is a common cause of hospitalization 
and a predictor of poor outcome.
Increased atrial pressure and atrial structural remodelling, 
together with activation of the sympathetic and renin-
angiotensin system.
Focal AF Patients with repetitive atrial runs and frequent, short episodes of 
paroxysmal atrial fibrillation. Often highly symptomatic, younger
patients with distinguishable atrial waves (coarse AF), atrial ectopy, and/
or atrial tachycardia deteriorating in AF.
Localized triggers, in most cases originating from the pulmonary 
veins, initiate AF. 
AF due to one or a few re-entrant drivers is also considered to 
be part of this type of AF.
Polygenic AF AF in carriers of common gene variants that have been associated with 
early onset AF. 
Currently under study.  The presence of selected gene variants 
may also influence treatment outcomes.
Post-operative AF New onset of AF (usually self-terminating) after major (typically 
cardiac) surgery in patients who were in sinus rhythm before surgery 
and had no prior history of AF.
sympathetic tone, electrolyte changes, and volume overload, 
Acute factors: inflammation, atrial oxidative stress, high
possibly interacting with a pre-existing substrate.
AF in patients with 
mitral stenosis or 
prosthetic heart valves 
AF in patients with mitral stenosis, after mitral valve surgery and in 
some cases other valvular disease.
Left atrial pressure (stenosis) and volume (regurgitation) load 
are the main drivers of atrial enlargement and structural atrial 
remodelling in these patients.
AF in athletes Usually paroxysmal, related to duration and intensity of training. Increased vagal tone and atrial volume.
Monogenic AF AF in patients with inherited cardiomyopathies, including 
channelopathies.
The arrhythmogenic mechanisms responsible for sudden death 
are likely to contribute to the occurrence of AF in these patients.
AF ¼ atrial fibrillation; LV ¼ left ventricular; LVH ¼ left ventricular hypertrophy. It is recognized that these types of AF will overlap in clinical practice, and that their impact for
management needs to be evaluated systematically.
Table 7 Modified European Heart Rhythm





1 None AF does not cause any symptoms
2a Mild
Normal daily activity not affected 
by symptoms related to AFa
2b Moderate
Normal daily activity not affected
by symptoms related to AF, but 
patient troubled by symptomsa
3 Severe
Normal daily activity affected by 
symptoms related to AF
4 Disabling
Normal daily activity 
discontinued
AF ¼ atrial fibrillation; EHRA ¼ European Heart Rhythm Association.
aEHRA class 2a and 2b can be differentiated by evaluating whether patients are
functionally affected by their AF symptoms. AF-related symptoms are most
commonly fatigue/tiredness and exertional shortness of breath, or less frequently
palpitations and chest pain.42,194,200–202
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has been noted with both pharmacological and interventional
therapies,181 – 185 but there are limited data to compare the
benefit of different treatments.32,186 Assessment of quality of
life is further constrained by a lack of cross-validation of the
several AF-specific quality of life tools.187 – 191 With regard to
symptom assessment, EHRA suggested the EHRA symptom
scale (Table 7) to describe symptom severity in AF patients.192
A similar scale (the Canadian Cardiovascular Society Severity of
Atrial Fibrillation Scale) is used in Canada.193 The EHRA scale has
been used and validated.194 – 199 A modification was proposed in
2014, subdividing EHRA class 2 into mild (2a) or moderate (2b)
impact.199 As symptoms in class 2b (‘troubling’ symptoms) iden-
tified patients with a health utility benefit of rhythm control in
that study, this modification may provide a threshold for potential
treatment decisions, pending independent validation. While
some AF patients had no or minimal symptoms (25 – 40%),
many (15 – 30%) report severe or disabling symptoms.194,196
The modified EHRA scale should be used to guide symptom-
orientated treatment decisions and for longitudinal patient
profiling.
Recommendation on use of the modified European
Heart Rhythm Association symptom scale
Recommendation Classa Levelb Ref C
symptom scale is recommended 
Use of the modified EHRA
in clinical practice and research 
studies to quantify AF-related 
symptoms.
I C 192, 199




7. Detection and management of
risk factors and concomitant
cardiovascular diseases
Many cardiovascular diseases and concomitant conditions increase
the risk of developing AF (Table 8), recurrent AF, and AF-associated
complications. The identification of such conditions, their preven-
tion and treatment is an important leverage to prevent AF and
its disease burden. Knowledge of these factors and their manage-
ment is hence important for optimal management of AF
patients.203,204
7.1 Heart failure
Heart failure and AF coincide in many patients.215 – 217 They are
linked by similar risk factors and share a common pathophysi-
ology.218 Heart failure and AF can cause and exacerbate each other
through mechanisms such as structural cardiac remodelling,
Table 8 Cardiovascular and other conditions
independently associated with atrial fibrillation
Characteristic/comorbidity Association with AF
Genetic predisposition (based on 










4.98 (95% CI 3.49–7.10)
7.35 (95% CI 5.28–10.2)
9.33 (95% CI 6.68–13.0)
Hypertension (treated) vs. none19 HR 1.32 (95% CI 1.08–1.60) 
Heart failure vs. none19 HR 1.43 (95% CI 0.85–2.40) 
Valvular heart disease vs. none205 RR 2.42 (95% CI 1.62–3.60)






HR 1.23 (95% CI 0.77–1.97)
RR 1.31 (95% CI 1.19–1.44)
RR 1.42 (95% CI 1.22–1.63)
Obesity19, 208
None (BMI <25 kg/m²)
Overweight (BMI 25–30 kg/m²)
Obese (BMI ≥31 kg/m²)
HR:
1.00 (reference)
1.13 (95% CI 0.87–1.46)
1.37 (95% CI 1.05–1.78)
Diabetes mellitus vs. none19 HR 1.25 (95% CI 0.98–1.60) 







1.28 (95% CI 0.79–2.06)
2.53 (95% CI 1.45–4.42)
Obstructive sleep apnoea vs. none210 HR 2.18 (95% CI 1.34–3.54)
Chronic kidney disease211
None
Stage 1 or 2 
Stage 3 
Stage 4 or 5
OR:
1.00 (reference)
2.67 (95% CI 2.04–3.48)
1.68 (95% CI 1.26–2.24) 







1.32 (95% CI 1.10–1.57) 









1.01 (95% CI 0.94–1.09)  
1.07 (95% CI 0.98–1.17)
1.14 (95% CI 1.01–1.28) 









0.90 (95% CI 0.68−1.20)
1.09 (95% CI 0.95−1.26)
1.04 (95% CI 0.91−1.19)
1.20 (95% CI 1.02−1.41)
AF ¼ atrial fibrillation; BMI ¼ body mass index; CI ¼ confidence interval;
FEV1 ¼ forced expiratory volume in 1 second; HR ¼ hazard ratio; OR ¼ odds
ratio; RR ¼ risk ratio.
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activation of neurohormonal mechanisms, and rate-related impair-
ment of left ventricular (LV) function. Patients with AF and concomi-
tant heart failure, both with preserved ejection fraction [LV ejection
fraction (LVEF) ≥50%] and reduced ejection fraction (LVEF
,40%),219,220 suffer from a worse prognosis, including increased
mortality.16,221 The recent ESC Guidelines on heart failure222
have also introduced a new category of heart failure with mid-range
ejection fraction (HFmrEF; LVEF 40–49%), although data on AF
patients in this group are limited. Prevention of adverse outcomes
and maintenance of a good quality of life are the aims of manage-
ment in all patients with AF and concomitant heart failure, regard-
less of LVEF.223 The general approach to AF management does
not differ between heart failure patients and others, but a few con-
siderations are worthwhile. Of note, the only therapy with proven
prognostic value in these patients is anticoagulation, and appropriate
OAC should be prescribed in all patients at risk of stroke (see
Chapter 9).
7.1.1 Patients with atrial fibrillation and heart failure with
reduced ejection fraction
In addition to OAC, standard heart failure therapy should be used
in patients with heart failure with reduced ejection fraction
(HFrEF), as detailed in the ESC Guidelines.222 This includes
angiotensin-converting enzyme (ACE) inhibitors or angiotensin
receptor blockers (ARBs), mineralocorticoid antagonists,
defibrillators, cardiac resynchronization therapy,218 and combined
angiotensin receptor neprilysin inhibition (ARNI) in patients
able to tolerate an ACE inhibitor or ARB with ongoing
symptoms.224
Rate control of AF is discussed in detail in Chapter 10. In brief,
only beta-blockers and digoxin are suitable in HFrEF because of
the negative inotropic potential of verapamil and diltiazem. Beta-
blockers are usually the first-line option in patients with clinically
stable HFrEF, although a meta-analysis using individual patient data
from randomized controlled trials (RCTs) found no reduction in
mortality from beta-blockers vs. placebo in those with AF at base-
line (HR 0.97, 95% CI 0.83–1.14).23 Digoxin is commonly pre-
scribed in clinical practice, but no head-to-head RCTs in AF
patients have been performed. In a meta-analysis of observational
studies, digoxin had a neutral effect on mortality in patients with
AF and concomitant heart failure (adjusted observational studies
HR 0.90, 95% CI 0.70–1.16; propensity-matched observational
studies RR 1.08, 95% CI 0.93–1.26).225 Therefore, initial and com-
bination rate control therapy for AF in HFrEF should take account of
individual patient characteristics and symptoms; beta-blocker initi-
ation should be delayed in patients with acute decompensated heart
failure, and digoxin can accumulate and provoke adverse effects in
patients with kidney dysfunction (see Chapter 10).
Patients with AF and HFrEF who present with severe symp-
toms may require rhythm control therapy in addition to rate con-
trol therapy. For patients who develop HFrEF as a result of rapid
AF (tachycardiomyopathy), a rhythm control strategy is pre-
ferred, based on several relatively small patient cohorts and trials
reporting improved LV function after restoration of sinus
rhythm.185,226 – 228 The diagnosis of tachycardiomyopathy can
be challenging, and at times requires the restoration of sinus
rhythm.229 Catheter ablation may be a useful method to restore
LV function and quality of life in AF patients with HFrEF,185,226 –
228 but further data are needed. Figure 4 summarizes the approach
to patients with AF and heart failure.
7.1.2 Atrial fibrillation patients with heart failure with
preserved ejection fraction
The diagnosis of heart failure with preserved ejection fraction
(HFpEF) in patients with AF is problematic because of the difficulty
in separating symptoms that are due to HF from those due to AF.
Although diagnostic differentiation can be achieved by cardioversion
and clinical reassessment but should be reserved for symptomatic
improvement as a specific therapy that improves prognosis in HFpEF
is currently lacking. Echocardiography can support the detection of
HFpEF in patients with symptomatic AF by providing evidence of
relevant structural heart disease [e.g. LV hypertrophy (LVH)] and/
or measurement of diastolic dysfunction. Reduced early diastolic
myocardial velocity e’ by tissue Doppler reflects impaired LV relax-
ation, while the ratio of E/e’ is correlated with invasive measurement of
LV filling pressures.230–234 Natriuretic peptide levels are part of the
diagnostic assessment of HFpEF,222 although natriuretic peptide levels
are elevated in AF patients and the optimum diagnostic cut-off is still
unknown.235 The management of patients with AF
and concomitant HFpEF should focus on the control of fluid
balance and concomitant conditions such as hypertension and
myocardial ischaemia.
7.1.3 Atrial fibrillation patients with heart failure with
mid-range ejection fraction
HFmrEF is a recently defined entity, describing patients with symp-
toms and signs of heart failure, LVEF 40–49%, elevated levels of
natriuretic peptides, and either LV hypertrophy, left atrial (LA) en-
largement, or evidence of diastolic dysfunction.222 However, diag-
nosis is more difficult in patients with AF, as natriuretic peptides
are elevated in AF and LA dilatation is common, regardless of con-
comitant heart failure. LVEF is also variable and difficult to assess in
AF patients because of AF-induced reduction in systolic LV function
and variable cardiac cycle length. Further study of this group is re-
quired before particular treatment strategies in AF patients with
HFmrEF can be recommended.
7.1.4 Prevention of atrial fibrillation in heart failure
Retrospective analyses from large randomized trials have reported a
lower incidence of new-onset AF in patients treated with ACE inhi-
bitors/ARBs compared with placebo.236 – 238 The reduced incidence
of AF with ACE inhibitors/ARBs is less evident in patients with
HFpEF239 and is lost in patients without heart failure.240 –242 Nepri-
lysin inhibition does not seem to add to this effect.224 Beta-blocker
therapy was associated with a 33% reduction in the adjusted odds of
incident AF in HFrEF patients pre-treated with ACE inhibitors/ARBs,
reinforcing the importance of beta-blocker therapy in HFrEF pa-
tients in sinus rhythm.23 Eplerenone, a mineralocorticoid receptor
antagonist, also reduced the risk of new-onset AF in patients with
LVEF ≤35%, New York Heart Association (NYHA) Class II, when
added to ACE inhibitors/ARBs and beta-blockers.243
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Hypertension is a stroke risk factor in AF; uncontrolled high blood
pressure enhances the risk of stroke and bleeding events and may
lead to recurrent AF. Therefore, good blood pressure control should
form an integral part of the management of AF patients.247 Inhibition
of the renin–angiotensin–aldosterone system can prevent structural
remodelling and recurrent AF.236,244 A recent analysis of the Danish
healthcare database with long-term monitoring of the effect of differ-
ent antihypertensive agents on the occurrence of overt AF suggests a
beneficial effect of ACE inhibitors or ARBs.245 Secondary analyses of
ACE inhibitors or ARBs in patients with heart failure or LVH show a
lower incidence of new-onset AF.238,246 In patients with established
AF, but without LV dysfunction or heart failure, ARBs do not prevent
recurrent AF better than placebo.240,241 ACE inhibitors or ARBs may
reduce recurrent AF after cardioversion when co-administered with
antiarrhythmic drug therapy compared with an antiarrhythmic drug
alone.248,249 Meta-analyses driven by these studies suggested a lower
risk of recurrent AF,236–238,250 but at least one controlled trial failed
to demonstrate benefit.240,251
7.3 Valvular heart disease
Valvular heart disease is independently associated with
incident AF.252 Approximately 30% of patients with AF have
some form of valvular heart disease, often detected only by
echocardiogram.201,253 – 255 AF worsens prognosis in patients
with severe valvular heart disease,256 including those undergoing
surgery or transcatheter interventions for aortic or mitral valve
disease.257 – 262 Valvular heart disease can be associated with an in-
creased thrombo-embolic risk, which probably also adds to the
stroke risk in AF patients.263 Similar to heart failure, valvular dis-
ease and AF interact with and sustain each other through volume
and pressure overload, tachycardiomyopathy, and neurohumoral
factors.264 – 270 When valve dysfunction is severe, AF can be
regarded as a marker for progressive disease, thus favouring valve
repair or replacement.271
Traditionally, patients with AF have been dichotomized into
‘valvular’ and ‘non-valvular’ AF.272 Although slightly different defini-
tions have been used, valvular AF mainly refers to AF patients that
have either rheumatic valvular disease (predominantly mitral sten-
osis) or mechanical heart valves. In fact, while AF implies an incre-
mental risk for thrombo-embolism in patients with mitral valve
stenosis,263,273,274 there is no clear evidence that other valvular dis-
eases, including mitral regurgitation or aortic valve disease, need to
be considered when choosing an anticoagulant or indeed to esti-
mate stroke risk in AF.275 Therefore, we have decided to replace
the historic term ‘non-valvular’ AF with reference to the specific
underlying conditions.
Cardiovert if unstable
Management of patients presenting acutely with AF and heart failure
Acute management Chronic management
Anticoagulate according to stroke risk
Normalise fluid balance with diuretics to improve symptoms
Control rate: Initial rate target <110 bpm; stricter if persistent HF/AF symptoms
Inhibit the renin–angiotensin–aldosterone systema
Early consideration of rhythm control
Advanced HF therapies, including devicesa
Treatment of other cardiovascular disease, especially ischaemia and hypertension
heart failure.
aIn patients with heart failure and reduced ejection fraction.  Also consider combined ARNI in patients able to tolerate an ACE inhibitor or ARB with ongoing symptoms.
Figure 4 Initial management of patients presenting acutely with atrial fibrillation and heart failure. (Adapted from Kotecha and Piccini.128)
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Recommendations for patients with valvular heart
disease and atrial fibrillation
Recommendations Classa Levelb Ref C
Early mitral valve surgery should 
be considered in severe mitral 
regurgitation, preserved LV function, 
and new-onset AF, even in the 
absence of symptoms, particularly 
when valve repair is feasible.
IIa C 276
Mitral valvulotomy should be 
considered for asymptomatic 
patients with severe mitral stenosis 
and suitable valve anatomy who 
have new-onset AF.
IIa C





Diabetes and AF frequently coexist because of associations with
other risk factors.277 – 283 Diabetes is a risk factor for stroke and
other complications in AF.284 In patients with AF, a longer duration
of diabetes appears to confer a higher risk of thrombo-embolism,
albeit without greater risk of OAC-related bleeding.285 Unfortu-
nately, intensive glycaemic control does not affect the rate of
new-onset AF,284 while treatment with metformin seems to be
associated with a decreased long-term risk of AF in diabetic
patients286 and may even be associated with a lower long-term
stroke risk.13 Diabetic retinopathy, a measure of disease severity,
does not increase the risk of ocular bleeding in anticoagulated
patients.287
7.5 Obesity and weight loss
7.5.1 Obesity as a risk factor
Obesity increases the risk for AF (Table 8)288 – 291 with a progressive
increase according to body mass index (BMI).288,290 – 292 Obese pa-
tients may have more LV diastolic dysfunction, increased sympathet-
ic activity and inflammation, and increased fatty infiltration of the
atria.293 – 295 Obesity may also be a risk factor for ischaemic stroke,
thrombo-embolism, and death in AF patients.292
7.5.2 Weight reduction in obese patients with atrial
fibrillation
Intensive weight reduction in addition to the management of other
cardiovascular risk factors (in the range of 10–15 kg weight loss
achieved), led to fewer AF recurrences and symptoms compared
with an approach based on general advice in obese patients with
AF.203,204,296 Improved cardiorespiratory fitness can further de-
crease AF burden in obese patients with AF.297 Although the find-
ings in these studies have to be confirmed, they underpin the
positive effect of weight reduction in obese AF patients.
7.5.3 Catheter ablation in obese patients
Obesity may increase the rate of AF recurrence after catheter abla-
tion,298– 301 with obstructive sleep apnoea as an important potential
confounder. Obesity has also been linked to a higher radiation dose
and complication rate during AF ablation.302,303 Notably, the symp-
tomatic improvement after catheter ablation of AF in obese patients
seems comparable to the improvement in normal-weight pa-
tients.298 In view of the potential to reduce AF episodes by weight
reduction (see chapter 7.5.2.), AF ablation should be offered to ob-
ese patients in conjunction with lifestyle modifications that lead to
weight reduction.
Recommendation for obese patients with atrial
fibrillation
Recommendation Classa Levelb Ref C
In obese patients with AF, weight 
loss together with management 
of other risk factors should be 









7.6 Chronic obstructive pulmonary
disease, sleep apnoea, and other
respiratory diseases
AF has been associated with obstructive sleep apnoea.304,305 Mul-
tiple pathophysiological mechanisms can contribute to AF in
obstructive sleep apnoea, including autonomic dysfunction, hypoxia,
hypercapnia, and inflammation.96,304 – 307 Obstructive sleep apnoea
exaggerates intrathoracic pressure changes, which in itself and via
vagal activation can provoke shortening of the atrial action potential
and induce AF. Risk factor reduction and continuous positive airway
pressure ventilation can reduce AF recurrence.308 – 312 It seems rea-
sonable to consider obstructive sleep apnoea screening in AF pa-
tients with risk factors. Obstructive sleep apnoea treatment
should be optimized to improve AF treatment results in appropriate
patients. Servo-controlled pressure support therapy should not be
used in HFrEF patients with predominantly central sleep apnoea (of
which 25% had concomitant AF).313
Patients with chronic obstructive pulmonary disease often suffer
from atrial tachycardias, which need to be differentiated from AF
by ECG. Agents used to relieve bronchospasm, notably theophyl-
lines and beta-adrenergic agonists, may precipitate AF and make con-
trol of the ventricular response rate difficult. Non-selective
beta-blockers, sotalol, propafenone, and adenosine should be used
with caution in patients with significant bronchospasm, while they
can safely be used in patients with chronic obstructive pulmonary dis-
ease. Beta-1 selective blockers (e.g. bisoprolol, metoprolol, and nebi-
volol), diltiazem, and verapamil are often tolerated and effective (see
Chapter 10).
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Recommendations for patients with atrial fibrillation
and respiratory diseases
Recommendations Classa Levelb Ref C
Correction of hypoxaemia and 
acidosis should be considered as 
initial management for patients 
who develop AF during an acute 
pulmonary illness or exacerbation 
of chronic pulmonary disease.
IIa C
Interrogation for clinical signs of 
obstructive sleep apnoea should be 




Obstructive sleep apnoea treatment 
should be optimized to reduce 
AF recurrences and improve AF 
treatment results.
IIa B 307–311




7.7 Chronic kidney disease
AF is present in 15–20% of patients with CKD.316 The definition of
CKD in most AF trials is relatively strict. Although an estimated
creatinine clearance (CrCl) rate of ,60 mL/min is indicative of
CKD, a number of trials in AF patients have used CrCl ,50 mL/
min to adapt NOAC dosage, usually estimated using the Cock-
roft – Gault formula. CrCl in AF patients can deteriorate over
time.317 The management of OAC in patients with CKD is dis-
cussed in chapter 9.2.4.
Recommendations for patients with kidney disease and
atrial fibrillation
Recommendations Classa Levelb Ref C
The assessment of kidney function 
by serum creatinine or creatinine 
clearance is recommended in all AF 
patients to detect kidney disease 





All AF patients treated with 
oral anticoagulation should be 
considered for at least yearly 
renal function evaluation to detect 
chronic kidney disease.
IIa B




8. Integrated management of
patients with atrial fibrillation
Most patients initially access the healthcare system through pharma-
cists, community health workers, or primary care physicians. As AF
is often asymptomatic (“silent AF”), these healthcare professionals
are important stakeholders to enable the adequate detection of
AF and to ensure consistent management. The initial assessment
should be performed at the point of first contact with the healthcare
system, and is feasible in most healthcare settings (when an ECG is


















Improved quality of life,
autonomy, social
functioning
Lifestyle changes, treatment of
underlying cardiovascular conditions
Oral anticoagulation in







preservation of LV function
Symptom
improvement
Treatment Desired outcome Patient benefit
Figure 5 Acute and chronic management of atrial fibrillation patients, desired cardiovascular outcomes, and patient benefits. Adapted from the
report on the 4th AFNET/EHRA consensus conference.76
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assessment of patients presenting with newly diagnosed AF (Fig-
ure 5). These domains are:
(1) Haemodynamic instability or limiting, severe symptoms;
(2) Presence of precipitating factors (e.g. thyrotoxicosis, sepsis, or
postoperative AF) and underlying cardiovascular conditions;
(3) Stroke risk and need for anticoagulation;
(4) Heart rate and need for rate control;
(5) Symptom assessment and decision for rhythm control.
An integrated, structured approach to AF care, as applied suc-
cessfully to other domains of medicine,322 – 324 will facilitate consist-
ent, guideline-adherent AF management for all patients325 (Figure 6),
with the potential to improve outcomes.42,326,327 Such approaches
are consistent with the Innovative Care for Chronic Conditions
Framework proposal put forward by the World Health Organiza-
tion.328 Review by an AF service, or at least referral to a cardiologist,
will usually be required after the initial assessment to fully evaluate
the effect of AF on cardiovascular health.329 There may also be rea-
sons for early or urgent referral (Table 9). Integrated care of all pa-
tients with newly diagnosed AF should help to overcome the
current shortcomings of AF management, such as underuse of anti-
coagulation, access to rate and rhythm control therapy, and incon-
sistent approaches to cardiovascular risk reduction. Integrated AF
care requires the cooperation of primary care physicians, cardiolo-
gists, cardiac surgeons, AF specialists, stroke specialists, allied health
practitioners, and patients, encompassing lifestyle interventions,
treatment of underlying cardiovascular diseases, and AF-specific
therapy (Figure 7).
8.1 Evidence supporting integrated atrial
fibrillation care
Several structured approaches to AF care have been developed.
Some evidence underpins their use, while more research is needed
into the best way of delivering integrated AF care. Integrated AF
management in an RCT increased the use of evidence-based care,
and reduced by approximately one-third the composite outcome
of cardiovascular hospitalization and cardiovascular death over a
mean follow-up of 22 months (14.3% vs. 20.8%, HR 0.65; 95% CI
Provision of all therapy optionsa





Service accessible for all patients
aOn-site or through institutionalized cooperation.
bSafety outcomes should be collected in published and monitored central 
databases.
Figure 6 Achieving optimal management of atrial fibrillation
patients.
Table 9 Clinical signs calling for urgent involvement of




Symptomatic bradycardia not amenable to reduction of rate control agents
Severe angina or worsening left ventricular function
Transient ischaemic attack or stroke
aAnticoagulation should be initiated early in all suitable patients and will not
routinely require specialist input.
Integrated AF management
Patient involvement Multidisciplinary teams Technology tools
Access to all treatment
options for AF
• Central role in care process
• Patient education
• Encouragement and empowerment
 for self-management
• Advice and education on lifestyle
 and risk factor management
• Shared decision making
• Informed, involved,
 empowered patient
• Phycisians (general physicians, 
 cardiology and stroke AF 
 specialists, surgeons) and allied 
 health professionals work in a 
 collaborative practice model
• 
 skills, education, and experience
• Working together in a 
 multidisciplinary chronic AF 
 care team
• Information on AF
• Clinical decision support
• Checklist and communication tools
• Used by healthcare professionals 
 and patients
• Monitoring of therapy adherence  
 and effectiveness
• Navigation system to support  
 decision making in treatment   
 team





• Catheter and surgical interventions 
 (ablation, LAA occluder, AF surgery, 
 etc.)
• Complex management 
 decisions underpinned by an 
 AF Heart Team
Figure 7 Fundamentals of integrated care in atrial fibrillation patients.
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0.45–0.93; P ¼ 0.017) compared with usual care in a large tertiary
care centre.330 Integrated AF management appeared cost-effective
in that study.331 However, an Australian RCT showed only a margin-
al effect on unplanned admissions and death using integrated AF
care limited to the initial care period, possibly emphasizing the
need for sustained integration of AF care.332 Two observational
studies of integrated AF care found fewer hospitalizations,333,334
one study showed fewer cases of stroke,333 and a further non-
randomized study identified a trend for a lower rate of the compos-
ite outcome of death, cardiovascular hospitalization, and AF-related
emergency visits.335 More research is needed, and integrated AF
care is likely to require different designs in different healthcare
settings.
8.2 Components of integrated atrial
fibrillation care
8.2.1 Patient involvement
Patients should have a central role in the care process. As treatment
of AF requires patients to change their lifestyles and adhere to
chronic therapy, at times without an immediately tangible benefit,
they need to understand their responsibilities in the care process.
Physicians and healthcare professionals are responsible for provid-
ing access to evidence-based therapy, but adherence to therapy is
ultimately the responsibility of informed and autonomous patients,
best described as ‘shared accountability’.336 Hence, information and
the education of patients, and often of their partners and relatives, is
indispensable to encourage a self-management role and to em-
power patients to participate in shared decision-making,326,328 and
to support understanding of the disease and the suggested
treatments.337
8.2.2 Multidisciplinary atrial fibrillation teams
Delegation of tasks from specialists to general physicians and from
physicians to allied health professionals is a fundamental concept of
integrated care models. A multidisciplinary AF team approach in-
cludes an efficient mix of interpersonal and communication skills,
education, and expertise in AF management, as well as the use of
dedicated technology. This approach underlines the importance of
redesigning daily practice in a way that encourages non-specialists
and allied professionals to have an important role in educating pa-
tients and co-ordinating care, while the specialist remains medically
responsible. Cultural and regional differences will determine the
composition of AF teams.
8.2.3 Role of non-specialists
Some non-specialist health care professionals, e.g. physicians in
primary care have extensive expertise in stroke prevention and
initial management of AF patients. Others may seek training to
acquire such knowledge. Other components of AF management
(e.g. assessment of concomitant cardiovascular conditions,
antiarrhythmic drug therapy, or interventional treatment) often
require specialist input. Integrated AF care structures should
support treatment initiation by non-specialists where appropriate,
and provide ready access to specialist knowledge to optimize
AF care.
8.2.4 Technology use to support atrial fibrillation care
Technology, such as decision support software, has the potential
to enhance the implementation of evidence-based care and im-
prove outcomes, when used to enhance expert advice.338 Elec-
tronic tools can also ensure coherent communication within the
AF team. With a view to support the wider use of such technol-
ogy, this Task Force is providing digital decision tools, in the form
of freely accessible smartphone apps, to AF healthcare profes-
sionals and to AF patients.
Recommendations for an integrated approach to care
Recommendations Classa Levelb Ref C
An integrated approach with 
structured organization of care and 
follow-up should be considered in all 
patients with AF, aiming to improve 




Placing patients in a central role 
in decision-making should be 
considered in order to tailor 
management to patient preferences 










8.3 Diagnostic workup of atrial fibrillation
patients
AF is often found in patients with other, at times undiagnosed, car-
diovascular conditions. Thus, all AF patients will benefit from a
comprehensive cardiovascular assessment.339
8.3.1 Recommended evaluation in all atrial fibrillation
patients
A complete medical history should be taken and all patients should
undergo clinical evaluation that includes thorough assessment for
concomitant conditions, establishing the AF pattern, estimation
of stroke risk and AF-related symptoms, and assessment of
arrhythmia-related complications such as thrombo-embolism or
LV dysfunction. A 12-lead ECG is recommended to establish a sus-
pected diagnosis of AF, to determine rate in AF, and to screen for
conduction defects, ischaemia, and signs of structural heart disease.
Initial blood tests should evaluate thyroid and kidney function, as
well as serum electrolytes and full blood count. Transthoracic echo-
cardiography is recommended in all AF patients to guide treatment
decisions. Transthoracic echocardiography should be used to iden-
tify structural disease (e.g. valvular disease) and assess LV size and
function (systolic and diastolic), atrial size, and right heart func-
tion.339,340 Although biomarkers such as natriuretic peptides are
elevated in AF patients, there is insufficient data to suggest that
blood-based parameters are independent markers for AF.341 – 343
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8.3.2 Additional investigations in selected patients with
atrial fibrillation
Ambulatory ECG monitoring in AF patients can assess the adequacy
of rate control, relate symptoms with AF recurrences, and detect
focal induction of bouts of paroxysmal AF. Transoesophageal echo-
cardiography (TOE) is useful to further assess valvular heart disease
and to exclude intracardiac thrombi, especially in the LAA, to facili-
tate early cardioversion or catheter ablation.344 Patients with symp-
toms or signs of myocardial ischaemia should undergo coronary
angiography or stress testing as appropriate. In patients with AF
and signs of cerebral ischaemia or stroke, computed tomography
(CT) or magnetic resonance imaging (MRI) of the brain is recom-
mended to detect stroke and support decisions regarding acute
management and long-term anticoagulation. Delayed-enhancement
MRI of the left atrium using gadolinium contrast,345 –347 T1 mapping
using cardiac MRI,347 and intracardiac echo348 may help to guide
treatment decisions in AF, but require external validation in multi-
centre studies.
8.4 Structured follow-up
Most AF patients need regular follow-up to ensure continued
optimal management. Follow-up may be undertaken in primary
care, by specially trained nurses, by cardiologists, or by AF specia-
lists.325,330 A specialist should co-ordinate care and follow-up.
Follow-up should ensure implementation of the management plan,
continued engagement of the patient, and therapy adaptation where
needed.
Recommendations for diagnostic workup of atrial
fibrillation patients
Recommendations Classa Levelb Ref C
ECG documentation is required to 
establish the diagnosis of AF.
I B 349
A full cardiovascular evaluation, 
including an accurate history, careful 
clinical examination, and assessment 
of concomitant conditions, is 
recommended in all AF patients.
I C
Transthoracic echocardiography is 
recommended in all AF patients to 
guide management.
I C 339
Long-term ECG monitoring should 
be considered in selected patients to 
assess the adequacy of rate control 
in symptomatic patients and to relate 
symptoms with AF episodes.
IIa C




8.5 Defining goals of atrial fibrillation
management
AF management comprises therapies with prognostic impact (an-
ticoagulation and treatment of cardiovascular conditions) and
therapies predominantly providing symptomatic benefit (rate
control and rhythm control, Table 10). Therapies with prognostic
benefit need careful explanation to patients when their benefits
are not directly felt. Rhythm control therapy can be successful if
symptoms are controlled, even when AF recurs. Explaining the
expected benefits to each patient at the start of AF management
will prevent unfounded expectations and has the potential to
optimize quality of life.
9. Stroke prevention therapy in
atrial fibrillation patients
OAC therapy can prevent the majority of ischaemic strokes in AF
patients and can prolong life.38,39,42,194,201,329,350 – 352 It is superior
to no treatment or aspirin in patients with different profiles for
stroke risk.353,354 The net clinical benefit is almost universal,
with the exception of patients at very low stroke risk, and OAC
should therefore be used in most patients with AF (Figure 8). Des-
pite this evidence, underuse or premature termination of OAC
therapy is still common. Bleeding events, both severe and nuis-
ance bleeds, a perceived ‘high risk of bleeding’ on anticoagulation,
and the efforts required to monitor and dose-adjust VKA therapy
are among the most common reasons for withholding or ending
OAC.352,355 – 359 However, the considerable stroke risk without
OAC often exceeds the bleeding risk on OAC, even in the elderly,
in patients with cognitive dysfunction, or in patients with frequent
falls or frailty.360,361 The bleeding risk on aspirin is not different to
the bleeding risk on VKA362 or NOAC therapy,354,363 while VKA
and NOACs, but not aspirin, effectively prevent strokes in AF
patients.38,354,362,363
9.1 Prediction of stroke and bleeding
risk
9.1.1 Clinical risk scores for stroke and systemic
embolism
Simple, clinically applicable stroke risk-stratification schemes
in AF patients were developed in the late 1990s in small cohort
studies, and have later been refined and validated in larger
populations.364 – 368 The introduction of the CHA2DS2-VASc
score (Table 11) has simplified the initial decision for OAC in
AF patients. Since its first incorporation in the ESC guidelines in
2010,369 it has been widely used.370 We recommend estimating
stroke risk in AF patients based on the CHA2DS2-VASc score.
368
In general, patients without clinical stroke risk factors do not need
antithrombotic therapy, while patients with stroke risk factors (i.e.
CHA2DS2-VASc score of 1 or more for men, and 2 or more for
women) are likely to benefit from OAC.
Other, less established risk factors for stroke include unstable
international normalized ratio (INR) and low time in therapeutic
range (TTR) in patients treated with VKAs; previous bleed or an-
aemia; alcohol excess and other markers for decreased therapy ad-
herence; CKD; elevated high-sensitivity troponin; and elevated
N-terminal pro-B-type natriuretic peptide.
9.1.2 Anticoagulation in patients with a CHA2DS2-VASc
score of 1 in men and 2 in women
Controlled trials studying OAC in AF patients have been enriched
for patients at high risk of stroke,38,39,42,194,201,329,351,352 and
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hence there is strong evidence that patients with a CHA2DS2-
VASc risk score of 2 or more in men, and 3 or more in women,
benefit from OAC. Fortunately, we now have a growing evidence
base regarding stroke risk in patients with one clinical risk factor
(i.e. a CHA2DS2-VASc score of 1 for men, and 2 for women), al-
though this relies largely on observed stroke rates in patients not
receiving OAC. In many of these patients, anticoagulation seems
to provide a clinical benefit.371 – 375 The rates of stroke and
thrombo-embolism vary considerably in patients with CHA2DS2-
VASc scores of 1 or 2 due to differences in outcomes, populations,
and anticoagulation status (Web Table 1.)371,376,377,1041 We there-
fore commissioned an analysis of stroke risk in men and women
with one additional stroke risk factor to inform these guidelines
(Web Table 1, last line). OAC should be considered for men
with a CHA2DS2-VASc score of 1 and women with a score of 2,
balancing the expected stroke reduction, bleeding risk, and pa-
tient preference. Importantly, age (65 years and older) conveys
a relatively high and continuously increasing stroke risk that also
potentiates other risk factors (such as heart failure and sex).
Hence, an individualized weighing of risk, as well as patient prefer-
ences, should inform the decision to anticoagulate patients with
only one CHA2DS2-VASc risk factor, apart from female sex. Fe-
male sex does not appear to increase stroke risk in the absence
of other stroke risk factors (Web Table 1).378,379
Measurement of cardiac troponin (high-sensitivity troponin T or I)
and N-terminal pro-B-type natriuretic peptide may provide
additional prognostic information in selected AF patients.380 – 382
Biomarker-based risk scores may, in the future, prove helpful to bet-
ter stratify patients (e.g. those at a truly low risk of stroke).75,382
9.1.3 Clinical risk scores for bleeding
Several bleeding risk scores have been developed, mainly in pa-
tients on VKAs. These include HAS-BLED [hypertension, abnor-
mal renal/liver function (1 point each), stroke, bleeding history or
predisposition, labile INR, elderly (.65 years), drugs/alcohol con-
comitantly (1 point each)], ORBIT (Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation), and more recently, the
ABC (age, biomarkers, clinical history) bleeding score, which also
makes use of selected biomarkers.383 – 385 Stroke and bleeding risk
factors overlap (compare Tables 11 and 12). For example, older
age is one of the most important predictors of both ischaemic
stroke and bleeding in AF patients.386,387 A high bleeding risk
score should generally not result in withholding OAC. Rather,
bleeding risk factors should be identified and treatable factors
corrected (see chapter 8.5). Table 12 provides details of modifi-
able bleeding risk factors.
Table 10 Goal-based follow-up
Category Intervention Follow-up aspects Performance indicator 
(examples)











Heart failure therapy and hospitalizations
Statin and antiplatelet therapy;     
  revascularization
Glycaemic control
Valve repair or replacement
Prognostic Anticoagulation
Adherence (NOAC or VKA) and INR (if  VKA).
Indication (risk profile; timing, e.g. post-cardioversion).













Symptomatic at present Rhythm control Symptoms vs. side effects




Patient education and 
self-care capabilities
Knowledge (about disease; about treatment; about 
management goals)
Capabilities (what to do if…)
Adherence to therapy
Directed evaluation, preferably based on 
systematic checklists
Relevant for chronic care 
management
Caregiver involvement Who? (spouse; GP; home nurse; pharmacist)
Clearly spelling out participation roles
Knowledge and capabilities
Directed evaluation of task performance 
(e.g. via patient card)
Dispensed medication
Log of follow-up visits
bpm ¼ beats per minute; mEHRA symptoms scale ¼ modified European Heart Rhythm Association symptoms scale; GP ¼ general practitioner; INR ¼ international normalized
ratio; LV ¼ left ventricular; NOAC ¼ non-vitamin K antagonist oral anticoagulant; VKA ¼ vitamin K antagonist.
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Recommendations for prediction of stroke and
bleeding risk
Recommendations Classa Levelb Ref C
The CHA2DS2-VASc score is 
recommended for stroke risk 




Bleeding risk scores should be 
considered in AF patients on oral 
risk factors for major bleeding.




Biomarkers such as high-sensitivity 
troponin and natriuretic peptide 
stroke and bleeding risk in AF 





AF ¼ atrial fibrillation; CHA2DS2-VASc ¼ Congestive Heart failure,
hypertension, Age ≥75 (doubled), Diabetes, Stroke or transient ischaemic






9.2.1 Vitamin K antagonists
Warfarin and other VKAs were the first anticoagulants used in AF
patients. VKA therapy reduces the risk of stroke by two-thirds and
mortality by one-quarter compared with control (aspirin or no ther-
apy).38 VKAs have been used in many patients throughout the world
with good outcomes,394 – 396 and this is reflected in the warfarin
arms of the NOAC trials (see chapter 9.2.2.). The use of VKAs is limited
by the narrow therapeutic interval, necessitating frequent monitoring
and dose adjustments, but VKAs, when delivered with adequate time
in therapeutic range (TTR), are effective for stroke prevention in AF pa-
tients. Clinical parameters can help to identify patients who are likely to
achieve a decent TTR on VKA therapy.397 These have been summar-
ized in the SAMe-TT2R2 score. Patients who fare well on this score,
when treated with a VKA, have on average a higher TTR than patients
who do not fare well on the score.398,399 VKAs are currently the only
treatment with established safety in AF patients with rheumatic mitral
valve disease and/or a mechanical heart valve prosthesis.400
9.2.2 Non-vitamin K antagonist oral anticoagulants
NOACs, including the direct thrombin inhibitor dabigatran and the
factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, are
No
YesMechanical heart valves or moderate or severe
mitral stenosis






may be considered in
patients with clear
contra-indications
for OAC (IIbC) NOAC (IA)c VKA (IA)c,d








aCongestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes, prior Stroke/TIA/embolus (2 points), Vascular disease, age 65–74 years, female Sex.
bIncludes women without other stroke risk factors. 
cIIaB for women with only one additional stroke risk factor.
dIB for patients with mechanical heart valves or mitral stenosis.
≥2
Figure 8 Stroke prevention in atrial fibrillation.
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suitable alternatives to VKAs for stroke prevention in AF (Table 13).
Their use in clinical practice is increasing rapidly.401 All NOACs have
a predictable effect (onset and offset) without need for regular an-
ticoagulation monitoring. The phase III trials have been conducted
with carefully selected doses of the NOACs, including clear rules
for dose reduction that should be followed in clinical practice
(Table 13).
9.2.2.1 Apixaban
In the ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thrombo-embolic Events in Atrial Fibrillation) trial,319 apixaban 5 mg
twice daily reduced stroke or systemic embolism by 21% compared
with warfarin, combined with a 31% reduction in major bleeding and
an 11% reduction in all-cause mortality (all statistically significant).
Rates of haemorrhagic stroke and intracranial haemorrhage, but not
of ischaemic stroke, were lower on apixaban. Rates of gastrointestinal
bleeding were similar between the two treatment arms.402
Apixaban is the only NOAC that has been compared with aspirin
in AF patients; apixaban significantly reduced stroke or systemic em-
bolism by 55% compared with aspirin, with no or only a small differ-
ence in rates of major bleeding or intracranial haemorrhage.354,403
9.2.2.2 Dabigatran
In the RE-LY (Randomized Evaluation of Long-Term Anticoagula-
tion Therapy) study,318,404 dabigatran 150 mg twice daily reduced
stroke and systemic embolism by 35% compared with warfarin with-
out a significant difference in major bleeding events. Dabigatran
110 mg twice daily was non-inferior to warfarin for prevention of
stroke and systemic embolism, with 20% fewer major bleeding
events. Both dabigatran doses significantly reduced haemorrhagic
stroke and intracranial haemorrhage. Dabigatran 150 mg twice daily
significantly reduced ischaemic stroke by 24% and vascular mortality
by 12%, while gastrointestinal bleeding was significantly increased by
50%. There was a non-significant numerical increase in the rate of
myocardial infarction with both dabigatran doses,318,404 which has
not been replicated in large post-authorization analyses.396 These
observational data have also replicated the benefit of dabigatran
over VKA found in the RE-LY trial in patients who were mainly trea-
ted with the higher dabigatran dose (150 mg twice daily).396
9.2.2.3 Edoxaban
In the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Fac-
tor Xa Next Generation in Atrial Fibrillation–Thrombolysis in
Table 11 Clinical risk factors for stroke, transient
ischaemic attack, and systemic embolism in the
CHA2DS2-VASc score
CHA2DS2-VASc risk factor Points
Congestive heart failure 
Signs/symptoms of heart failure or objective evidence of 
reduced left ventricular ejection fraction
+1 
Hypertension
Resting blood pressure >140/90 mmHg on at least two 
occasions or current antihypertensive treatment
+1 
Age 75 years or older +2 
Diabetes mellitus
Fasting glucose >125 mg/dL (7 mmol/L) or treatment 
with oral hypoglycaemic agent and/or insulin
+1 




Previous myocardial infarction, peripheral artery disease, 
or aortic plaque
+1 
Age 65–74 years +1 
Sex category (female) +1 
CHA2DS2-VASc ¼ Congestive Heart failure, hypertension, Age ≥75 (doubled),
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female).
Table 12 Modifiable and non-modifiable risk factors
for bleeding in anticoagulated patients based on
bleeding risk scores
Hypertension (especially when systolic blood pressure is >160 mmHg)a,b,c
Labile INR or time in therapeutic range <60%a in patients on vitamin 
K antagonists
Medication predisposing to bleeding, such as antiplatelet drugs and 




Reduced platelet count or functionb
Agee (>65 years)a (≥75 years)b,c,d
History of major bleedinga,b,c,d
Previous strokea,b







Modifiable bleeding risk factors
Potentially modifiable bleeding risk factors
Non-modifiable bleeding risk factors
Biomarker-based bleeding risk factors
non-steroidal anti-inflammatory drugsa,d
ABC ¼ age, biomarkers, clinical history; ATRIA ¼ AnTicoagulation and Risk
factors In Atrial fibrillation; CKD ¼ chronic kidney disease; CrCl ¼ creatinine
clearance; HAS-BLED ¼ hypertension, abnormal renal/liver function (1 point
each), stroke, bleeding history or predisposition, labile INR, elderly (.65 years),
drugs/alcohol concomitantly (1 point each); HEMORR2HAGES ¼ hepatic or renal
disease, ethanol abuse, malignancy, older (age .75), reduced platelet count or
function, rebleeding risk (prior bleed; 2 points), hypertension (uncontrolled),
anaemia, genetic factors (CYP 2C9 polymorphisms), excessive fall risk (including
neuropsychiatric disease), and stroke; INR ¼ international normalized ratio;
ORBIT ¼ Outcomes Registry for Better Informed Treatment of Atrial Fibrillation;
TTR ¼ time in therapeutic range; VKA ¼ vitamin K antagonist.
aDerived from the HAS-BLED score.384
bDerived from the HEMORR2HAGES score.
383
cDerived from the ATRIA score.385
dDerived from the ORBIT score.388
eDerived from the ABC bleeding score.387
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Myocardial Infarction 48) trial,321 edoxaban 60 mg once daily and
edoxaban 30 mg once daily (with dose reductions in certain pa-
tients, Table 13), were compared with adjusted-dose warfarin.405
Edoxaban 60 mg once daily was non-inferior to warfarin (Table 13).
In an on-treatment analysis, edoxaban 60 mg once daily significant-
ly reduced stroke or systemic embolism by 21% and significantly
reduced major bleeding events by 20% compared with warfarin,
while edoxaban 30 mg once daily was non-inferior to warfarin
for prevention of stroke and systemic embolism but significantly
reduced major bleeding events by 53%. Cardiovascular death
was reduced in patients randomized to edoxaban 60 mg once
daily or edoxaban 30 mg once daily compared with warfarin.
Only the higher dose regimen has been approved for stroke pre-
vention in AF.
9.2.2.4 Rivaroxaban
In the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Fac-
tor Xa Inhibition Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial Fibrillation) trial,320
patients were randomized to rivaroxaban 20 mg once daily
or VKA, with a dose adjustment to 15 mg daily for those with
estimated CrCl 30–49 mL/min by the Cockroft–Gault formula
(Table 13). Rivaroxaban was non-inferior to warfarin for the pre-
vention of stroke and systemic embolism in the intent-to-treat









Mechanism Oral direct thrombin inhibitor Oral direct factor Xa inhibitor Oral direct factor Xa inhibitor Oral direct factor Xa inhibitor
Bioavailability, % 6 66 fasting, 80–100 with food 50 62
Time to peak levels, hours 3 2–4 3 1–2
Half-life, hours 12–17 5–13 9–14 10–14
Excretion 80% renal 66% liver, 33% renal 27% renal 50% renal
Dose 150 mg twice daily or 110 mg twice daily 20 mg once daily 5 mg twice daily 60 mg once daily or 30 mg once daily 
Dose reduction in selected 
patients
Rivaroxaban 15 mg once daily if CrCl 30-49 
mL/min
Apixaban 2.5 mg twice daily if at least
2 of age ≥80 years, body weight ≤60 kg 
or serum creatinine level ≥1.5 mg/dL
(133 µmol/L)
Edoxaban 60 mg reduced to 30 mg once daily, and 
edoxaban 30 mg reduced to 15 mg once daily, if any of 
the following: creatinine clearance of 30–50 mL/min, body 
weight ≤60 kg, concomitant use of verapamil or quinidine 
or dronedarone
Study design Randomized, open-label Randomized, double-blind Randomized, double-blind Randomized, double-blind
Number of patients 18 113 14 264 18 201 21 105
Follow-up period, years 2 1.9 1.8 2.8
Randomized groups Dose-adjusted warfarin vs. blinded doses 
of dabigatran (150 mg twice daily, 110 mg twice daily)
Dose-adjusted warfarin vs. rivaroxaban 
20 mg once daily
Dose-adjusted warfarin vs. apixaban 5 
mg twice daily
Dose-adjusted warfarin vs. edoxaban 
(60 mg once daily, 30 mg once daily)   
Age, years 71.5 ± 8.7 (mean ± SD) 73 (65–78) [median (interquartile range)] 70 (63–76) [median (interquartile 
range)]
72 (64–78) [median (interquartile range)]
Male sex, % 63.6 60.3 64.5 61.9
CHADS2 score (mean) 2.1 3.5 2.1 2.8
Warfarin Dabigatran 150 Dabigatran 110 Warfarin Rivaroxaban Warfarin Apixaban Warfarin Edoxaban 60 Edoxaban 30
n = 6022 n = 6076 n = 6015 n = 7133 n = 7131 n = 9081 n = 9120 n = 7036 n = 7035 n = 7034
Event rate, 
%/year
Event rate, %/year 
(RR vs. warfarin)
Event rate, %/
year (RR vs. 
warfarin) 








 Event rate, %/year 
(HR vs. warfarin)   
Event rate, %/year 



















P <0.001 for non-
inferiority,
P = 0.01 for superiority)
1.80
1.57 (0.87, 0.73–1.04;
P <0.001 for non-
inferiority, P = 0.08 for 
superiority)
2.04 (1.13, 0.96–1.34;
P = 0.005 for non-













































3.45 3.60 (1.04; 0.90-2.30; 





2.75 (0.80, 0.71–0.91; 
P <0.001)
















0.39 (0.47, 0.34–0.63; 
P <0.001) 


















1.51 (1.23, 1.02–1.50; 
P = 0.03)
















0.70 (0.94, 0.74–1.19; 
P = 0.60)
0.89 (1.19, 0.95–1.49; 
P = 0.13)














3.99 (0.92, 0.83–1.01; 
P = 0.08)
3.80 (0.87, 0.79–0.96; 
P = 0.006)
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analysis, while the per-protocol on-treatment analysis achieved
statistical superiority with a 21% reduction in stroke or systemic
embolism compared with warfarin. Rivaroxaban did not reduce
the rates of mortality, ischaemic stroke, or major bleeding events
compared to VKA. There was an increase in gastrointestinal
bleeding events, but a significant reduction in haemorrhagic stroke
and intracranial haemorrhage with rivaroxaban compared with
warfarin. Comparable event rates have been reported in post-
authorization analyses, which are part of the post-approval risk
management process.406,407
9.2.3 Non-vitamin K antagonist oral anticoagulants or
vitamin K antagonists
Both VKAs and NOACs are effective for the prevention of stroke
in AF. A meta-analysis39 based on the high-dose treatment groups
of the pivotal studies of warfarin vs. NOACs included 42 411 pa-
tients receiving a NOAC and 29 272 receiving warfarin. NOACs in
these dosages significantly reduced stroke or systemic embolic
events by 19% compared with warfarin (RR 0.81; 95% CI 0.73–
0.91; P, 0.0001), mainly driven by a reduction in haemorrhagic
stroke (RR 0.49; 95% CI 0.38–0.64; P, 0.0001). Mortality was
10% lower in patients randomized to NOAC therapy (RR 0.90;
95% CI 0.85 – 0.95; P ¼ 0.0003) and intracranial haemorrhage
was halved (RR 0.48; 95% CI 0.39 – 0.59; P , 0.0001), while
gastrointestinal bleeding events were more frequent (RR 1.25;
95% CI 1.01 – 1.55; P ¼ 0.04).39 The stroke reduction with
NOACs was consistent in all evaluated subgroups, while there
was a suggestion of greater relative reduction in bleeding with
NOACs at centres with poor INR control (interaction P ¼
0.022). Notably, the substantial reduction in intracranial haemor-
rhage by NOACs compared with warfarin seems unrelated to the
quality of INR control.408,409
9.2.4 Oral anticoagulation in atrial fibrillation patients
with chronic kidney disease
CKD is associated with stroke and bleeding in large data sets.410,411
Anticoagulation can be safely used in AF patients with moderate or
moderate-to-severe CKD [glomerular filtration rate (GFR) ≥15
mL/min]: the SPAF (Stroke Prevention in Atrial Fibrillation) III trial
randomized 805/1936 participants with stage 3 CKD (estimated
GFR ,59 mL/min/1.73 m2), and reported good outcomes on war-
farin (INR 2–3).412 This finding is supported by a large Swedish data-
base, in which stroke risk was lower in CKD patients with AF treated
with warfarin (adjusted HR 0.76; 95% CI 0.72–0.80),413 while bleed-
ing was also slightly increased, especially during therapy initiation.414
In a meta-analysis of the major NOAC trials, patients with mild or
moderate CKD suffered fewer strokes, systemic emboli, or major
bleeding events on NOACs than on warfarin.415 Kidney function
should be regularly monitored in AF patients on OACs to allow
dose adaptation for those on NOACs (Table 14) and to refine
risk estimation.416
9.2.5 Oral anticoagulation in atrial fibrillation patients on
dialysis
Approximately one in eight dialysis patients suffer from AF, with
an incidence rate of 2.7/100 patient-years.417 AF is associated
Table 14 Dose adjustment for NOACs as evaluated in the PHASE III trials (adapted from Hart et al.316)
Dabigatran Rivaroxaban Apixaban Edoxaban 
Renal clearance 80% 35% 25% 50%
Number of patients 18 113 14 264 18 201 21 105
Dose 150 mg or 
110 mg twice daily




CrCl <30 mL/min CrCl <30 mL/min Serum creatinine >2.5 mg/dL or
CrCl <25 mL/min
CrCl <30 mL/min
Dose adjustment with 
CKD
None 15 mg once daily 
if CrCl 30–49 mL/min
2.5 mg twice daily if serum 
creatinine ≥1.5 mg/dL 
(133 µmol/L) plus age ≥80 years 
or weight ≤60 kg
30 mg (or 15 mg) once daily if
CrCl <50 mL/min










Reduction of stroke 
and systemic embolism
No interaction with 
CKD status





Reduction in major 
haemorrhages 
compared to warfarin
Reduction in major 
haemorrhage with dabigatran 
was greater in patients 




Reduction in major 
haemorrhage with apixaban
NA
(RE-LY) 318, 425 (ROCKET-AF) 320, 426 (ARISTOTLE) 319, 427 (ENGAGE AF-TIMI 48) 321
CKD ¼ chronic kidney disease; CrCl ¼ creatinine clearance; GFR ¼ glomerular filtration rate; NA ¼ not available.
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with increased mortality in patients on dialysis.417 There are no
randomized trials assessing OAC in haemodialysis patients,418
and no controlled trials of NOACs in patients with severe CKD
(CrCl ,25–30 mL/min).318 – 321 Warfarin use was associated ei-
ther with a neutral or increased risk of stroke in database analyses
of patients on dialysis,419 – 421 including a population-based ana-
lysis in Canada (adjusted HR for stroke 1.14; 95% CI 0.78–1.67,
adjusted HR for bleeding 1.44; 95% CI 1.13–1.85).422 In contrast,
data from Denmark suggest a benefit of OAC in patients on renal
replacement therapy.423 Hence, controlled studies of anticoagu-
lants (both VKAs and NOACs) in AF patients on dialysis are
needed.424
9.2.6 Patients with atrial fibrillation requiring kidney
transplantation
There are no randomized trials assessing OAC in patients after kid-
ney transplantation. The prescription of NOAC therapy should be
guided by the estimated GFR of the transplanted kidney. Potential
pharmacokinetic interactions of OAC with immunosuppressive
agents should be considered.
9.2.7 Antiplatelet therapy as an alternative to oral
anticoagulants
The evidence supporting antiplatelet monotherapy for stroke pre-
vention in AF is very limited.38,428 – 430 VKA therapy prevents stroke,
systemic embolism, myocardial infarction, and vascular death better
than single or dual antiplatelet therapy with aspirin and clopidogrel
(annual risk of 5.6% for aspirin and clopidogrel vs. 3.9% with VKA
therapy).431 Even greater benefits were seen in VKA-treated pa-
tients with a high TTR.432 Antiplatelet therapy increases bleeding
risk, especially dual antiplatelet therapy (2.0% vs. 1.3% with antipla-
telet monotherapy; P, 0.001),433 with bleeding rates that are simi-
lar to those on OAC.354,362,431,434 Thus, antiplatelet therapy cannot
be recommended for stroke prevention in AF patients.
Recommendations for stroke prevention in patients with atrial fibrillation
Recommendations Class a Level b Ref C
Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA2DS2-VASc 





Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA2DS2-VASc 





Oral anticoagulation therapy to prevent thromboembolism should be considered in male AF patients with a 




Oral anticoagulation therapy to prevent thromboembolism should be considered in female AF patients with a 




Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke prevention in AF patients with 




When oral anticoagulation is initiated in a patient with AF who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or 





When patients are treated with a vitamin K antagonist, time in therapeutic range (TTR) should be kept as high as 




AF patients already on treatment with a vitamin K antagonist may be considered for NOAC treatment if TTR is not well 





Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk and should be avoided in AF patients 




In male or female AF patients without additional stroke risk factors, anticoagulant or antiplatelet therapy is not 











NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves 






AF ¼ atrial fibrillation; CHA2DS2-VASc ¼ Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female);











9.3 Left atrial appendage occlusion and
exclusion
9.3.1 Left atrial appendage occlusion devices
Interventional LAA occlusion,446 – 449 and limited experience
with percutaneous LAA ligation, has mainly been reported in ob-
servational studies and registries. Only one device (Watchmanw)
has been compared with VKA therapy in randomized trials
[PROTECT AF (Watchman Left Atrial Appendage System for
Embolic Protection in Patients With AF trial), see Web Table 2;
and PREVAIL (Prospective Randomized Evaluation of the Watch-
man LAA Closure Device In Patients with AF Versus Long Term
Warfarin Therapy trial)].449 – 451 In these data sets, LAA occlusion
was non-inferior to VKA treatment for the prevention of stroke in
AF patients with moderate stroke risk, with a possibility of lower
bleeding rates in the patients who continued follow-up.452,453
These data were confirmed in a patient-level meta-analysis of
the two trials and their associated registries.453 LAA occlusion
may also reduce stroke risk in patients with contraindications to
OAC.454,455 The implantation procedure can cause serious com-
plications,446,456 – 458 with high event rates reported in analyses
from insurance databases and systematic reviews, possibly identi-
fying a certain degree of reporting bias.446,456 A large recent Euro-
pean registry reported a high rate of implantation success (98%),
with an acceptable procedure-related complication rate of 4% at
30 days.459 Most patients who historically would be considered
unsuitable for OAC therapy seem to do relatively well on contem-
porarily managed OAC.396,407,460 Adequately powered con-
trolled trials are urgently needed to inform the best use of
these devices, including LAA occluders in patients who are truly
unsuitable for OAC or in patients who suffer a stroke on OAC,
randomized comparisons of LAA occluders with NOACs, and as-
sessment of the minimal antiplatelet therapy acceptable after LAA
occlusion.
9.3.2 Surgical left atrial appendage occlusion or
exclusion
Surgical LAA occlusion or exclusion concomitant to cardiac sur-
gery has been performed for many decades and with various
techniques. Multiple observational studies indicate the feasibility
and safety of surgical LAA occlusion/exclusion, but only limited
controlled trial data are available.461 – 464 Residual LAA flow or in-
complete LAA exclusion can increase stroke risk.465 In most
studies, LAA occlusion/exclusion was performed during other
open heart surgery, and more recently in combination with sur-
gical ablation of AF463 or as a stand-alone thoracoscopic proced-
ure. One randomized trial evaluating the role of concomitant AF
surgery and LAA occlusion reported in 2015, without a clear
benefit of LAA exclusion for stroke prevention in the subgroup
undergoing AF surgery.466 A large randomized trial is currently
underway.467
Recommendations for occlusion or exclusion of the
left atrial appendage
Recommendations Classa Levelb Ref C
After surgical occlusion or exclusion 
of the LAA, it is recommended to 
continue anticoagulation in 
at-risk patients with AF for stroke 
prevention.
I B 461, 462
LAA occlusion may be considered 
for stroke prevention in patients 
with AF and contra-indications for 
long-term anticoagulant treatment 
(e.g. those with a previous 





Surgical occlusion or exclusion of 
the LAA may be considered for 
stroke prevention in patients with 
AF undergoing cardiac surgery.
IIb B 463
Surgical occlusion or exclusion of the 
LAA may be considered for stroke 
prevention in patients undergoing 
thoracoscopic AF surgery.
IIb B 468




9.4 Secondary stroke prevention
The most important risk factors for stroke in patients with AF are
advanced age and previous cardioembolic stroke or TIA,382 empha-
sizing the need for OAC in these patients. The highest risk of recur-
rent stroke is in the early phase after a first stroke or TIA.469,470
9.4.1 Treatment of acute ischaemic stroke
Systemic thrombolysis with recombinant tissue plasminogen activator
(rtPA) is an effective and approved medical treatment for acute ischae-
mic stroke in patients presenting within 4.5 h of symptom onset.471 Sys-
temic thrombolysis is contraindicated in patients on therapeutic
OAC.472,473 Recombinant tissue plasminogen activator can be given in
patients treated with a VKA if the INR is below 1.7,474 or in dabigatran-
treated patients with a normal activated partial thromboplastin time and
last intake of drug .48 h previously (based on expert consensus).472
Whether specific NOAC antidotes475 could be used followed by sys-
temic thrombolysis needs to be investigated. Thrombectomy can be
performed in anticoagulated patients with distal occlusion of the internal
carotid artery or middle cerebral artery in a 6 h window.476
9.4.2 Initiation of anticoagulation after transient ischaemic
attack or ischaemic stroke
Data on the optimal use of anticoagulants (heparin, low-molecular-
weight heparin, heparinoid, VKA, NOAC) in the first days after a
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stroke are scarce. Parenteral anticoagulants seem to be associated
with a non-significant reduction in recurrent ischaemic stroke
when administered 7–14 days after the acute stroke [odds ratio
(OR) 0.68; 95% CI 0.44–1.06), with a significant increase in symp-
tomatic intracranial bleeding (OR 2.89; 95% CI 1.19–7.01), and a
similar rate of death or disability at final follow-up.477 It seems likely
that the bleeding risk on parenteral anticoagulation exceeds the
stroke prevention benefit in the first days after a large stroke,
whereas patients with a TIA or a small stroke may benefit from early
(immediate) initiation or continuation of anticoagulation. Therefore,
we propose to initiate anticoagulation in AF patients between 1
and 12 days after an ischaemic stroke, depending on stroke severity
(Figure 9).478 We suggest repeat brain imaging to determine the op-
timal initiation of anticoagulation in patients with a large stroke at
risk for haemorrhagic transformation. Long-term OAC with a
VKA363,479 – 481 or NOAC482 conveys benefits in AF patients who
survived a stroke. NOACs seem to convey slightly better outcomes,
mainly driven by fewer intracranial haemorrhages and haemorrhagic
strokes (OR 0.44; 95% CI 0.32–0.62).482 Detailed data for edoxaban
have not yet been published.321 If a patient suffers a stroke or TIA
whilst taking an anticoagulant, switching to another anticoagulant
should be considered.
9.4.3 Initiation of anticoagulation after intracranial
haemorrhage
No prospective studies have investigated the benefit or risk of the ini-
tiation of OAC after intracranial haemorrhage,483 and patients with a
history of intracranial bleeding were excluded from the randomized
trials comparing NOACs with VKAs. The available evidence indicates
that anticoagulation in patients with AF can be reinitiated after 4–8
weeks, especially when the cause of bleeding or the relevant risk fac-
tor (e.g. uncontrolled hypertension, see Table 12) has been treated,
and that such treatment leads to fewer recurrent (ischaemic) strokes
and lower mortality.460,484 If anticoagulation is resumed, it seems rea-
sonable to consider anticoagulants with a low bleeding risk.39 Figure 10
depicts a consensus opinion on the initiation or resumption of OAC
Start
OAC








CT or MRI at day 6
Evaluate haemorrhagic
transformation by









Factors favouring early initiation of OAC:
Low NIHSS (<8):
Small/no brain infarction on imaging
High recurrence risk, e.g. cardiac thrombus on echo
No need for percutaneous endoscopic gastrostomy




Blood pressure is controlled
Factors favouring delayed initiation of OAC:
Large/moderate brain infarction on imaging







Patient with atrial fibrillation and acute TIA or ischaemic stroke
Exclusion of intracerebral bleeding by CT or MRI




Figure 9 Initiation or continuation of anticoagulation in atrial fibrillation patients after a stroke or transient ischaemic attack. This approach is
based on consensus rather than prospective data.
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after an intracranial haemorrhage. We recommend a multidisciplinary
decision with input from stroke physicians/neurologists, cardiologists,
neuroradiologists, and neurosurgeons.
Recommendations for secondary stroke prevention
Recommendations Classa Levelb Ref C
Anticoagulation with heparin or LMWH 
immediately after an ischaemic stroke is 




In patients who suffer a TIA or stroke 
while on anticoagulation, adherence 
to therapy should be assessed and 
optimized.
IIa C
In patients who suffer a moderate-
to-severe ischaemic stroke while 
on anticoagulation, anticoagulation 
should be interrupted for 3–12 
days based on a multidisciplinary 
assessment of acute stroke and 
bleeding risk.
IIa C
In AF patients who suffer a stroke, 
aspirin should be considered for 
prevention of secondary stroke until 
the initiation or resumption of oral 
anticoagulation.
IIa B 485
Systemic thrombolysis with rtPA is 
not recommended if the INR is above 
1.7 (or, for patients on dabigatran, if 




NOACs are recommended in 
preference to VKAs or aspirin in AF 
patients with a previous stroke. 
I B 363,482
After TIA or stroke, combination 





After intracranial haemorrhage, oral 
anticoagulation in patients with AF 
may be reinitiated after 4–8 weeks 
provided the cause of bleeding or the 





AF ¼ atrial fibrillation; INR ¼ international normalized ratio; LMWH ¼ Low
Molecular Weight Heparin; NOAC ¼ non-vitamin K antagonist oral
anticoagulant; OAC ¼ oral anticoagulation;




9.5 Strategies to minimize bleeding on
anticoagulant therapy
In a meta-analysis of 47 studies, the overall incidence of major bleeding
with VKAs was 2.1 (range 0.9–3.4) per 100 patient-years in controlled
trials and 2.0 (range 0.2–7.6) per 100 patient-years for observational
data sets.488 Minimizing treatable bleeding risk factors (see Table 12)
seems paramount to reduce the bleeding rate on anticoagulants.
9.5.1 Uncontrolled hypertension
Uncontrolled hypertension increases the risk of bleeding on
OAC.53 Hence, keeping systolic blood pressure well controlled
is of particular relevance in anticoagulated patients with AF. Treat-
ment according to current guidelines is recommended in patients
with known hypertension.489
9.5.2 Previous bleeding event
History of bleeding events and the presence of anaemia are import-
ant parts of the assessment of all patients receiving OAC. The ma-
jority of bleeding events are gastrointestinal. Compared with
warfarin, the risk of gastrointestinal bleeds was increased for dabiga-
tran 150 mg twice daily,396,490 rivaroxaban 20 mg once daily,491 and
edoxaban 60 mg once daily.321 The risk of gastrointestinal bleeds
was comparable to warfarin on dabigatran 110 mg twice daily490
and on apixaban 5 mg twice daily.319 Recent observational analyses
do not replicate these findings, suggesting a smaller effect.396,492,493
In patients in whom the source of bleeding has been identified and
corrected, OAC can be reinitiated. This also appears true for pa-
tients who have had an intracranial haemorrhage, once modifiable
bleeding risk factors (e.g. uncontrolled hypertension) have been
corrected.460,484
9.5.3 Labile international normalized ratio and adequate
non-vitamin K antagonist oral anticoagulant dosing
TTR on VKA therapy is an important predictor of major haemor-
rhage.432,441,494 Therefore, we recommend targeting the INR be-
tween 2.0 and 3.0 in patients on VKAs, maintaining a high TTR
(e.g. ≥70%494), and to consider switching to a NOAC when a
high TTR cannot be sustained.444 NOAC dosing should follow the
dose-reduction criteria evaluated in the clinical trials, considering
renal function, age, and weight. Patient information and empower-
ment, best delivered through integrated AF management, seem
paramount to achieve this goal.
9.5.4 Alcohol abuse
Alcohol excess is a risk factor for bleeding in anticoagulated pa-
tients,384 mediated by poor adherence, liver disease, variceal bleed-
ing, and risk of major trauma. Severe alcohol abuse and binge
drinking habits should be corrected in patients eligible for OAC.
9.5.5 Falls and dementia
Falls and dementia are associated with increased mortality in AF pa-
tients,495 without evidence that these conditions markedly increase
the risk of intracranial haemorrhage.495,496 Hence, anticoagulation
should only be withheld from patients with severe uncontrolled falls
(e.g. epilepsy or advanced multisystem atrophy with backwards
falls), or in selected patients with dementia where compliance and
adherence cannot be ensured by a caregiver.
9.5.6 Genetic testing
In addition to food and drug interactions, multiple genetic variations
affect the metabolism of VKAs.497 The systematic use of genetic in-
formation for adjustment of VKA dosage has been evaluated in sev-
eral controlled clinical studies.498 – 500 Genetic testing has little effect
on TTR or bleeding risk on warfarin, and is not recommended for
clinical use at present.501
9.5.7 Bridging periods off oral anticoagulation
Most cardiovascular interventions (e.g. percutaneous coronary
intervention or pacemaker implantation) can be performed safely
on continued OAC. When interruption of OAC is required,
bridging does not seem to be beneficial, except in patients with
mechanical heart valves: In a randomized trial of 1884 patients
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with AF, interruption of anticoagulation was non-inferior to hep-
arin bridging for the outcome of arterial thrombo-embolism (inci-
dence of 0.4% and 0.3%, respectively) and resulted in a lower risk
of major bleeding (1.3% and 3.2%, respectively).502 OAC interrup-
tions should be minimized to prevent stroke.
9.6 Management of bleeding events in
anticoagulated patients with atrial
fibrillation
9.6.1 Management of minor, moderate, and severe bleeding
General assessment of an anticoagulated patient with AF experien-
cing a bleeding event should include the assessment of bleeding site,
onset, and severity of the bleeding, the time-point of last intake of
OAC and other antithrombotic drugs, and other factors influencing
bleeding risk such as CKD, alcohol abuse, and concurrent medica-
tions. Laboratory tests should include haemoglobin, haematocrit,
platelet count, renal function, and, for VKA patients, prothrombin
time, activated partial thromboplastin time, and INR. Coagulation
tests do not provide much information in patients on NOACs, ex-
cept for activated partial thromboplastin time in the case of dabiga-
tran. More specific coagulation tests do exist, including diluted
thrombin time (HEMOCLOT) for dabigatran and calibrated quanti-
tative anti-factor Xa assays for factor Xa inhibitors.503 However,
these tests are not always readily available and are often unneces-
sary for bleeding management.504
We propose a simple scheme to manage bleeding events in patients
on OAC (Figure 11). Minor bleeding events should be treated with
supportive measures such as mechanical compression or minor sur-
gery to achieve haemostasis. In patients receiving VKAs, the next dose
of VKA can be postponed. NOACs have a short plasma half-life of ap-
proximately 12 h, and improved haemostasis is expected within 12–
24 h after a delayed or omitted dose. Treatment of moderate bleeding
events may require blood transfusions and fluid replacement. Specific
diagnostic and treatment interventions directed against the cause of
the bleeding (e.g. gastroscopy) should be performed promptly. If
Consider further information to allow informed judgementContra-indication
for OAC
Initiate or resume OAC, choosing 
an agent with low intracranial bleeding risk, 







Factors supporting withholding of OAC:
Bleeding occured on adequately dosed
NOAC or in setting of treatment interruption 





Multiple microbleeds (e.g. >10)
Cause of bleed cannot be removed or treated
Chronic alcohol abuse
Need for dual antiplatelet therapy after PCI
Factors supporting reinitiation of OAC:
Bleeding occured on VKA or in setting of
  overdose




No or mild white matter lesions
Surgical removal of subdural haematoma
Subarachnoid bleed: aneurysm clipped or 
  coiled
High-risk of ischaemic stroke
Patient with AF suffering from an intracranial bleed on OAC
If acute event: establish intensity of anticoagulation (see bleeding flow chart)
Patient or next of kin choice informed
by multidisciplinary team advice
VKA = vitamin K antagonist.
Figure 10 Initiation or resumption of anticoagulation in atrial fibrillation patients after an intracranial bleed. This approach is based on consensus
opinion and retrospective data. In all patients, evaluation by a multidisciplinary panel is required before treatment (stroke physician/neurologist,
cardiologist, neuroradiologist, and neurosurgeon).
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the intake of NOAC was recent (,2–4 h), charcoal administration
and/or gastric lavage will reduce further exposure. Dialysis clears da-
bigatran but is less effective for the other NOACs.
Immediate reversal of the antithrombotic effect is indicated in se-
vere or life-threatening bleeding events. An agreed institutional
procedure for the management of life-threatening bleeds should be
documented and accessible at all times to ensure adequate initial man-
agement. For VKAs, administration of fresh frozen plasma restores co-
agulation more rapidly than vitamin K, and prothrombin complex
concentrates achieve even faster blood coagulation.505 Registry data
suggest that the combination of plasma and prothrombin complex
concentrates is associated with the lowest case fatality following intra-
cranial haemorrhage on VKA treatment with an INR ≥1.3.506 In a mul-
ticentre randomized trial of 188 patients, four-factor prothrombin
complex concentrates achieved more rapid INR reversal and effective
haemostasis than plasma in patients undergoing urgent surgical or in-
vasive procedures.507 Administration of prothrombin complex con-
centrates may also be considered for severe bleeding on NOAC
treatment if specific antidotes are not available.
Several antidotes to NOACs are under development. Idarucizumab
(approved in 2015 by the US Food and Drug Administration and the
European Medicines Agency) is a clinically available humanized anti-
body fragment that binds dabigatran and rapidly and dose-dependently
reverses its effects without over-correction or thrombin gener-
ation.475 Andexanet alpha, a modified recombinant human factor Xa
that lacks enzymatic activity, reverses the anticoagulant activity of fac-
tor Xa antagonists in healthy subjects within minutes after administra-
tion and for the duration of infusion, with a transient increase in
markers of coagulation activity of uncertain clinical relevance.508 An-
other agent under development is ciraparantag (PER977), an antidote
designed to reverse both direct thrombin and factor Xa inhibitors as
well as the indirect inhibitor enoxaparin.509 The clinical usefulness of
these specific antidotes needs further evaluation.
9.6.2 Oral anticoagulation in atrial fibrillation patients at
risk of or having a bleeding event
While anticoagulation therapy should be paused to control active
bleeding, absolute contraindications to long-term OAC after a
VKA NOAC

















Consider to add oral charcoal
if recently ingested NOAC
Consider PCC and FFP
Consider replacement of platelets
where appropriate
Consider specific antidote, or
PCC if no antidote available
Consider replacement of platelets
where appropriate
Patient with active bleeding
Compress bleeding sites mechanically
Assess haemodynamic status, blood pressure, basic coagulation
parameters, blood count, and kidney function
Obtain anticoagulation history (last NOAC / VKA dose)
FFP = fresh frozen plasma; INR = international normalized ratio; i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; PCC = 
prothrombin complex concentrates;  VKA = vitamin K antagonist.
Figure 11 Management of active bleeding in patients receiving anticoagulation. Institutions should have an agreed procedure in place.
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bleeding episode are rare. When nuisance bleeds are the reason to
stop OAC, a change from one anticoagulant to another seems rea-
sonable. Many causes or triggers of major bleeding events can be
treated and/or eliminated, including uncontrolled hypertension,
gastrointestinal ulcers, and intracranial aneurysms. Reinitiation of an-
ticoagulation after a bleeding event is often clinically justified.460,510
Difficult decisions, including the discontinuation and recommence-
ment of OAC, should be taken by a multidisciplinary team, balancing
the estimated risk of recurrent stroke and bleeding, and considering
the bleeding risk of different stroke prevention therapies. LAA ex-
clusion or occlusion might be an alternative in selected patients.
Recommendations for management of bleeding
Recommendations Classa Levelb Ref C
Blood pressure control in 
anticoagulated patients with 
hypertension should be considered 
to reduce the risk of bleeding
IIa B 511
When dabigatran is used, a reduced 
dose (110 mg twice daily) may be 
considered in patients >75 years to 
reduce the risk of bleeding.
IIb B 490
In patients at high-risk of 
gastrointestinal bleeding, a VKA or 
another NOAC preparation should 
be preferred over dabigatran 
150 mg twice daily, rivaroxaban 
20 mg once daily, or edoxaban 






Advice and treatment to avoid 
alcohol excess should be considered 
in all AF patients considered for 
OAC.
IIa C
Genetic testing before the 






Reinitiation of OAC after a bleeding 
event should be considered in all 
eligible patients by a
multidisciplinary AF team, 
considering different anticoagulants 
and stroke prevention interventions, 
improved management of factors 
that contributed to bleeding, and 
stroke risk. 
IIa B 460
In AF patients with severe active 
bleeding events, it is recommended 
to interrupt OAC therapy until the 
cause of bleeding is resolved.
I C
AF ¼ atrial fibrillation; NOAC ¼ non-vitamin K antagonist oral anticoagulant;




9.7 Combination therapy with oral
anticoagulants and antiplatelets
Approximately 15% of AF patients in contemporary trials513 and
registries514 – 516 have a history of myocardial infarction. Between
5–15% of AF patients will require stenting at some point in their
lives. This scenario requires careful consideration of antithrombotic
therapy, balancing bleeding risk, stroke risk, and risk of acute coron-
ary syndromes (ACS).516 Co-prescription of OAC with antiplatelet
therapy, in particular triple therapy, increases the absolute risk of
major haemorrhage.445,517,518 A recent meta-analysis involving 30
866 patients with a recent ACS evaluated the effects of adding
NOAC therapy to single (4135 patients) or dual (26 731 patients)
antiplatelet therapy.519 The addition of a NOAC increased the
bleeding risk by 79–134%, while reducing recurrent ischaemic events
only marginally in patients without AF. OAC monotherapy, and not
combination therapy with antiplatelets, is recommended in AF pa-
tients with stable CAD but without an ACS and/or coronary interven-
tion in the previous 12 months. In patients treated for ACS, and in
those receiving a coronary stent, short-term triple combination ther-
apy of OAC, clopidogrel, and aspirin seems warranted (Figure 12).
9.7.1 Antithrombotic therapy after acute coronary
syndromes and percutaneous coronary intervention in
patients requiring oral anticoagulation
The optimal combination antithrombotic therapy or duration of
combination therapy for AF patients undergoing percutaneous cor-
onary intervention is not known, but the continued bleeding risk
suggests a short duration. Expert consensus,520 reviewed and re-
considered by this Task Force, suggests the following principles:
AF patients at risk for stroke, patients with mechanical valves, and
patients with recent or recurrent deep vein thrombosis or pulmonary
embolism should continue OAC during and after stenting. In general, a
short period of triple therapy (OAC, aspirin, clopidogrel) is recom-
mended, followed by a period of dual therapy (OAC plus a single anti-
platelet) (Figure 13). When a NOAC is used, the consensus
recommendation is that the lowest dose effective for stroke preven-
tion in AF should be considered. Dose reduction beyond the approved
dosing tested in phase III trials (see Table 13) is not currently recom-
mended, and awaits assessment in ongoing controlled trials. The com-
bination of aspirin, clopidogrel, and low-dose rivaroxaban (2.5 mg
twice daily) is not recommended for stroke prevention in AF.521
The use of prasugrel or ticagrelor as part of triple therapy should
be avoided unless there is a clear need for these agents (e.g. stent
thrombosis on aspirin plus clopidogrel), given the lack of evidence
and the greater risk of major bleeding compared with clopido-
grel.522,523 Ongoing trials will inform about such combination ther-
apies in the future.
The omission of aspirin while maintaining clopidogrel and OAC
has been evaluated in the WOEST (What is the Optimal antiplatElet
and anticoagulant therapy in patients with oral anticoagulation and
coronary StenTing) trial, in which 573 anticoagulated patients
undergoing percutaneous coronary intervention (70% with AF)
were randomized to either dual therapy with OAC and clopidogrel
(75 mg once daily) or to triple therapy with OAC, clopidogrel, and
aspirin.524 Bleeding was lower in the dual vs. triple therapy arm, dri-
ven by fewer minor bleeding events. The rates of myocardial infarc-
tion, stroke, target vessel revascularization, and stent thrombosis
did not differ (albeit with low event numbers), but all-cause mortal-
ity was lower in the dual therapy group at 1 year (2.5% vs. triple
therapy 6.4%). Although the trial was too small to assess ischaemic
outcomes, dual therapy with OAC and clopidogrel may emerge in
the future as an alternative to triple therapy in patients with AF
and ACS and/or coronary intervention.525
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Recommendations for combination therapy with oral anticoagulants and antiplatelets
Recommendations Classa Levelb Ref C
After elective coronary stenting for stable coronary artery disease in AF patients at risk of stroke, combination triple 
therapy with aspirin, clopidogrel and an oral anticoagulant should be considered for 1 month to prevent recurrent coronary 
and cerebral ischaemic events.  
IIa B 522, 524
After an ACS with stent implantation in AF patients at risk of stroke, combination triple therapy with aspirin, clopidogrel and 
an oral anticoagulant should be considered for 1–6 months to prevent recurrent coronary and cerebral ischaemic events.  
IIa C 520
After an ACS without stent implantation in AF patients at risk of stroke, dual treatment with an oral anticoagulant and aspirin 
or clopidogrel should be considered for up to 12 months to prevent recurrent coronary and cerebral ischaemic events.
IIa C
The duration of combination antithrombotic therapy, especially triple therapy, should be kept to a limited period, balancing 
the estimated risk of recurrent coronary events and bleeding.
IIa B 520
Dual therapy with any oral anticoagulant plus clopidogrel 75 mg/day may be considered as an alternative to initial triple 
therapy in selected patients.
IIb C 524, 525




AF patient in need of OAC after an ACS
Bleeding risk low














compared to risk for ACS
or stent thrombosis






PCI = percutaneous coronary intervention.
aDual therapy with OAC and aspirin or clopidogrel may be considered in selected patients, especially those not receiving a stent or patients at a longer time from the index event. 
bOAC plus single antiplatelet. 
cDual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high risk of coronary events.
Figure 12 Antithrombotic therapy after an acute coronary syndrome in atrial fibrillation patients requiring anticoagulation.
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10. Rate control therapy in atrial
fibrillation
Rate control is an integral part of the management of AF patients,
and is often sufficient to improve AF-related symptoms. Compared
with stroke prevention and rhythm control, very little robust evi-
dence exists to inform the best type and intensity of rate control
treatment, with the majority of data derived from short-term cross-
over trials and observational studies.41,526 –528 Pharmacological rate
control can be achieved for acute or long-term rate control with
beta-blockers, digoxin, the calcium channel blockers diltiazem and
verapamil, or combination therapy (Table 15). A number of antiar-
rhythmic drugs also have rate-limiting properties (amiodarone, dro-
nedarone, sotalol, and to some extent propafenone), but they
should only be used in patients needing rhythm control therapy
(see Chapter 11).
10.1 Acute rate control
In the setting of acute new-onset AF, patients are often in need of
heart rate control. Physicians should evaluate underlying causes of
elevated heart rate, such as infection, endocrine imbalance, anaemia,
and pulmonary embolism. For acute rate control, beta-blockers and
diltiazem/verapamil are preferred over digoxin because of their
rapid onset of action and effectiveness at high sympathetic
tone.528 – 532 The choice of drug (Table 15) and target heart
rate will depend on patient characteristics, symptoms, LVEF and
haemodynamics, but a lenient initial approach to heart rate seems
acceptable. Combination therapy may be required (Figure 14). In
patients with HFrEF, beta-blockers, digitalis (digoxin or digitoxin),
or their combination should be used,218,533 as diltiazem and
verapamil can have negative inotropic effects in patients with
LVEF ,40%.222,534,535 In critically ill patients and those with
severely impaired LV systolic function, intravenous amiodarone
can be used where excess heart rate is leading to haemodynamic
instability.536 – 538 Urgent cardioversion should be considered in
unstable patients (see chapter 11.1).
10.2 Long-term pharmacological rate
control
10.2.1 Beta-blockers
Beta-adrenoreceptor blocker monotherapy is often the first-line
rate-controlling agent,539 largely based on observations of better
acute heart rate control than digoxin. Interestingly, the prognostic
benefit of beta-blockers seen in HFrEF patients with sinus rhythm
AF patient in need of OAC after elective PCI with stent
Bleeding risk low













compared to risk for ACS
or stent thrombosis







aDual therapy with OAC and aspirin or clopidogrel may be considered in selected patients. 
bOAC plus single antiplatelet. 
cDual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high risk of coronary events.
Figure 13 Antithrombotic therapy after elective percutaneous intervention in atrial fibrillation patients requiring anticoagulation.
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is lost in those with AF. In an individual patient-level meta-analysis of
RCTs, beta-blockers did not reduce all-cause mortality compared
to placebo in those with AF at baseline (HR 0.97; 95% CI 0.83–
1.14; P ¼ 0.73), whereas there was a clear benefit in patients with
sinus rhythm (HR 0.73; 95% CI 0.67–0.80; P, 0.001).23 The ana-
lysis, which included 3066 participants with HFrEF and AF, showed
consistency across all subgroups and outcomes, with no heterogen-
eity between the 10 RCTs included (I2 ¼ 0%). Despite this lack of
prognostic benefit in HFrEF, this Task Force still considers beta-
blockers as a useful first-line rate control agent across all AF
patients, based on the potential for symptomatic and functional im-
provement as a result of rate control, the lack of harm from pub-
lished studies, and the good tolerability profile across all ages in
sinus rhythm and in AF.23,540
10.2.2 Non-dihydropyridine calcium channel blockers
Verapamil or diltiazem provide reasonable rate control in AF pa-
tients.541 They should be avoided in patients with HFrEF because
of their negative inotropic effects.222,534,535 Verapamil or diltiazem
can improve arrhythmia-related symptoms,526 in comparison with
Table 15 Rate control therapy in atrial fibrillation
Therapy Acute intravenous rate 
control




Bisoprolol Not available 1.25–20 mg once daily or split. Most common reported adverse 
symptoms are lethargy, headache, 
peripheral oedema, upper 
respiratory tract symptoms, 
gastrointestinal upset and 
dizziness. Adverse effects include 
bradycardia, atrioventricular block 
and hypotension.
Bronchospasm is rare – in cases 
of asthma, recommend beta-1 
selective agents (avoid carvedilol).  
Contra-indicated in acute cardiac 
failure and a history of severe 
bronchospasm.
Carvedilol Not available 3.125–50 mg twice daily.
Metoprolol 2.5–10 mg intravenous bolus 
(repeated as required).
100–200 mg total daily dose 
(according to preparation).
Nebivolol Not available 2.5–10 mg once daily or split.
Esmolol 0.5 mg/kg intravenous bolus over 
1 min; then 0.05–0.25 mg/kg/min. 
Calcium-channel blockers
Diltiazem 15–25 mg intravenous bolus 
(repeated as required).
60 mg 3 times daily up to 
360 mg total daily dose 
(120–360 mg once daily 
Most common reported adverse 
symptoms are dizziness, malaise, 
gastrointestinal upset and 
oedema.  Adverse effects include 
bradycardia, atrioventricular block 
and hypotension (prolonged 
hypotension possible with 
verapamil).
Use with caution in combination 
with beta-blockers. Reduce dose 
with hepatic impairment and 
start with smaller dose in renal 
impairment. Contra-indicated 
in LV failure with pulmonary 
congestion or LVEF <40%.
Verapamil 2.5–10 mg intravenous bolus 
(repeated as required).
40–120 mg 3 times daily 
(120–480 mg once daily 
Cardiac glycosides
Digoxin 0.5 mg intravenous bolus 
(0.75–1.5 mg over 24 hours in 
divided doses).
0.0625–0.25 mg daily dose Most common reported adverse 
symptoms are gastrointestinal 
upset, dizziness, blurred vision, 
headache and rash. In toxic 
states (serum levels >2 ng/
mL), digoxin is proarrhythmic 
and can aggravate heart failure, 
particularly with 
co-existent hypokalaemia.
High plasma levels associated with 
increased risk of death. Check 
renal function before starting and 
adapt dose in patients with CKD. 
Contra-indicated in patients with 
accessory pathways, ventricular 
tachycardia and hypertrophic 
tract obstruction.Digitoxin 0.4–0.6 mg intravenous bolus. 0.05–0.3 mg daily dose.
Amiodarone 300 mg intravenously diluted in 
250 mL 5% dextrose over 30–60 
minutes (preferably via central 
venous cannula).b
200 mg daily Hypotension, bradycardia, nausea, 
QT prolongation, pulmonary 
toxicity, skin discolouration, 
thyroid dysfunction, corneal 
deposits and cutaneous reaction 
with extravasation.
Suggested as adjunctive therapy 
in patients where heart rate 








AF ¼ atrial fibrillation; CKD ¼ chronic kidney disease; i.v. ¼ intravenous; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction.
aA number of other beta-blockers are also available, but are not recommended as specific rate control therapy in AF. These include atenolol (25–100 mg once daily with a short
biological half-life), propranolol [non-selective, 1 mg over 1 min and repeat up to 3 mg at 2-min intervals (acute) or 10–40 mg three times daily (long-term)], or labetalol
[non-selective, 1–2 mg/min (acute)].
bIf ongoing requirement for amiodarone, follow with 900 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula.
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beta-blockers, which reduced exercise capacity and increased
B-type natriuretic peptide in one small trial of low-risk patients
with preserved LVEF.542
10.2.3 Digitalis
Cardiac glycosides such as digoxin and digitoxin have been in use for
over two centuries, although prescriptions have been declining
steadily over the past 15 years.543 In the randomized Digitalis Inves-
tigation Group (DIG) trial, digoxin had no effect on mortality com-
pared to placebo in HFrEF patients in sinus rhythm (RR 0.99; 95% CI
0.91–1.07), but reduced hospital admissions (RR 0.72; 95% CI
0.66–0.79).544,545 There have been no head-to-head RCTs of di-
goxin in AF patients.546 Observational studies have associated di-
goxin use with excess mortality in AF patients,547 – 549 but this
association is likely due to selection and prescription biases rather
than harm caused by digoxin,550– 553 particularly as digoxin is com-
monly prescribed to sicker patients.225 In a crossover mechanistic
trial of 47 patients with HFrEF and AF, there were no differences
in heart rate, blood pressure, walking distance, or LVEF between
carvedilol and digoxin, although beta-blockers did result in
higher B-type natriuretic peptide levels, combination carvedilol/
digoxin improved LVEF, and digoxin withdrawal reduced LVEF.554
Comparisons with other rate control therapies are based on small,
short-duration studies that identify no or marginal differences
in exercise capacity, quality of life, or LVEF compared to
digoxin.526,554 – 558 Lower doses of digoxin (≤250 mg once daily),
corresponding to serum digoxin levels of 0.5–0.9 ng/mL, may be
associated with better prognosis.225
10.2.4 Amiodarone
Amiodarone can be useful for rate control as a last resort. The wide
array of extracardiac adverse effects associated with amiodarone
renders it a reserve agent in patients whose heart rate cannot be
controlled with combination therapy (e.g. beta-blocker or verap-
amil/diltiazem combined with digoxin).
In summary, there is equipoise for the use of different rate control
agents in AF. The choice of beta-blocker, diltiazem/verapamil, di-
goxin, or combination therapy should be made on an individual ba-
sis, after consideration of patient characteristics and patient
Acute heart rate control of AF
LVEF <40% or signs of
congestive heart failure
Smallest dose of beta-blocker to
achieve rate control
Beta-blocker or diltiazem or
verapamil
Amiodarone is an option in patients with 
haemodynamic instability or severely 
reduced LVEF 
Initial resting heart rate target <110 bpm 
Check previous drug history to avoid
concomitant administration




choice of maintenance therapy
Consider need for anticoagulation
Add digoxin Add digoxin
Initial resting heart rate target <110 bpm Initial resting heart rate target <110 bpm 
See Table 15 for medication dosage. Digitoxin is a suitable alternative to digoxin, where available. 
LVEF ≥40%
Figure 14 Acute heart rate control in patients with atrial fibrillation.
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preference. All available therapies have the potential for adverse ef-
fects and patients should initially be treated with a low dose and up-
titrated to achieve symptom improvement. In practice, achieving a
heart rate ,110 b.p.m. will often require combination therapy
(Figure 15). The benefit of different rate control strategies on symp-
toms, quality of life, and other intermediate outcomes is under
investigation.559
10.3 Heart rate targets in atrial
fibrillation
The optimal heart rate target in AF patients is unclear. The RACE
(Rate Control Efficacy in Permanent Atrial Fibrillation) II study ran-
domized 614 patients with permanent AF to either a target heart
rate ,80 b.p.m. at rest and ,110 b.p.m. during moderate exercise,
or to a lenient heart rate target of ,110 b.p.m. There was no differ-
ence in a composite of clinical events (14.9% in the strict rate con-
trol group, 12.9% in the lenient group),560 NYHA class, or
hospitalizations.560,561 Similar results were found in a pooled ana-
lysis of the AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) and RACE trials (1091 participants), albeit
with smaller heart rate differences and without randomization.562
It is worthwhile to note that many ‘adequately rate-controlled’ pa-
tients (resting heart rate 60–100 b.p.m.) are severely symptomatic,
calling for additional management.194 Nonetheless, lenient rate
control is an acceptable initial approach, regardless of heart failure
status, unless symptoms call for stricter rate control.
10.4 Atrioventricular node ablation and
pacing
Ablation of the atrioventricular node/His bundle and implantation of
a VVI pacemaker can control ventricular rate when medications fail
to control rate and symptoms. It is a relatively simple procedure with
a low complication rate and low long-term mortality risk,563,564 es-
pecially when the pacemaker is implanted a few weeks before the AV
nodal ablation and the initial pacing rate after ablation is set at 70–90
b.p.m.565,566 The procedure does not worsen LV function567 and
may even improve LVEF in selected patients.568 – 570 In selected
HFrEF patients treated with biventricular pacing (cardiac resynchro-
nization therapy), AF can terminate,571 although such a ‘rhythm con-
trol’ effect of cardiac resynchronization therapy is likely to be small
and clearly needs confirmation.572 AV nodal ablation renders pa-
tients pacemaker-dependent for the rest of their lives, limiting AV
nodal ablation and pacing to patients whose symptoms cannot be
managed by rate-controlling medication or by reasonable rhythm
control interventions (see AF Heart Team, chapter 11.6). The
choice of pacing therapy (right ventricular or biventricular pacing
with or without an implantable defibrillator) will depend on individ-
ual patient characteristics, including LVEF.573,574
Long-term heart rate control of AF
Perform echocardiogram (IC)
Choose initial rate control therapy (IB) and combination therapy if required (IIaC)
Target initial resting heart rate <110 bpm (IIaB), avoiding bradycardia
Consider early low-dose 
combination therapy
Add therapy to achieve target heart rate or
if ongoing symptoms
Beta-blocker Digoxin Beta-blocker DigoxinDiltiazem/verapamil





See Table 15 for medication dosage. Digitoxin is a suitable alternative to digoxin, where available. 
LVEF <40% LVEF ≥40%
Figure 15 Long-term heart rate control in patients with atrial fibrillation.
ESC Guidelines 1647





11. Rhythm control therapy in
atrial fibrillation
Restoring and maintaining sinus rhythm is an integral part of AF
management. Antiarrhythmic drugs approximately double the rate
of sinus rhythm compared with placebo.580–584 Catheter ablation or
combination therapy is often effective when antiarrhythmic drugs
fail.226,585–587 Although many clinicians believe that maintaining sinus
rhythm can improve outcomes in AF patients,588 all trials that have
compared rhythm control and rate control to rate control alone
(with appropriate anticoagulation) have resulted in neutral out-
comes.41,578,579,582,589 – 593 Whether modern rhythm control
management involving catheter ablation, combination therapy, and
early therapy leads to a reduction in major cardiovascular events is
currently under investigation, e.g. in the EAST – AFNET 4 (Early
treatment of Atrial fibrillation for Stroke prevention Trial)40 and
CABANA (Catheter Ablation vs. Anti-arrhythmic Drug Therapy
for Atrial Fibrillation Trial)594 trials. For now, rhythm control therapy
is indicated to improve symptoms in AF patients who remain symp-
tomatic on adequate rate control therapy.
11.1 Acute restoration of sinus rhythm
11.1.1 Antiarrhythmic drugs for acute restoration of sinus
rhythm (‘pharmacological cardioversion’)
Antiarrhythmic drugs can restore sinus rhythm in patients with
AF (pharmacological cardioversion) as shown in small controlled
trials, meta-analyses,41,584,595,596 and in a few larger controlled
trials.597 – 605 Outside of Europe, dofetilide is available and can con-
vert recent-onset AF.606 Pharmacological cardioversion restores si-
nus rhythm in approximately 50% of patients with recent-onset AF
(Table 16).607 – 609 In the short-term, electrical cardioversion
restores sinus rhythm quicker and more effectively than pharmaco-
logical cardioversion and is associated with shorter hospitaliza-
tion.609 – 613 Pharmacological cardioversion, conversely, does not
require sedation or fasting (Figure 16).
Flecainide and propafenone are effective for pharmacological cardi-
oversion,595,602–605,614,615 but their use is restricted to patients with-
out structural heart disease. Ibutilide is an alternative where available,
but carries a risk of torsades de pointes.615 Vernakalant602–605 can
be given to patients with mild heart failure (NYHA Class I or II), includ-
ing those with ischaemic heart disease, provided they do not present
with hypotension or severe aortic stenosis.616–618 Amiodarone can
be used in patients with heart failure and in patients with ischaemic
heart disease (although patients with severe heart failure were ex-
cluded from most of the AF cardioversion trials).596 Amiodarone
also slows heart rate by 10–12 b.p.m. after 8–12 h when given intra-
venously.596 Both amiodarone and flecainide appear more effective
than sotalol in restoring sinus rhythm.600,601,619
11.1.2 ‘Pill in the pocket’ cardioversion performed by
patients
In selected patients with infrequent symptomatic episodes of parox-
ysmal AF, a single bolus of oral flecainide (200–300 mg) or propafe-
none (450–600 mg) can be self-administered by the patient at home
(‘pill in the pocket’ therapy) to restore sinus rhythm, after safety has
been established in the hospital setting.620 This approach seems mar-
ginally less effective than hospital-based cardioversion,621 but is prac-
tical and provides control and reassurance to selected patients.
11.1.3 Electrical cardioversion
Synchronized direct current electrical cardioversion quickly and ef-
fectively converts AF to sinus rhythm, and is the method of choice
in severely haemodynamically compromised patients with new-onset
AF (Figure 16).626–628 Electrical cardioversion can be performed safe-
ly in sedated patients treated with intravenous midazolam and/or pro-
pofol. Continuous monitoring of blood pressure and oximetry during
the procedure is important.629 Skin burns may occasionally be ob-
served. Intravenous atropine or isoproterenol, or temporary transcu-
taneous pacing, should be available to mitigate post-cardioversion
bradycardia. Biphasic defibrillators are more effective than
Recommendations for rate control
Recommendations Classa Levelb Ref C
Beta-blockers, digoxin, diltiazem, 
or verapamil are recommended to 







Beta-blockers and/or digoxin are 
recommended to control heart rate 






Combination therapy comprising 
different rate controlling agents 
should be considered if a single agent 





In patients with haemodynamic 
instability or severely depressed
LVEF, amiodarone may be considered 
for acute control of heart rate.
Ilb B 536 –538
In patients with permanent AF (i.e. 
where no attempt to restore sinus 
rhythm is planned), antiarrhythmic 







A resting heart rate of <110 bpm 
(i.e. lenient rate control) should be 
considered as the initial heart rate 
target for rate control therapy.  
IIa B 560
Rhythm rather than rate control 
strategies should be considered as 
the preferred management in pre-
excited AF and AF during pregnancy.
IIa C
Atrioventricular node ablation 
should be considered to control 
heart rate in patients unresponsive 
or intolerant to intensive rate and 
rhythm control therapy, accepting 





AF ¼ atrial fibrillation; bpm ¼ beats per minute; LVEF ¼ left ventricular ejection
fraction.
Digitoxin is a suitable alternative to digoxin, where available. In patients with heart
failure with reduced ejection fraction (LVEF ,40%), recommended beta-blockers










monophasic waveforms, and have become the industry stand-
ard.626,628 Anterior–posterior electrode positions generate a stron-
ger shock field in the left atrium than anterolaterally positioned
electrodes, and restore sinus rhythm more effectively.626,627,630
Pre-treatment with amiodarone (requiring a few weeks of ther-
apy),631,632 sotalol,631 ibutilide,633 or vernakalant634 can improve
the efficacy of electrical cardioversion, and similar effects are likely
for flecainide584 and propafenone.635 Beta-blockers,636 verapamil,
diltiazem,637 – 639 and digoxin640,641 do not reliably terminate AF
or facilitate electrical cardioversion. When antiarrhythmic drug
therapy is planned to maintain sinus rhythm after cardioversion, it
seems prudent to start therapy 1–3 days before cardioversion
(amiodarone: a few weeks) to promote pharmacological conversion
and to achieve effective drug levels.584,601
11.1.4 Anticoagulation in patients undergoing
cardioversion
Cardioversion carries an inherent risk of stroke in non-anticoagulated
patients,642 which is reduced substantially by the administration of an-
ticoagulation.643 Immediate initiation of anticoagulation is important
in all patients scheduled for cardioversion.644 – 646 Patients who
have been in AF for longer than 48 h should start OAC at least 3
weeks before cardioversion and continue it for 4 weeks afterwards
(in patients without a need for long-term anticoagulation). OAC
should be continued indefinitely in patients at risk of stroke. This prac-
tice has never been evaluated in controlled trials, but seemed safe in a
large observational data set from Finland.647 When early cardiover-
sion is desired, TOE can exclude the majority of left atrial thrombi,
allowing immediate cardioversion.648,649 Ongoing studies will inform
about the safety and efficacy of newly initiated anticoagulation using
NOACs in patients scheduled for cardioversion.
11.2 Long-term antiarrhythmic drug
therapy
The aim of antiarrhythmic drug therapy is improvement in
AF-related symptoms.41,580 Hence, the decision to initiate long-
term antiarrhythmic drug therapy needs to balance symptom bur-
den, possible adverse drug reactions, and patient preferences. The
principles of antiarrhythmic drug therapy outlined in the 2010
ESC AF guidelines369 are still relevant and should be observed:
(1) Treatment is aimed at reducing AF-related symptoms;
(2) Efficacy of antiarrhythmic drugs to maintain sinus rhythm is modest;
(3) Clinically successful antiarrhythmic drug therapy may reduce ra-
ther than eliminate the recurrence of AF;
(4) If one antiarrhythmic drug ‘fails’, a clinically acceptable response
may be achieved with another agent;
(5) Drug-induced pro-arrhythmia or extracardiac side-effects are
frequent;
(6) Safety rather than efficacy considerations should primarily guide
the choice of antiarrhythmic drug.
Antiarrhythmic drug therapy approximately doubles sinus rhythm
maintenance compared with no therapy.580 There is no appreciable
effect on mortality or cardiovascular complications, but rhythm
control therapy can slightly increase the risk of hospitalizations (of-
ten for AF).41,578,579,582,589 – 593 To reduce the risk of side-
effects,201,580 a shorter duration of antiarrhythmic drug therapy
seems desirable. As an example, short-term treatment (4 weeks)
with flecainide for 4 weeks after cardioversion of AF was well-
tolerated and prevented most (80%) AF recurrences when com-
pared with long-term treatment.584 Short-term antiarrhythmic
drug therapy is also used to avoid early AF recurrences after
Table 16 Antiarrhythmic drugs for pharmacological cardioversion





over 10 min 
N/A 595, 598
Amiodarone IVa 5–7 mg/kg 
over 1–2 hours
50 mg/hour to a maximum 
of 1.0 g over 24 hours
Phlebitis, hypotension, bradycardia/AV block.  Will slow ventricular rate.
Avoid in patients with IHD and/or significant structural heart disease.
Hypotension, atrial flutter with 1:1 conduction, QT prolongation.








Avoid in patients with IHD and/or significant structural heart disease.
Hypotension, atrial flutter with 1:1 conduction, QRS prolongation 622, 625
Ibutilideb IV 1 mg over 
10 min
1 mg over 10 min after 
waiting for 10 min
QT prolongation, polymorphic ventricular tachycardia/torsades de 
pointes (3–4% of patients). Will slow ventricular rate. 
Avoid in patients with QT prolongation, hypokalemia, severe LVH or 
low ejection fraction.
614, 615
Vernakalant IV 3 mg/kg over 
10 min
2 mg/kg over 10 min after 
waiting for 15 min
Hypotension, non-sustained ventricular arrhythmias, QT and QRS 
prolongation.  
Avoid in patients with SBP <100 mmHg, recent (<30 days) ACS, 
NYHA Class III and IV heart failure, QT interval prolongation 
(uncorrected QT >440 ms) and severe aortic stenosis.
602–605, 
618
ACS ¼ acute coronary syndromes; AV ¼ atrio-ventricular; IHD ¼ ischaemic heart disease; i.v. ¼ intravenous; LVH ¼ left ventricular hypertrophy; NYHA ¼ New York Heart
Association; SBP ¼ systolic blood pressure.
aUse a large peripheral vessel and change to oral amiodarone within 24 h of i.v. (central line) administration.
bIbutilide is only available in selected European countries.
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catheter ablation,650 and may be reasonable in patients deemed at
increased risk of antiarrhythmic drug side-effects or in those with
a low perceived risk of recurrent AF.
In addition to antiarrhythmic drug therapy and catheter ablation
(see Chapter 11.3), management of concomitant cardiovascular
conditions can reduce symptom burden in AF and facilitate the
maintenance of sinus rhythm.203,204,296,312 This includes weight re-
duction, blood pressure control, heart failure treatment, increasing
cardiorespiratory fitness, and other measures (see Chapter 7).
11.2.1 Selection of antiarrhythmic drugs for long-term
therapy: safety first!
Usually, the safety of antiarrhythmic drug therapy determines the
initial choice of antiarrhythmic drugs (Figure 17). The following ma-
jor antiarrhythmic drugs are available to prevent AF:
11.2.1.1 Amiodarone
Amiodarone is an effective multichannel blocker, reduces ven-
tricular rate, and is safe in patients with heart failure.582,651 Torsades
de pointes pro-arrhythmia can occur, and QT interval and TU waves
should be monitored on therapy (see Table 17).652 Amiodarone of-
ten causes extracardiac side-effects, especially on long-term ther-
apy,653,654 rendering it a second-line treatment in patients who
are suitable for other antiarrhythmic drugs. Amiodarone appears
less suitable to episodic short-term therapy (unless after catheter
ablation),655 probably because of its long biological half-life.
11.2.1.2 Dronedarone
Dronedarone maintains sinus rhythm, reduces ventricular rate, and
preventscardiovascularhospitalizations(mostlyduetoAF)andcardio-
vascular death in patients with paroxysmal or persistent AF or flutter
who had at least one relevant cardiovascular comorbidity.583,588,656
Dronedarone increases mortality in patients with recently decompen-
satedheart failure(withorwithoutAF),657and inpatientswithperman-
ent AF in whom sinus rhythm is not restored.658 Dronedarone
moderately increases serum creatinine, reflecting a reduction in cre-
atinine excretion rather than a decline in kidney function.659
11.2.1.3 Flecainide and propafenone
Flecainide and propafenone are effective in preventing recurrent
AF.581,584,620 They should only be used in patients without significant
ischaemic heart disease or heart failure to avoid the risk of life-
threatening ventricular arrhythmias.660 High ventricular rates result-
ing from the conversion of AF into atrial flutter with 1:1 conduction
by flecainide or propafenone can be prevented by pre-administering
a beta-blocker, verapamil, or diltiazem.
11.2.1.4 Quinidine and disopyramide
Quinidineanddisopyramidehavebeenassociatedwith an increase in






































fraction; LVH = left ventricular hypertrophy.
aIbutilide should not be used in patients with long QT interval.
Figure 16 Rhythm control management of recent onset atrial fibrillation.
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tricular arrhythmias (torsades de pointes).580,661 Although this
pro-arrhythmic effect is more common at higher doses, they are less
commonly used for rhythm control in AF. Disopyramide may be useful
in ‘vagally mediated’ AF (e.g. AF occurring in athletes and/or during
sleep76), and has been shown to reduce LV outflow gradient and im-
prove symptoms inpatientswithhypertrophic cardiomyopathy.662–664
11.2.1.5 Sotalol
Sotalol has a relevant risk of torsades de pointes [1% in the Pre-
vention of Atrial Fibrillation After Cardioversion (PAFAC) trial118].
Its d-enantiomer is associated with increased mortality compared to
placebo in patients with LV dysfunction after a myocardial infarc-
tion,665 probably due to ventricular arrhythmias (OR 2.47; 95% CI
1.2–5.05; number needed to harm 166; 95% CI 61–1159).580,665
On the other hand, d,l-sotalol has been used in AF patients without
safety signals in two controlled trials.581,601
11.2.1.6 Dofetilide
Dofetilide is another potassium channel blocker that is mainly
available outside of Europe. Dofetilide restores and maintains sinus
rhythm in heart failure patients,666 and occasionally in patients re-
fractory to other antiarrhythmic drugs.667
Overall, it seems prudent to limit the use of quinidine, disopyra-
mide, dofetilide, and sotalol to specific situations. Furthermore,
combinations of QT-prolonging antiarrhythmic drugs should gener-
ally be avoided for rhythm control in AF (Table 17).
11.2.2 The twelve-lead electrocardiogram as a tool to
identify patients at risk of pro-arrhythmia
Identifying patients at risk of pro-arrhythmia can help to mitigate the
pro-arrhythmic risk of antiarrhythmic drugs.668 In addition to the clinical
characteristics mentioned above, monitoring PR, QT, and QRS dura-
tions during initiation of antiarrhythmic drug therapy can identify pa-
tients at higher risk of drug-induced pro-arrhythmia on longer-term
treatment.669–671 In addition, the presence of ‘abnormal TU waves’ is
a sign of imminent torsades de pointes.652 Periodic ECG analysis for
pro-arrhythmia signs has been used successfully in recent antiarrhyth-
mic drug trials.118,584,672 Specifically, ECG monitoring was used system-
atically on days 1–3 in patients receiving flecainide, propafenone, or
sotalol to identify those at risk of pro-arrhythmia.118,584,601 Based on
this evaluated practice, we suggest to record an ECG in all patients
before initiation of antiarrhythmic drugs. Scheduled ECGs during the
initiation period seem reasonable (Table 17).
11.2.3 New antiarrhythmic drugs
Several compounds that inhibit the ultrarapid potassium current
(IKur) and other inhibitors of atypical ion channels are in clinical de-
velopment.673 – 675 They are not available for clinical use at present.
The antianginal compound ranolazine inhibits potassium and sodium
currents and increases glucose metabolism at the expense of free
fatty acid metabolism, thereby enhancing the efficient use of oxy-
gen.676,677 Ranolazine was safe in patients with non–ST-segment
elevation myocardial infarction and unstable angina evaluated in
the MERLIN (Metabolic Efficiency With Ranolazine for Less Ische-
mia in Non ST-Elevation Acute Coronary Syndrome) trial.678 In a
post hoc analysis of continuous ECG recordings obtained during
the first 7 days after randomization, patients assigned to ranolazine
had a trend towards fewer episodes of AF than those on placebo [75
(2.4%) vs. 55 (1.7%) patients; P ¼ 0.08].679 In the HARMONY
(A Study to Evaluate the Effect of Ranolazine and Dronedarone
When Given Alone and in Combination in Patients With
Initiation of long term rhythm control therapy to improve symptoms in AF
No or minimal signs 
for structural heart disease
Coronary artery disease, 


















Patient choice Patient choice Patient choice
aSotalol requires careful evaluation of proarrhythmic risk.
bCatheter ablation should isolate pulmonary veins and can be performed using radiofrequency or cryoballoon catheters. 
c
dAmiodarone is a second-choice therapy in many patients because of its extracardiac side-effects.
Figure 17 Initiation of long-term rhythm control therapy in symptomatic patients with atrial fibrillation.
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Paroxysmal Atrial Fibrillation) trial, the highest tested dose of a com-
bination of ranolazine (750 mg twice daily) and dronedarone
(225 mg twice daily) slightly reduced AF burden in 134 subjects
with paroxysmal AF and dual-chamber pacemakers.680 Small, open-
label studies suggest that ranolazine might enhance the antiarrhythmic
effect of amiodarone for cardioversion,681–683 whereas the results
from a controlled trial of ranolazine and the ranolazine–dronedarone
combination to prevent AHRE in pacemaker patients were ambigu-
ous.684 At present, there is insufficient evidence to recommend rano-
lazine as an antiarrhythmic drug, alone or in combination with other
antiarrhythmic drugs. Of note, the ‘funny channel blocker’ ivabradine,
which is used for angina and heart failure, increases the risk of AF.685
11.2.4 Antiarrhythmic effects of non-antiarrhythmic drugs
ACE inhibitors or ARBs appear to prevent new-onset AF in patients
with LV dysfunction and in hypertensive patients with LV hyper-
trophy.219,236,237,239,246,250,686 Neprilysin inhibition needs to be
studied further, but does not seem to enhance this effect.224 A Danish
cohort study also suggested that initial treatment of uncomplicated
hypertension with ACE inhibitors or ARBs reduces incident AF com-
pared with other hypertensive agents.245 ARB therapy did not reduce
the AF burden in patients with AF without structural heart disease.241
Thus, ACE inhibitors or ARBs are unlikely to have a relevant direct
antiarrhythmic effect. However, it might be justified to consider adding
ACE inhibitors or ARB therapy to antiarrhythmic drugs to reduce AF
recurrences after cardioversion.248,249,687
Compared with placebo, beta-blockers are associated with a re-
duced risk of new-onset AF in patients with HFrEF and sinus
rhythm.23 Beta-blockers have also been reported to reduce symp-
tomatic AF recurrences,580,636,688 but this finding may be driven
by the beneficial effect of rate control, which will render AF more
often asymptomatic.
Peri-operative statin therapy appeared to reduce the risk of post-
operative AF in a number of small RCTs689,690; however, an ad-
equately powered placebo-controlled trial has shown no effect of
peri-operative rosuvastatin therapy on post-operative AF.691 Statin
treatment does not prevent AF in other settings.692,693 Similarly,
polyunsaturated fatty acids failed to show convincing bene-
fit.241,694 – 698 The role of aldosterone antagonists in the manage-
ment of AF has not been extensively investigated in humans.
Although preliminary evidence from trials of eplerenone is encour-
aging for primary prevention,243 at present there is no robust evi-
dence to make any recommendation for the use of aldosterone
antagonists for secondary prevention of AF.699– 701
Table 17 Oral antiarrhythmic drugs used for maintaining sinus rhythm after cardioversion








Amiodarone 600 mg in divided 
doses for 
4 weeks, 400 mg 
for 4 weeks, 
then 200 mg 
once daily
Caution when using concomitant therapy with 
QT-prolonging drugs and in patients with SAN or AV node 
and conduction disease. 
The dose of  VKAs and of digitalis should be reduced. 
Increased risk of myopathy with statins.





Baseline, 1 week, 
4 weeks
Dronedarone 400 mg 
twice daily
Contra-indicated in NYHA Class III or IV or unstable heart 
failure, during concomitant therapy with QT-prolonging drugs, 
or powerful CYP3A4 inhibitors (e.g. verapamil, diltiazem, azole 
antifungal agents), and when CrCl <30 ml/min.
The dose of digitalis, beta-blockers, and of some statins should 
be reduced. 
Elevations in serum creatinine of 0.1–0.2 mg/dL are common 














Contra-indicated if CrCl <50 mg/mL, liver disease, IHD or 
reduced LV ejection fraction.
Caution in the presence of SAN or AV node or conduction 
disease.













Contra-indicated in IHD or reduced LV ejection fraction.
Caution in the presence of SAN or AV node and conduction 
disease, renal or liver impairment, and asthma.




Slight Baseline, day 1, 
day 2–3
d,l sotalol 80–160 mg 
twice daily hypertrophy, systolic heart failure, asthma, pre-existing QT 
prolongation, hypokalaemia, CrCl<50 mg/mL. 
Moderate renal dysfunction requires careful adaptation of 
dose.
QT interval 
>500 ms, QT 
prolongation by 





Baseline, day 1, 
day 2–3
and do not reflect a decline in renal function.
CYP2D6 inhibitors (e.g. fluoxetine or tricyclic
Contra-indicated in the presence of significant LV
AF ¼ atrial fibrillation; AV ¼ atrio-ventricular; bpm ¼ beats per minute; CrCl ¼ creatinine clearance; CYP2D6 ¼ cytochrome P450 2D6; CYP3A4 ¼ cytochrome P450 3A4;
ECG ¼ electrocardiogram; IHD ¼ ischaemic heart disease; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; SAN ¼ sino-
atrial node; VKA ¼ vitamin K antagonist.
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Recommendations for rhythm control therapy
Recommendations Classa Levelb Ref C
General recommendations
Rhythm control therapy is indicated for symptom improvement in patients with AF. I B
120, 586, 
601
Management of cardiovascular risk factors and avoidance of AF triggers should be pursued in patients on rhythm control 




With the exception of AF associated with haemodynamic instability, the choice between electrical and pharmacological 
cardioversion should be guided by patient and physician preferences.
IIa C
Cardioversion of AF
Electrical cardioversion of AF is recommended in patients with acute haemodynamic instability to restore cardiac output. I B
612, 
702-704
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent or 





cardioversion and prevent recurrent AF.




recommended for pharmacological cardioversion of new-onset AF.










In selected patients with recent-onset AF and no significant structural or ischaemic heart disease, a single oral dose of
flecainide or propafenone (the ‘pill in the pocket’ approach) should be considered for patient-led cardioversion, following IIa B 620, 621
In patients with ischaemic and/or structural heart disease, amiodarone is recommended for cardioversion of AF. I A 597–601
Vernakalant may be considered as an alternative to amiodarone for pharmacological conversion of AF in patients without 




Stroke prevention in patients designated for cardioversion of AF
Anticoagulation with heparin or a NOAC should be initiated as soon as possible before every cardioversion of AF or atrial 
IIa B 708, 709
cardioversion.
For cardioversion of AF/atrial flutter, effective anticoagulation is recommended for a minimum of 3 weeks before
flutter.
I B 648, 708
Transoesophageal echocardiography (TOE) is recommended to exclude cardiac thrombus as an alternative to 
preprocedural anticoagulation when early cardioversion is planned.
I B 648, 708
IIa B 648
In patients at risk for stroke, anticoagulant therapy should be continued long-term after cardioversion according to the 
Early cardioversion can be performed without TOE in patients with a definite duration of AF <48 hours.
long-term anticoagulation recommendations, irrespective of the method of cardioversion or the apparent maintenance 
of sinus rhythm. In patients without stroke risk factors, anticoagulation is recommended for 4 weeks after cardioversion.
I B 353, 710
I C
A repeat TOE to ensure thrombus resolution should be considered before cardioversion.
In patients where thrombus is identified on TOE, effective anticoagulation is recommended for at least 3 weeks.
IIa C
Anti-arrhythmic drugs for the long-term maintenance of sinus rhythm/prevention of recurrent AF
The choice of AAD needs to be carefully evaluated, taking into account the presence of comorbidities, cardiovascular risk 
and potential for serious proarrhythmia, extracardiac toxic effects, patient preferences, and symptom burden. 
I A 41, 580
patients with normal left ventricular function and without pathological left ventricular hypertrophy.  




Dronedarone is recommended for prevention of recurrent symptomatic AF in patients with stable coronary artery disease, 
and without heart failure. 
I A 583, 588
Amiodarone is recommended for prevention of recurrent symptomatic AF in patients with heart failure. I B 596–598
Amiodarone is more effective in preventing AF recurrences than other AAD, but extracardiac toxic effects are common 
and increase with time. For this reason, other AAD should be considered first.














Since the initial description of triggers in the pulmonary veins that
initiate paroxysmal AF,108 catheter ablation of AF has developed
from a specialized, experimental procedure into a common treat-
ment to prevent recurrent AF.587,715 This is primarily achieved
through isolation of the pulmonary veins, probably requiring com-
plete isolation for full effectiveness,716 and additional ablation in
the posterior left atrial wall. AF ablation, when performed in experi-
enced centres by adequately trained teams, is more effective than
antiarrhythmic drug therapy in maintaining sinus rhythm, and the
complication rate, though not negligible, is similar to the complica-
tion rate for antiarrhythmic drugs.585,717
11.3.1 Indications
Catheter ablation of AF is effective in restoring and maintaining sinus
rhythm in patients with symptomatic paroxysmal, persistent, and
probably long-standing persistent AF, in general as second-line treat-
ment after failure of or intolerance to antiarrhythmic drug therapy. In
such patients, catheter ablation is more effective than antiarrhythmic
drug therapy.185,586,713,717–720 As first-line treatment for paroxysmal
AF, randomized trials showed only modestly improved rhythm out-
come with catheter ablation compared to antiarrhythmic drug ther-
apy.585,721–723 Complication rates were similar, when ablation was
performed in expert centres, justifying catheter ablation as first-line
therapy in selected patients with paroxysmal AF who ask for interven-
tional therapy. Fewer data are available reporting the effectiveness
and safety of catheter ablation in patients with persistent or long-
standing persistent AF, but all point to lower recurrence rates after
catheter ablation compared to antiarrhythmic drug therapy with or
without cardioversion (Web Figure 2).185,717,723 – 726,1039 In patients
who experience symptomatic recurrences of AF despite antiarrhyth-
mic drug therapy, all RCTs showed better sinus rhythm maintenance
with catheter ablation than on antiarrhythmic drugs.586,713,727,728
There is no current indication for catheter ablation to prevent cardio-
vascular outcomes (or desired withdrawal of anticoagulation), or to
reduce hospitalization.40,594
11.3.2 Techniques and technologies
Complete pulmonary vein isolation (PVI) on an atrial level is the best
documented target for catheter ablation,716,729 – 731 achievable by
point-by-point radiofrequency ablation, linear lesions encircling
the pulmonary veins, or cryoballoon ablation, with similar out-
comes.732 – 734 Complete isolation of the pulmonary veins has better
rhythm outcomes than incomplete isolation.716 PVI was initially
tested in patients with paroxysmal AF, but appears to be non-
inferior to more extensive ablation in persistent AF as well.729,735
More extensive ablations have been used in patients with persistent
Recommendations for rhythm control therapy (continued)
Recommendations Class a Level b Ref C
AAD for the long-term maintenance of sinus rhythm/prevention of recurrent AF (continued)
ECG recording during the initiation of AAD therapy should be considered to monitor heart rate, detect QRS and QT 








Adding atrial-based bradycardia pacing to drug treatment that induces or exacerbates sinus node dysfunction should be 
considered to allow continuation of AAD therapy in patients in whom AF ablation is declined or not indicated.
IIa B 711, 712
Continuation of AAD therapy beyond the blanking period after AF ablation should be considered to maintain sinus rhythm 
when recurrences seem likely.
IIa B 713
Antiarrhythmic effects of non-antiarrhythmic drugs












Pre-treatment with ACE-Is or ARBs may be considered in patients with recurrent AF undergoing electrical cardioversion 




ACE-Is or ARBs are not recommended for the secondary prevention of paroxysmal AF in patients with little or no 
underlying heart disease.
III 
(no B 241, 697
AAD therapy is not recommended in patients with prolonged QT interval (>0.5 s) or those with significant sinoatrial
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial fibrillation; ARB ¼ angiotensin receptor blocker; CHA2DS2-VASc ¼ Congestive Heart failure, hypertension, Age ≥75
(doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); ECG ¼ electrocardiogram; LV ¼ left ventricular; LVH ¼ left ventricular hypertrophy;










AF, but there are insufficient data to guide the use of these at pre-
sent.117,718,719,735 – 737 Extended ablation procedures (beyond PVI)
consistently require longer procedures and more ionizing radiation,
potentially creating risk for patients. Left atrial macro re-entrant
tachycardia is relatively uncommon after PVI (≈5%). It also seems
rare after cryoballoon ablation,734 but may occur in up to 25% of pa-
tients after left atrial substrate modification ablation, often due to in-
complete ablation lines. Thus, for patients with persistent AF, ablation
of complex fractionated electrograms, ablation of rotors, or routine
deployment of linear lesions or other additional ablations does not
seem justified in the first procedure.735,738,739 However, additional
ablation on top of complete PVI716 may be considered in patients
with recurrent AF after the initial ablation procedure.719,740,741 In pa-
tients with documented right atrial isthmus-dependent flutter under-
going AF ablation, right atrial isthmus ablation is recommended.
Adenosine testing to identify patients in need of additional ablation
remains controversial after evaluation in several reports.739,742– 744
Ablation of so-called ‘rotors’, guided by body surface mapping or
endocardial mapping, is under evaluation and cannot be recom-
mended for routine clinical use at present.
11.3.3 Outcome and complications
11.3.3.1 Outcome of catheter ablation for atrial fibrillation
The rhythm outcome after catheter ablation of AF is difficult to
predict in individual patients.173,227,713,728 Most patients require
more than one procedure to achieve symptom control.713,726,728
In general, better rhythm outcome and lower procedure-related
complications can be expected in younger patients with a short his-
tory of AF and frequent, short AF episodes in the absence of signifi-
cant structural heart disease.745 Catheter ablation is more effective
than antiarrhythmic drug therapy in maintaining sinus rhythm (Web
Figure 2).746,1039 Sinus rhythm without severely symptomatic recur-
rences of AF is found in up to 70% of patients with paroxysmal AF,
and around 50% in persistent AF.713,728,735 Very late recurrence of
AF after years of sinus rhythm is not uncommon and may reflect dis-
ease progression, with important implications for continuation of AF
therapies.728 Multiple variables have been identified as risk factors for
recurrence after catheter ablation of AF, but their predictive power is
weak. The decision for catheter ablation, thus, should be based on a
shared decision-making process747 (see Chapter 8), following thor-
ough explanation of the potential benefits and risks, and of the alter-
natives such as antiarrhythmic drugs or acceptance of the current
symptoms without rhythm control therapy.175
11.3.3.2 Complications of catheter ablation for atrial fibrillation
There is a clear need to systematically capture complications in
clinical practice to improve the quality of AF ablation procedures.175
The median length of hospital stay in AF patients undergoing their
first ablation as part of the EURObservational Research Programme
(EORP) was 3 days (interquartile range 2–4 days), based on data
from 1391 patients from hospitals performing at least 50 ablations
per year. Five to seven per cent of patients will suffer severe com-
plications after catheter ablation of AF, and 2–3% will experience
life-threatening but usually manageable complications.727,748– 750 In-
traprocedural death has been reported, but is rare (,0.2%).751 The
most important severe complications are stroke/TIA (,1%), cardiac
tamponade (1–2%), pulmonary vein stenosis, and severe
oesophageal injury leading to atrio-oesophageal fistula weeks after
ablation (Table 18). ‘Silent strokes’ (i.e. white matter lesions detect-
able by brain MRI) have been observed in around 10% of patients
treated with radiofrequency and cryoballoon ablation.752 The clinical
relevance of this observation is unclear.749 Post-procedural complica-
tions include stroke, with the highest risk within the first week,753 late
pericardial tamponade several days after catheter ablation,751 and oe-
sophageal fistulas, which usually become apparent 7–30 days after
ablation. Timely detection of atrio-oesophageal fistulas can be life-
saving and should be based on the typical triad of infection without
a clear focus, retrosternal pain, and stroke or TIA.748
11.3.4 Anticoagulation: before, during, and after ablation
Patients anticoagulated with VKAs should continue therapy during
ablation (with an INR of 2–3).760 Anticoagulation with NOACs is
an alternative to warfarin.478,761 –765 There is no safety signal from
observational cohorts treated with uninterrupted NOAC therapy
undergoing catheter ablation in experienced centres.761,763,766,767
The first controlled trial comparing continuous NOAC and VKA
therapy in AF ablation patients, enrolling around 200 patients, has
recently been published,768 as well as several observational data
sets.761,769,770 Ongoing studies compare uninterrupted VKA with
NOAC therapy in AF patients undergoing ablation [e.g. AXAFA –
AFNET 5 (Anticoagulation using the direct factor Xa inhibitor
apixaban during Atrial Fibrillation catheter Ablation: Comparison
to vitamin K antagonist therapy; NCT02227550) and RE-CIRCUIT
(Randomized Evaluation of dabigatran etexilate Compared to war-
farin in pulmonaRy vein ablation: assessment of different peri-
proCedUral anticoagulation sTrategies; NCT02348723)]. During















Severe complications Pulmonary vein stenosis <1%
Persistent phrenic nerve palsy 1–2%
Vascular complications 2–4%
Other severe complications ≈1%







TIA ¼ transient ischaemic attack.
aOesophageal fistula should be suspected in patients presenting with the triad of
unspecific signs of infection, chest pain, and stroke or TIA in the first weeks after an
ablation procedure. It requires immediate therapy.
b,10% for cryoablation or radiofrequency ablation, .20% for phased
radiofrequency ablation.
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ablation, heparin should be given to maintain an activated clotting
time .300 s. Anticoagulation should be maintained for at least 8
weeks after ablation for all patients. The true incidence of thrombo-
embolic events after catheter ablation has never been systematically
studied and the expected stroke risk has been adopted from non-
ablation AF cohorts. Although observational studies suggest a rela-
tively low stroke rate in the first few years after catheter ablation of
AF,737,771 –776 the long-term risk of recurrent AF and the safety pro-
file of anticoagulation in ablated patients need to be considered. In
the absence of controlled trial data, OAC after catheter ablation
should follow general anticoagulation recommendations, regardless
of the presumed rhythm outcome.
11.3.5 Ablation of atrial fibrillation in heart failure patients
Catheter ablation, compared with amiodarone therapy, significantly
reduces recurrent AF in AF patients with HFrEF.777 Selected
patients with HFrEF and AF can achieve recovery of LV systolic func-
tion after catheter ablation (probably reflecting tachycardiomyopa-
thy). Several smaller trials suggest improved LV function after
catheter ablation in HFrEF patients185,226 – 228,778,779 and reduced
hospitalizations,720,777 especially in patients without a previous myo-
cardial infarction.780 Larger trials are warranted to confirm these
findings. Catheter ablation can be demanding in these patients.
Thus, indications for catheter ablation in HFrEF patients should be
carefully balanced, and the procedures performed in experienced
centres.
11.3.6 Follow-up after catheter ablation
Patients and physicians involved in the follow-up after catheter abla-
tion should know the signs and symptoms of late complications to al-
low swift referral for treatment (Table 18). Patients should also be
aware that symptomatic and asymptomatic AF recurrences are fre-
quent after catheter ablation.119,781,782 In line with the primary goal
of rhythm control therapy, asymptomatic episodes should generally
not trigger further rhythm control therapy in routine care. Patients
should be seen at least once by a rhythm specialist in the first 12
months after ablation. Further rhythm control options should be con-
sidered in patients with symptomatic recurrences, including discus-
sion in a Heart Team (Figure 17, Figure 19).
11.4 Atrial fibrillation surgery
11.4.1 Concomitant atrial fibrillation surgery
The Cox maze procedure was first performed 30 years ago as a
‘cut-and-sew’ technique, including isolation of the posterior left at-
rium, a connection to the posterior mitral annulus, a cavotricuspid
connection, a cavocaval connection, and exclusion of the LAA
Figure 18 A: Surgical lesion sets for the biatrial Cox maze procedure. Surgeon’s view showing left atrial lesions (left panel) and right atrial le-
sions (middle and right panel). B: Left atrial lesions in a thoracoscopic minimally invasive surgical procedure (dashed lines), including left atrial
appendage exclusion (double line).
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(Figure 18).783 Thereby, the Cox maze procedure creates an electrical
labyrinth (maze) of passages through which the sinoatrial node im-
pulse finds a route to the atrioventricular node while preventing fibril-
latory conduction. The Cox maze procedure and other, often
simpler, forms of AF surgery have mainly been used in patients under-
going other open heart surgical procedures.461,466,784–798 In a system-
atic review commissioned for these guidelines, performing
concomitant AF surgery resulted in increased freedom from AF, atrial
flutter, and atrial tachycardia compared to no concomitant AF sur-
gery (RR 1.94; 95% CI 1.51–2.49; n ¼ 554 from seven RCTs) (Web
Figure 3).1040 Patients undergoing the Cox maze procedure required
pacemaker implantation more often (RR 1.69; 95% CI 1.12–2.54; n ¼
1631 from 17 RCTs), without a detectable difference in other out-
comes or complications. These findings are underpinned by an ana-
lysis of the Society of Thoracic Surgeons database comprising 67
389 patients in AF undergoing open heart surgery: mortality or major
morbidity was not affected by concomitant AF surgery (adjusted OR
1.00; 95% CI 0.83–1.20), but pacemaker implantation was more fre-
quent (adjusted OR 1.26; 95% CI 1.07–1.49).799 Predictors of AF re-
currence after surgery include left atrial dilatation, older age,
.10-year history of AF, and non-paroxysmal AF.800–804 Regarding
AF type, surgical PVI seems effective in paroxysmal AF.805 Biatrial le-
sion patterns may be more effective in persistent and long-standing
persistent AF.797,803,806 The suggested management of patients with
AF-related symptoms undergoing cardiac surgery is displayed in Fig-
ure 19, with an important contribution of the AF Heart Team to ad-
vise and inform patient choice.
11.4.2 Stand-alone rhythm control surgery
Current technology (e.g. bipolar radiofrequency or cryothermy)
renders the Cox maze procedurec easier, and more reproducible
and feasible, via a mini-thoracotomy.786,807,808 Thoracoscopic PVI
with bipolar radiofrequency prevents recurrence of paroxysmal
AF (69–91% freedom from arrhythmias at 1 year, see Figure 18B
for lesion set),468,809,810 and seems effective in patients refractory
to catheter ablation.811 The average length of hospital stay for thor-
acoscopic ablation varies from 3.6 to 6.0 days.468,812,813 The FAST
(Atrial Fibrillation Catheter Ablation vs. Surgical Ablation Treat-
ment) trial,468 and another smaller trial,814 suggested that thoraco-
scopic AF surgery could be more effective than catheter ablation for
the maintenance of sinus rhythm,468,814 while also causing more
complications (Table 19).815 To improve results,468,816 – 818 more
extensive lesion sets have been performed, including connecting
lines between the PVI (“box lesion”) and lines towards the mitral an-
nulus.812,819 – 822 To improve the generation of transmural le-
sions,716 endo-epicardial ablation strategies have recently been
proposed.812,823 – 825 Although preliminary experience with hybrid
Rhythm control therapy 





Patient choice informed by AF Heart Team
Consider to add surgical LAA exclusion in selected patients (IIbC)b
aAF surgery may be PVI in paroxysmal AF and biatrial maze in persistent or long-standing persistent AF. 
bOral anticoagulation should be continued in patients at risk of stroke irrespective of AF surgery or LAA exclusion.
AF patient undergoing open heart surgery (e.g. CABG, valve surgery)
Figure 19 Surgical rhythm control in patients with atrial fibrillation undergoing cardiac surgery.
Table 19 Complications of thoracoscopic atrial
fibrillation surgery
Complication Rate 468, 815, 822, 826
Conversion to sternotomy 0–1.6%
Pacemaker implantation 0–3.3%
Drainage for pneumothorax 0–3.3%
Pericardial tamponade 0–6.0%
Transient ischaemic attacka 0–3.0%
aThe rate of asymptomatic cerebral embolism is unknown.
ESC Guidelines 1657





simultaneous ablation shows promise, procedural time and rates of
bleeding complications are higher.812,823
11.5 Choice of rhythm control following
treatment failure
There is insufficient evidence to underpin clear recommendations on
how to treat patients with recurrent AF after catheter ablation. Early
recurrences of AF or atrial tachycardias after ablation (occurring with-
in 8 weeks) may be treated with cardioversion. Many of the published
series of patients undergoing AF ablation included those who failed
antiarrhythmic drug therapy. Thus, considering ablation therapy in pa-
tients who have symptomatic recurrences on antiarrhythmic drug
therapy is often reasonable. Alternatively, trialling another antiar-
rhythmic drug can be considered. Combining an antiarrhythmic
drug with ablation (‘hybrid therapy’, see Chapter 12) should be con-
sidered based on the different and possibly synergistic effects of these
drugs with AF ablation, possibly benefitting patients in whom either
treatment alone was previously ineffective. Rate control without
rhythm control, surgical ablation, or repeat catheter ablation should
be considered as well (Figure 20). Patient preferences and local access
to therapy are important considerations to inform the therapy choice
in patients who are in need of further rhythm control therapy after an
initial therapy failure.
11.6 The Atrial Fibrillation Heart Team
In view of the complexity of the different treatment options in patients
with failed rhythm control therapy who still require or demand further
rhythm control therapy, this Task Force proposes that decisions in-
volving AF surgery or extensive AF ablation should be based on advice
from an AF Heart Team. This will also apply to reversal to a rate con-
trol strategy in patients with severe (EHRA III or IV) AF symptoms. An
AF Heart Team should consist of a cardiologist with expertise in anti-
arrhythmic drug therapy, an interventional electrophysiologist, and a
cardiac surgeon with expertise in appropriate patient selection, tech-
niques, and technologies for interventional or surgical AF ablation (Fig-
ure 20). Such AF Heart Teams—and a collaborative infrastructure
supporting a continued interaction between physicians delivering con-
tinued care, AF cardiologists, interventional electrophysiologists, and
AF surgeons—should be established to provide optimal advice, and ul-
timately to improve rhythm outcomes for patients in need of advanced
and complex rhythm control interventions.






















Patient choice Patient choice
Patient choice informed by AF Heart Team
Rate control (IB)AF surgery (IIaC)b Hybrid therapy (IIaC)c
Patient choice
acatheter ablation should target PVI. IA for paroxysmal AF, IIaB for persistent and long-standing persistent AF. 
bAF surgery may be PVI (e.g. in paroxysmal AF) or maze surgery (e.g. in therapy-refractory or persistent and long-standing persistent AF). 
cHybrid therapy involves combination of antiarrhythmic drugs, catheter ablation, and/or AF surgery.
Figure 20 Choice of rhythm control therapy following treatment failure.
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12. Hybrid rhythm control therapy
AF has many different drivers, which are only partially targeted by
antiarrhythmic drugs or catheter ablation.96 Hence, combination
or ‘hybrid’ rhythm control therapy seems reasonable, although
there is little evidence from controlled trials supporting its use.
12.1 Combining antiarrhythmic drugs
and catheter ablation
Antiarrhythmic drug therapy is commonly given for 8–12 weeks
after ablation to reduce early recurrences of AF after catheter abla-
tion, supported by a recent controlled trial where amiodarone
halved early AF recurrences compared with placebo.650 Prospective
studies have not been done, but a meta-analysis of the available
(weak) evidence suggests slightly better prevention of recurrent AF
in patients treated with antiarrhythmic drugs after catheter ablation.713
Many patients are treated with antiarrhythmic drug therapy after cath-
eter ablation (most often amiodarone or flecainide),587 and this seems
a reasonable option in patients with recurrent AF after ablation. It
seems common sense to consider antiarrhythmic drug therapy in pa-
tients who are in need of further rhythm control therapy after catheter
ablation, but controlled trials to confirm this are desirable.
Combining cavotricuspid isthmus ablation and antiarrhythmic
drugs may lead to improved rhythm control without the need for
left atrial ablation in patients who develop ‘drug-induced atrial flut-
ter’ on therapy with flecainide, propafenone, or amiodarone,834–836 al-
though recurrent AF is a concern in the long-term.837,838
Recommendations for catheter ablation of atrial fibrillation and atrial fibrillation surgery
Recommendations Classa Levelb Ref C
Catheter ablation of symptomatic paroxysmal AF is recommended to improve AF symptoms in patients who have 
sotalol) and who prefer further rhythm control therapy, when performed by an electrophysiologist who has received 
symptomatic recurrences of AF on antiarrhythmic drug therapy (amiodarone, dronedarone, flecainide, propafenone,




documented or occurring during the AF ablation.
Ablation of common atrial flutter should be considered to prevent recurrent flutter as part of an AF ablation procedure if
IIa B 827
selected patients with symptomatic paroxysmal AF as an alternative to antiarrhythmic drug therapy, considering patient 
choice, benefit, and risk.
Catheter ablation of AF should be considered as first-line therapy to prevent recurrent AF and to improve symptoms in
IIa B 585
All patients should receive oral anticoagulation for at least 8 weeks after catheter (IIaB) or surgical (IIaC) ablation. IIa B C 727
ablation of AF in patients at high-risk of stroke.
Anticoagulation for stroke prevention should be continued indefinitely after apparently successful catheter or surgical
IIa C
When catheter ablation of AF is planned, continuation of oral anticoagulation with a VKA (IIaB) or NOAC (IIaC) should be
considered during the procedure, maintaining effective anticoagulation.
IIa B C 760, 768






AF ablation should be considered in symptomatic patients with AF and heart failure with reduced ejection fraction to 







AF ablation should be considered as a strategy to avoid pacemaker implantation in patients with AF-related bradycardia. IIa C 829, 830
Catheter or surgical ablation should be considered in patients with symptomatic persistent or long-standing persistent AF 
Team.




Minimally invasive surgery with epicardial pulmonary vein isolation should be considered in patients with symptomatic AF 




Maze surgery, possibly via a minimally invasive approach, performed by an adequately trained operator in an experienced 
centre, should be considered by an AF Heart Team as a treatment option for patients with symptomatic refractory 
persistent AF or post-ablation AF to improve symptoms.
IIa C 808, 832
Maze surgery, preferably biatrial, should be considered in patients undergoing cardiac surgery to improve symptoms 




















12.2 Combining antiarrhythmic drugs
and pacemakers
In selected patients with sick sinus syndrome and fast ventricular re-
sponse during AF paroxysms requiring rate control therapy, the add-
ition of a pacemaker not only optimizes rate control but may also help
to control rhythm.711,712 Moreover, when antiarrhythmic drug treat-
ment leads to sinus node dysfunction and bradycardia, pacing may per-
mit uptitration of the antiarrhythmic drug dose. Such strategies have
never been prospectively investigated and the existing populations
studied are highly selected.839,840 Some patients with AF-induced
bradycardia may benefit from catheter ablation of AF, obviating the
need for antiarrhythmic drugs and pacemaker implantation.829,830
13. Specific situations
13.1 Frail and ‘elderly’ patients
Many AF patients present at older age (e.g..75 or.80 years). There
are no studies suggesting that cardiovascular risk reduction is less ef-
fective in these ‘elderly’ AF patients than in younger patients. Rather,
age is one of the strongest predictors/risk factors for ischaemic stroke
in AF.382 Good data are available to support the use of anticoagulants
in older patients from BAFTA (Birmingham Atrial Fibrillation Treat-
ment of the Aged Study),362 the NOAC trials,39 and from analyses
in elderly Americans (Medicare).396 Elderly AF patients are at higher
risk of stroke and, thus, are more likely to benefit from OAC than
younger patients,841 and yet OAC is still underutilized in the elder-
ly.220,842 Although the evidence base is smaller for other treatment
options in AF, the available data support the use of available rate
and rhythm control interventions, including pacemakers and catheter
ablation, without justification to discriminate by age group. Individual
patients at older age may present with multiple comorbidities including
dementia, a tendency to falls, CKD, anaemia, hypertension, diabetes,
and cognitive dysfunction. Such conditions may limit quality of life
more than AF-related symptoms. Impairment of renal and hepatic
function and multiple simultaneous medications make drug interac-
tions and adverse drug reactions more likely. Integrated AF manage-
ment and careful adaptation of drug dosing seem reasonable to
reduce the complications of AF therapy in such patients.843
13.2 Inherited cardiomyopathies,
channelopathies, and accessory pathways
Several inherited cardiac conditions are associated with early-onset
AF (Table 20). Treatment of the underlying cardiac condition is an
important contribution to AF management in these young patients
(see also ESC guidelines on sudden cardiac death844 and hyper-
trophic cardiomyopathy845).
13.2.1 Wolff–Parkinson–White syndrome
Patients with pre-excitation and AF are at risk of rapid conduction
across the accessory pathway, resulting in a fast ventricular rate,
possible ventricular fibrillation, and sudden death. In AF patients
with evidence of an antegrade accessory pathway, catheter ablation
of the pathway is recommended.869,870 This procedure is safe and
effective and may be considered as a prophylactic treatment strat-
egy.871,872 In AF patients surviving a sudden death event with evidence
Table 20 Inherited cardiomyopathies, channelopathies, and pathways associated with atrial fibrillation
Syndrome Gene Functional alteration AF prevalence References


































Up to 70% 853, 856–858
Catecholaminergic VT RYR2
CASQ2
Abnormal Ca2+ release from sarcoplasmic reticulum Variable but common 859–861
Hypertrophic 
cardiomyopathy








genes, unknown gene loci
Reduced mechanical cell-cell contacts >40% in patients with  
VTs
867, 868
AF ¼ atrial fibrillation; VT ¼ ventricular tachycardia.
ESC Guidelines1660





of an accessory pathway, urgent catheter ablation of the pathway is
recommended.869 A documented short pre-excited RR interval
(,250 ms) during spontaneous or induced AF is one of the risk mar-
kers for sudden death in Wolff–Parkinson–White syndrome
(WPW) syndrome, in addition to a history of symptomatic tachycar-
dia, the presence of multiple accessory pathways, and Ebstein’s anom-
aly. Intravenous procainamide, propafenone, or ajmaline can be used
to acutely slow ventricular rate,873,874 whereas digoxin, verapamil,
and diltiazem are contraindicated.875 Intravenous amiodarone should
be used with caution, as there are case reports of accelerated ven-
tricular rhythms and ventricular fibrillation in patients with pre-
excited AF receiving intravenous amiodarone infusion.876
13.2.2 Hypertrophic cardiomyopathy
AF is the most common arrhythmia in patients with hypertrophic car-
diomyopathy, affecting approximately one-quarter of this popula-
tion.877 Observational data highlight a high stroke risk in hypertrophic
cardiomyopathy patients with AF, confirming the need for OAC.878
While there ismoreexperiencewithVKAs, therearenodata tosuggest
that NOACs cannot be used in these patients.845 Studies of rate or
rhythm control medications in patients with hypertrophic cardiomyop-
athy are relatively scarce. Beta-blockers and diltiazem or verapamil
seem reasonable treatment options for rate control in these patients.
In the absence of significant LV outflow tract obstruction, digoxin can
be used alone or in combination with beta-blockers.845 Amiodarone
seems a safe antiarrhythmic drug in AF patients with hypertrophic car-
diomyopathy,879 andexpertopinion suggests thatdisopyramidemaybe
beneficial in those with outflow tract obstruction. AF ablation is
effective to suppress symptomatic AF recurrences.880 – 884 Surgical
treatment of AF may be appropriate in patients with hypertrophic car-
diomyopathy undergoing surgery (e.g. for LV outflow tract obstruction
or mitral valve surgery), but experience is limited.
13.2.3 Channelopathies and arrhythmogenic right
ventricular cardiomyopathy
Many channelopathies and inherited cardiomyopathies are associated
with AF. AF prevalence ranges from 5–20% in patients with long QT
syndrome or Brugada syndrome, and is up to 70% in short QT syn-
drome (Table 20).853,856–858 Penetrance of disease phenotype includ-
ing AF is variable.61,852,885,886 Both shortening as well as prolongation
of the atrial action potential have been demonstrated as likely me-
chanisms underlying AF in these diseases. It seems reasonable to con-
sider antiarrhythmic drugs that reverse the suspected channel defect
in AF patients with inherited cardiomyopathies (e.g. a sodium channel
blocker in LQT3852, or quinidine in Brugada syndrome887). More im-
portantly, new-onset AF in young, otherwise healthy individuals
should trigger a careful search for such inherited conditions, including
clinical history, family history, ECG phenotype, and echocardiography
and/or other cardiac imaging.
Monogenic defects only account for 3–5% of all patients with AF,
even in younger populations.846,848,888 – 890 Furthermore, there is no
clear link between detected mutations and specific outcomes or
therapeutic needs. For these reasons, genetic testing is not recom-
mended in the general AF population.77 Other guidelines have de-
scribed the indications for genetic testing in patients with
inherited arrhythmogenic diseases.844,891
Recommendations for inherited cardiomyopathies
Recommendations Classa Levelb Ref C
WPW syndrome
Catheter ablation of the accessory pathway in WPW patients with AF and rapid conduction over the accessory pathway 
is recommended to prevent sudden cardiac death.
I B 892–894
Catheter ablation of the accessory pathway is recommended without delay in WPW patients who survive sudden cardiac 
death.
I C 869
Asymptomatic patients with overt pre-excitation and AF should be considered for accessory pathway ablation after careful 
counselling.
IIa B 872, 892
Hypertrophic cardiomyopathy
Lifelong oral anticoagulation to prevent stroke is recommended in HCM patients who develop AF. I B 878
Restoration of sinus rhythm by electrical or pharmacological cardioversion to improve symptoms is recommended in 
HCM patients with symptomatic new-onset AF.
I B 845




Amiodarone should be considered to achieve rhythm control and maintain sinus rhythm in HCM patients with recurrent 
Treatment of LV outflow tract obstruction should be considered in AF patients with HCM to improve symptoms.
symptomatic AF.
IIa C 845, 897
Inherited cardiomyopathies and channelopathies 
Targeted genetic testing should be considered in patients with AF and a suspicion of inherited cardiomyopathies or 
channelopathies based on clinical history, family history or electrocardiographic phenotype.
IIa A 852










13.3 Sports and atrial fibrillation
Physical activity improves cardiovascular health, which translates
into a lower risk of AF.898 Therefore, physical activity is a corner-
stone of preventing AF. Intensive sports practice, especially endur-
ance sports (.1500 h of endurance sports practice),899 increases
the risk of AF later in life,900 – 902 probably mediated by altered auto-
nomic tone, volume load during exercise, atrial hypertrophy, and
dilatation.903,904 This results in a U-shaped relationship of physical
activity and incident AF.214,898,902,905,906 Detraining can reduce AF
in models904 and reduces ventricular arrhythmias in athletes,907
but the role of detraining for AF in human athletes is unknown.
The management of athletes with AF is similar to general AF man-
agement, but requires a few special considerations. Clinical risk fac-
tors will determine the need for anticoagulation. Sports with direct
bodily contact or prone to trauma should be avoided in patients on
OAC. Beta-blockers are not well tolerated and at times prohibited,
and digoxin, verapamil, and diltiazem are often not potent enough to
slow heart rate during exertional AF. Catheter ablation for AF prob-
ably has similar outcomes in athletes as in non-athletes,908,909 but
further data are needed. Pill-in-the-pocket therapy has been used
as well.620 After ingestion of flecainide or propafenone as
pill-in-the-pocket, patients should refrain from sports as long as
AF persists and until two half-lives of the antiarrhythmic drug
have elapsed. Prophylactic ablation of the flutter circuit may be
considered in athletes treated with sodium channel blockers.910
Recommendations for physical activity in patients with
atrial fibrillation
Recommendations Classa Levelb Ref C
Moderate regular physical activity is 
recommended to prevent AF, while 
athletes should be counselled that 
long-lasting intense sports 





AF ablation should be considered to 
prevent recurrent AF in athletes.
IIa B 908, 909
The ventricular rate while exercising 
with AF should be evaluated in 
every athlete (by symptoms and/
or by monitoring), and titrated rate 
control should be instituted.
IIa C
After ingestion of pill-in-the-pocket 
flecainide or propafenone, patients 
should refrain from sports as long as 
AF persists and until two half-lives of 
the antiarrhythmic drug have elapsed.
IIa C 620





AF in pregnant women is rare and is usually associated with pre-
existing heart disease. AF is associated with increased complications
for the mother and foetus.911,912 Better treatment of congenital
heart diseases will probably increase the incidence of AF during
pregnancy in the future.913 Pregnant women with AF should be
managed as high-risk pregnancies in close collaboration with cardi-
ologists, obstetricians, and neonatologists.
13.4.1 Rate control
Owing to a lack of specific data, beta-blockers, verapamil, diltiazem,
and digoxin all carry a US Food and Drug Administration pregnancy
safety category of C (benefits may outweigh risk), except for atenolol
(category D: positive evidence of risk). Their use should be at the low-
est dose and for the shortest time required. None of the agents are
teratogenic, but they readily cross the placenta.914 Beta-blockers are
commonly used in pregnant women with cardiovascular conditions
(e.g. for management of gestational hypertension and pre-eclampsia),
but may be associated with intrauterine growth retardation,915 and
hence growth scans after 20 weeks’ gestation are recommended. Di-
goxin is considered safe for maternal and foetal arrhythmias.916 There
are insufficient data to comment on verapamil or diltiazem, hence rate
control using beta-blockers and/or digoxin is recommended.917 With
regards to breastfeeding, all rate control agents are present in breast
milk, although levels of beta-blockers, digoxin, and verapamil are too
low to be considered harmful. Diltiazem will be present at high levels
and should be considered second-line treatment.918
13.4.2 Rhythm control
Rhythm control therapy in pregnant patients with AF has only been
reported in case studies. Amiodarone is associated with severe ad-
verse foetal side-effects and should only be considered for emer-
gency situations.919 Flecainide and sotalol can both be used for
conversion of foetal arrhythmias without major adverse effects,920
and thus are likely to be safe to treat maternal symptomatic AF. Elec-
trical cardioversion can be effective for restoration of sinus rhythm
when tachyarrhythmia is causing haemodynamic instability, with low
rates of adverse outcomes for both mother and foetus.921 However,
in view of the risk of foetal distress, electrical cardioversion should
only be carried out where facilities are available for foetal monitor-
ing and emergency caesarean section. As with other emergencies
during pregnancy, patients should receive 100% oxygen, intravenous
access should be established early, and the mother should be posi-
tioned in the left lateral position to improve venous return.922
13.4.3 Anticoagulation
VKAs should be avoided in the first trimester because of teratogenic
effects, and in the 2–4 weeks preceding delivery to avoid foetal
bleeding. Low-molecular-weight heparins are a safe substitute, as
they do not cross the placenta.923 In the third trimester, frequent
laboratory checks for adequate anticoagulation (e.g. every 10–14
days) and corresponding dose adjustments are advised, given that
in some women high doses of both VKA and heparin may be needed
to maintain adequate anticoagulation. Pregnant patients with AF and
mechanical prosthetic valves who elect to stop VKA treatment in
consultation with their specialist team between 6–12 weeks of ges-
tation, should receive continuous, dose-adjusted unfractionated
heparin or dose-adjusted subcutaneous low-molecular-weight hep-
arin. As only limited data are available about teratogenesis for
NOACs, these drugs should be avoided during pregnancy.
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Recommendations Classa Levelb Ref C
Electrical cardioversion can be 
performed safely at all stages of 
pregnancy, and is recommended in 
patients who are haemodynamically 
unstable due to AF, and whenever the 
risk of ongoing AF is considered high
for the mother or the foetus.
I C
Anticoagulation is recommended 
in pregnant patients with AF 
at risk of stroke. To minimize 
teratogenic risk and intrauterine 
bleeding, dose-adjusted heparin 
trimester of pregnancy and in the 
is recommended during the first
2–4 weeks before delivery. Vitamin 
K antagonists or heparin can be 
used in the remaining parts of the 
pregnancy.
I B 923
NOACs should be avoided in 









13.5 Post-operative atrial fibrillation
AF is common after cardiac surgery (occurring in 15–45% of pa-
tients),924 – 926 and is associated with increased length of hospital
stay and higher rates of complications and mortality.927 Post-
operative AF is also not uncommon after other major surgery,
especially in elderly patients. The treatment of post-operative AF
is mainly based on studies of patients undergoing cardiac surgery,
with much less evidence in the non-cardiac surgery setting.
13.5.1 Prevention of post-operative atrial fibrillation
Beta-blockers reduce post-operative AF and supraventricular tachy-
cardias, albeit with high heterogeneity and moderate risk of bias in a
systematic review of published studies. The most commonly studied
drug was propranolol, with AF in 16.3% of the treatment group vs.
31.7% in the control group.925 In the majority of these studies, beta-
blockers were administered post-operatively, a regimen supported
in a recent meta-analysis.928 Amiodarone reduced the incidence of
post-operative AF compared to beta-blocker therapy in several
meta-analyses, also reducing hospital stay.925,929 – 931
Despite initial reports from meta-analyses,689,932,933 pre-operative
treatment with statins did not prevent post-operative AF in a prospect-
ive controlled trial.934 Other therapies have also been studied in small,
hypothesis-generating trials, but have not demonstrated clear beneficial
effects. These include magnesium,925,935,936 n-3 polyunsaturated fatty
acids,937–945 colchicine,946 corticosteroids,947,948 and posterior peri-
cardectomy.949 Post-operative overdrive biatrial pacing has not gained
widespread use despite some suggestion of prophylactic effects.925,950
13.5.2 Anticoagulation
Post-operative AF is associated with an increased early stroke risk, in-
creased morbidity, and 30-day mortality.927,951,952 In the long-term,
patients with an episode of post-operative AF have a two-fold increase
in cardiovascular mortality, and a substantially increased risk of future
AF and ischaemic stroke, compared with patients that remain in sinus
rhythm after surgery.952–958 OAC at discharge has been associated
with a reduced long-term mortality in patients with post,operative
AF,959 without evidence from controlled trials. Good quality data
are needed to determine whether long-term anticoagulation can pre-
vent strokes in patients with post-operative AF at high stroke
risk,368,386 and to assess whether short episodes of post-operative
AF (e.g. ,48 h) carry a similar risk as longer episodes.960 The indica-
tion and timing of OAC in post-operative AF patients should take into
consideration the risk of post-operative bleeding.
13.5.3 Rhythm control therapy in post-operative atrial
fibrillation
In haemodynamically unstable patients, cardioversion and consider-
ation of antiarrhythmic drugs is recommended. Amiodarone or ver-
nakalant have been efficient in converting post-operative AF to sinus
rhythm.603,950,961 A recent medium-sized trial randomizing patients
with post-operative AF to either rhythm control therapy with amio-
darone or to rate control did not find a difference in hospital admis-
sions during a 60-day follow-up,962 underpinning that the aim of
rhythm control therapy should be to improve AF-related symptoms
in post-operative AF. In asymptomatic patients and in those with ac-
ceptable symptoms, rate control or deferred cardioversion pre-
ceded by anticoagulation is a reasonable approach.
Recommendations for preventing postoperative atrial
fibrillation
Recommendations Classa Levelb Ref C
Peri-operative oral beta-blocker 
therapy is recommended for the 
prevention of post-operative AF after
cardiac surgery. 
I B 925, 928
Restoration of sinus rhythm 
by electrical cardioversion 
or antiarrhythmic drugs is 
recommended in postoperative AF 
with haemodynamic instability.
I C
Long-term anticoagulation should be 
considered in patients with AF after 
cardiac surgery at risk for stroke, 
considering individual stroke and 
bleeding risk.
IIa B 368, 386
Antiarrhythmic drugs should 
be considered for symptomatic 
postoperative AF after cardiac 
surgery in an attempt to restore 
sinus rhythm.
IIa C
Peri-operative amiodarone should be 
considered as prophylactic therapy 
to prevent AF after cardiac surgery.
IIa A 905
Asymptomatic postoperative AF 
should initially be managed with rate 
control and anticoagulation. 
IIa B 962
Intravenous vernakalant may be 
considered for cardioversion of 
postoperative AF in patients without 
severe heart failure, hypotension, 
or severe structural heart disease 
(especially aortic stenosis).
IIb B 603










13.6 Atrial arrhythmias in grown-up
patients with congenital heart disease
Atrial arrhythmias (AF, atrial flutter, atrial tachycardias) often occur
late after surgical repair of congenital heart defects, occurring in 15–
40% of grown-up patients with congenital heart disease (GUCH).
They are associated with heart failure, syncope, thrombo-embolic
events, and sudden death.963– 967 The pathophysiological substrate
is complex, associated with hypertrophy, fibrosis, hypoxaemia,
chronic haemodynamic overload, and surgical scars and patches.
Additionally, related primary anomalies in the conduction pathways
can lead to reentrant atrial and ventricular tachycardia, heart block,
and sinus node dysfunction.963 Macroreentrant atrial tachycardia or
atypical atrial flutter may be seen after nearly any surgical procedure
involving atriotomy or atrial patches.
13.6.1 General management of atrial arrhythmias in
grown-up patients with congenital heart disease
The conventional stroke risk factors should be used to inform deci-
sions on long-term anticoagulation in GUCH patients with AF. In
addition, anticoagulation should be considered in GUCH patients
with atrial arrhythmias when they present with intracardiac repair,
cyanosis, Fontan palliation, or systemic right ventricle.968 Beta-
blockers, verapamil, diltiazem, and digitalis can be used. Care should
be taken to avoid bradycardia and hypotension.
Sodium channel blockers suppress approximately half of atrial ar-
rhythmias in Fontan patients.969 Amiodarone is more effective, but
long-term treatment with an antiarrhythmic drug carries a high risk
of extracardiac side-effects in this relatively young population. Intra-
cardiac thrombi are common in GUCH patients undergoing cardio-
version for AF, but also in patients with atrial tachycardias or atrial
flutter.970 Therefore, both a TOE and anticoagulation for a few
weeks before the planned cardioversion should be considered.964
Radiofrequency ablation may be a good option for symptomatic
GUCH patients with atrial arrhythmias, especially in those with atrial
flutter and other macro re-entrant tachycardias. Interventions
should be performed in adequately qualified centres by specialized
teams.
13.6.2 Atrial tachyarrhythmias and atrial septal defects
Atrial flutter and fibrillation occur in 14–22% of adults with unoperated
atrial septal defects, especially in older patients,971 and can lead to heart
failure.972 Early repair can reduce but not eliminate the risk of AF.973
Biatrial volume overload,974 pulmonary hypertension,975 and possibly
the arrhythmogenic effect of atrial patches can contribute to these ar-
rhythmias.976 Anticoagulation should be decided upon based on stroke
risk factors. In patients with a history of paroxysmal or persistent AF, AF
surgery could be considered at the time of surgical closure, or catheter
ablationatthetimeof interventionalatrialseptaldefectclosure.Catheter
ablation of late atrial arrhythmias has been shown to be effective in small
cohorts of patients after surgical atrial septal defect.977
13.6.3 Atrial tachyarrhythmias after Fontan operation
Atrial arrhythmias occur in up to 40% of patients with a Fontan circu-
lation, and can manifest as atrial flutter, primary atrial tachycardia, AF,
and accelerated junctional rhythm or junctional tachycardia978 with or
without sinoatrial node dysfunction.979 Patients with atriopulmonary
anastomoses (possibly due to higher atrial volume and pressure
load) and those with early post-operative atrial arrhythmias are
more likely to develop long-term atrial arrhythmias.980 Atrial arrhyth-
mias can also be the first manifestation of obstruction of the atriopul-
monary anastomosis, a complication that must be identified. Right atrial
thrombus formation is common in Fontan patients with atrial arrhyth-
mias and requires oral anticoagulation.981 Operative conversion to to-
tal cavopulmonary artery connection with concomitant arrhythmia
surgery can, in some patients, improve heart failure symptoms and re-
duce recurrent arrhythmias,969,982 with low recurrence rates of clinic-
ally apparent atrial arrhythmias in the first few years after repeat
surgery.983–985 Catheter ablation of atrial arrhythmia in Fontan patients
has been successful in selected patients.986
13.6.4 Atrial tachyarrhythmias after tetralogy of Fallot
correction
After repair of tetralogy of Fallot, approximately one-third of pa-
tients develop atrial arrhythmias, including intra-atrial reentrant
tachycardia, focal atrial tachycardia, and AF.987 Circuits involving
the cavotricuspid isthmus and areas of presumed surgical right atrial
scarring have been described as responsible for atrial arrhythmias.
Recommendations in patients with grown-up congenital heart disease




In patients who need surgical closure of an atrial septal defect and who have a history of symptomatic atrial arrhythmia, AF 
Atrial septal defect closure should be considered before the fourth decade of life to diminish the chance of atrial flutter and





Cox maze surgery should be considered in patients with symptomatic AF and an indication for corrective repair of 
congenital heart defects. All such surgery should be done in experienced centres.
IIa C 988, 990
Oral anticoagulation should be considered in all adult patients with intracardiac repair, cyanosis, Fontan palliation or 
disease patients with AF, anticoagulation should be considered if CHA
systemic right ventricle and a history of AF, atrial flutter or intra- atrial reentrant tachycardia. In all other congenital heart
2DS2VASC score is ≥1.
IIa C 968
Catheter ablation of atrial arrhythmias associated with congenital heart defects may be considered when performed in 
experienced centres. 
IIb C 991
In patients with congenital heart disease, transoesophageal echocardiography may be considered together with 3-week 




AF ¼ atrial fibrillation; CHA2DS2-VASc ¼ Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female);










13.7 Management of atrial flutter
The goals for the management of atrial flutter are similar to those for
AF.992 Based on the available evidence, the stroke risk in patients with at-
rial flutter is not much different from that in AF.827 Furthermore, many
patientsdiagnosedwithatrial flutterdevelopAF.993–995 Thus, anticoagu-
lation should be used in patients with atrial flutter similar to that in pa-
tients with AF. Rate control in atrial flutter is achieved with the same
medicationsas inAF,but isoftenmoredifficult toachieve.Flecainide,pro-
pafenone,dofetilide,andintravenousibutilideareuseful forcardioversion
ofatrialflutter.Theyshouldbecombinedwitha rate-controllingagent to
avoid1:1conductionof slowingflutterwaves to theventricles. Ibutilide is
more effective for conversion of atrial flutter than AF, whereas vernaka-
lant is less effective in converting typical atrial flutter.996,997 Electrical
cardioversion of atrial flutter can be performed using lower energies
(50–100 J) than forAF.998,999Atrialoverdrivepacing throughpacemaker
leads orendocardial or transesophageal catheters can convert atrial flut-
ter to sinus rhythm.1000,1001 AnticoagulationandTOEaroundcardiover-
sion or overdrive pacing should be used similar to that in AF.
Ablation of the cavotricuspid isthmus for isthmus-dependent
right atrial flutter (either the common counter-clockwise atrial flut-
ter or the less-common clockwise atrial flutter) restores and main-
tains sinus rhythm with a success rate of 90–95%.1002 It may also
reduce AF recurrences in selected patients,1003,1004 and help to pre-
vent hospitalizations.1004,1005 Isthmus ablation is comparably safe
and more effective than antiarrhythmic drug therapy, and is recom-
mended for recurrent atrial flutter.585 –587,713 Catheter ablation of
left atrial macroreentrant tachycardia is more complex, with lower
success rates and higher recurrence rates.1006,1007
Recommendations for management of atrial flutter
Recommendations Classa Levelb Ref C
antithrombotic therapy is 
For patients with atrial flutter,
recommended according to the same 
risk profile used for AF.
I B 827
Overdrive atrial pacing of atrial 
as an alternative to electrical 
flutter should be considered





with ablation of the cavotricuspid 
Management of typical atrial flutter
isthmus is recommended for 
patients failing antiarrhythmic drug 
considering patient preference.
therapy or as first-line treatment
I B 158
before AF ablation, ablation of the 
If atrial flutter has been documented
cavotricuspid isthmus should be 
considered as part of the AF ablation 
procedure.
IIa C







Autonomous, informed patients are better placed to adhere to
long-term therapy, and it is very likely that long-term management
of chronic conditions such as AF will benefit from informed patients
who are aware of their own responsibilities in the disease manage-
ment process.328 Shared decision-making747 and patient-centred
organization of care can help to ensure adherence to management
and empower patients, and respect individual patient preferences,
needs, and values (see Chapter 8.2).326,1008,1009 Patients in an active
role tend to have better health outcomes and care experiences, and
engagement itself can be considered as an intermediate
outcome.1010
14.2 Integrated patient education
Education is a prerequisite for informed, involved patients
and patient-centred care. However, lack of AF-related knowledge
in patients is common, even in those who have received verbal
and written information,32,1011,1012 indicating the need to further
develop structured patient education. Several patient information
tools have been developed, largely focusing on oral antico-
agulation.1013 – 1016 This task force has developed a dedicated app
for AF patients to support patient information and education.Un-
derstanding patients’ perceptions and attitudes towards AF and its
management can improve AF management and related out-
comes.1017 This includes tailored patient education focusing on
the disease, symptom recognition, therapy, modifiable risk factors
for AF, and self-management activities.1018,1019
14.3 Self-management and shared
decision-making
Self-management is primarily focused on tasks to manage the condi-
tion, such as adhering to a therapeutic regimen or modifying behav-
iour (e.g. resulting in smoking cessation or weight loss).1020 It
requires understanding of the treatment modalities and goals.350
Within a multidisciplinary team, allied health professionals can guide
this interactive process in which communication, trust, and recipro-
cal respect foster patient engagement.1021 Shared decision-making
should be considered as a routine part of the decision-making pro-
cess,747 supported by decision aids where applicable.1022 Models of
care that integrate education, engagement, and shared decision
making are now available,1023 and may be of particular value in the
management of AF.
Recommendations for patient involvement,
education, and self-management
Recommendations Classa Levelb Ref C
Tailored patient education is 
recommended in all phases of AF 
management to support patients’ 





Patient involvement in the care 
process should be considered to 
encourage self-management and 




Shared decision making should be 
considered to ensure that care is 
based on the best available evidence 
preferences of the patient.
and fits the needs, values and
IIa C 747










15. Gaps in evidence
There are some areas of AF management that are supported by ex-
cellent evidence from multiple, adequately powered randomized
trials (e.g. oral anticoagulation). Other areas, such as rhythm control
therapy, integrated AF management, and lifestyle modifications are
clearly developing the required evidence, while areas such as rate
control are in dire need of better studies to underpin future guide-
lines. Here, we identify areas in need of further research.
15.1 Major health modifiers causing atrial
fibrillation
Atrial fibrillation has different causes in different patients. More re-
search is needed into the major causes (and electrophysiological
mechanisms) of AF in different patient groups.176,1024 Such research
should consider the major comorbidities associated with AF, and
characterize the response to AF therapy in patients with different,
pathophysiologically distinct types of AF.
15.2 How much atrial fibrillation
constitutes a mandate for therapy?
Technological advances allow screening for an irregular pulse using
patient-operated ECG devices, smartphones, and a variety of other
technologies. These may be very useful to detect silent, undiagnosed
AF.157 Adequately powered studies evaluating the diagnostic accuracy
of such technologies, the diagnostic yield in different populations, the
shortest duration and pattern of atrial arrhythmias conveying a stroke
risk, and the effect of ECG screening on outcomes are needed.
15.3 Atrial high-rate episodes (AHRE)
and need for anticoagulation
All of the information on the benefit of OAC has been generated in
patients with AF diagnosed by ECG. Technological advances allow
ready detection of AHRE in patients with implanted devices and
an atrial lead. Such patients are at increased stroke risk, but it is un-
clear whether they benefit from OAC. Controlled trials evaluating
OAC in AHRE patients are ongoing and will provide evidence on the
best antithrombotic therapy in these patients.
15.4 Stroke risk in specific populations
Several specific AF groups should be studied to better characterize
their risk for AF, stroke, and other AF-related complications (e.g.
patients with one stroke risk factor, and non-Caucasian patients).
Confounding factors (e.g. different therapy of concomitant cardio-
vascular diseases) may help to explain the variability in the reported
rates of incident AF, prevalent AF, and AF complications. This also
applies to the effect of gender in AF patients.47
15.5 Anticoagulation in patients with
severe chronic kidney disease
The use of NOACs has not been tested in patients with creatinine
clearance ,30 mL/min, and there is very little evidence on the
effects of OAC in patients on haemodialysis or on other forms of
renal replacement therapy. Studies evaluating OAC in patients
with severe CKD are needed to inform the best management in
this patient group at high risk for stroke and bleeding.
15.6 Left atrial appendage occlusion for
stroke prevention
The most common justification for LAA occlusion devices in clinical
practice is a perceived high bleeding risk and, less often, contraindica-
tions for OAC.459 Unfortunately, LAA occluders have not been
tested in such populations. Furthermore, LAA occluders have not
been compared with NOAC therapy in patients at risk for bleeding,
or with thoracoscopic LAA clipping. There is a clear need to conduct
adequately designed and powered trials to define the clinical role of
LAA occluders compared with NOAC therapy in patients with rela-
tive or absolute contraindications for anticoagulation, and/or in those
suffering from an ischaemic stroke on anticoagulant therapy.
15.7 Anticoagulation in atrial fibrillation
patients after a bleeding or stroke event
At least 2% of anticoagulated patients with AF will experience a ser-
ious bleeding event per year. Observational data suggest that OAC
can be reinitiated even after an intracerebral bleeding event.460,484
Controlled studies evaluating different anticoagulation and stroke
prevention interventions are urgently needed to provide evidence
on the best management of patients who have suffered a bleeding
event that would usually lead to withholding OAC. Some studies
(e.g. APACHE-AF [Apixaban versus Antiplatelet drugs or no antith-
rombotic drugs after anticoagulation-associated intraCerebral HaEm-
orrhage in patients with Atrial Fibrillation]1025) are ongoing, but
adequately powered trials are needed. Similarly, prospectively col-
lected data are needed on the stroke prevention and bleeding risk fol-
lowing (re-)initiation of OAC after stroke or intracranial bleeding.
15.8 Anticoagulation and optimal timing
of non-acute cardioversion
Based on retrospective data, previous recommendations on the safe
time-window in which a cardioversion can be performed in new-
onset AF used ≤48 h as the ‘gold standard’ for non-protected
cardioversion. However, new evidence has emerged that
initiating pre-cardioversion anticoagulation in patients with AF epi-
sodes of ,24 h or even ,12 h would provide even better
safety.642,647,1026– 1028 Further research is needed to establish a clear
safety margin in this clinical situation.
15.9 Competing causes of stroke or
transient ischaemic attack in atrial
fibrillation patients
Prospective RCTs have demonstrated the superiority of carotid
endarterectomy compared to stenting in patients with symptomatic
high-degree stenosis of the internal carotid artery.1029 As endartect-
omy minimizes the need for combination therapy with OAC and
antiplatelets,1030 this approach has appeal in patients with AF to re-
duce bleeding risk. However, few of these studies included patients
with AF. In a large observational study, the composite of in-hospital
mortality, post-procedural stroke, and cardiac complications was
higher in AF patients undergoing carotid stenting (457/7668; 6.0%)
compared with endarterectomy (4438/51 320; 8.6%; P,
0.0001).1031 Despite adjustment for baseline risk, this may just re-
flect the type of patients referred for each procedure, and further
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randomized studies are needed to confirm the optimal treatment
strategy in AF patients with carotid disease.
15.10 Anticoagulation in patients with
biological heart valves (including
transcatheter aortic valve implantation)
and specific forms of valvular heart disease
The optimal antithrombotic therapy in the first months after bio-
logical valve replacement (including after catheter-based valve re-
placement) is not known. VKAs remain the mainstay during the
initial post-operative period; NOACs probably deliver the same
protection. In patients without AF, many centres use platelet inhibi-
tors only. NOACs appear to be equally effective as VKAs in patients
with moderate aortic stenosis, based on a subanalysis from the
ROCKET-AF trial,1032 as well as the Loire Valley AF project.1033 Fur-
ther data would be helpful to confirm these observations.1034 The
safety and efficacy of NOACs in patients with rheumatic mitral valve
disease has not been evaluated and should be studied.
15.11 Anticoagulation after ‘successful’
catheter ablation
In view of the long-term recurrence rates of AF, this Task Force re-
commends that OAC is continued in AF patients after ‘successful’
catheter ablation. Nonetheless, observational data suggest that
the stroke risk may be lower after catheter ablation of AF compared
with other AF patients. The ongoing EAST – AFNET 4 trial will in-
form, in a more general way, whether rhythm control therapy can
reduce stroke rates in anticoagulated AF patients. In addition, there
seems to be a place for a controlled trial evaluating the termination
of OAC therapy at an interval after ‘successful’ catheter ablation.
15.12 Comparison of rate control agents
Although the use of rate control therapy is very common in AF pa-
tients, robust data comparing rate control therapies are scant, with
the majority of studies being small uncontrolled trials over short
periods of follow-up. Some studies are ongoing [e.g. RATE-AF
(Rate Control Therapy Evaluation in Permanent Atrial Fibrilla-
tion)559] and will investigate the potential benefits of different rate-
controlling agents, characteristics, or biomarkers that can help to
personalize the use of rate control, and the adverse event profile
of specific drugs in defined groups of patients.
15.13 Catheter ablation in persistent and
long-standing persistent atrial fibrillation
While a few recent randomized studies support the use of catheter
or surgical ablation in patients with persistent AF and long-standing
persistent AF,1042 there is a clear need for more data evaluating this
intervention in adequately powered randomized trials.
15.14 Optimal technique for repeat
catheter ablation
PVI emerges as the most important target for catheter ablation of AF.
Although a plethora of different additional ablation techniques have
been published, their added value is questionable in patients undergo-
ing a first catheter ablation, including those with persistent AF.735,1042
Many patients are in need of multiple catheter ablation procedures,
and such interventions often follow local or operator-specific proto-
cols without clear evidence to support the choice of ablation target
or intervention. There is a clear clinical need to define the best ap-
proach in patients who are in need of a second ablation procedure.
15.15 Combination therapy for
maintenance of sinus rhythm
In the follow-up after initially successful catheter ablation, even
when done in experienced centres, many patients will experience
symptomatic recurrences of AF. These patients are often managed
with antiarrhythmic drugs. There is a surprising paucity of data
evaluating different rhythm control interventions in patients with re-
current AF after catheter ablation. Such studies seem reasonable
and feasible.
15.16 Can rhythm control therapy convey
a prognostic benefit in atrial fibrillation
patients?
The progress in rhythm control therapy (catheter ablation, new antiar-
rhythmic drugs) and observational long-term analyses suggest that
rhythm control therapy may have a prognostic benefit in anticoagulated
AF patients. Ongoing trials such as CABANA and EAST – AFNET 4
will provide initial answers to this important question, but more data
are needed, including trials of surgical ablation techniques.
15.17 Thoracoscopic ‘stand-alone’ atrial
fibrillation surgery
Minimally invasive epicardial ablation surgery for the treatment of
stand-alone AF was reported a decade ago.1035 The procedure has
since evolved towards a totally thoracoscopic procedure,1036 and le-
sion sets were extended to a complete left atrial maze.822 Rando-
mized trials using a standardized procedure are urgently needed to
clearly define the benefits and risks of thoracoscopic AF ablation,
and to further support decisions of the AF Heart Team.
15.18 Surgical exclusion of the left atrial
appendage
Exclusion of the LAA has been performed by cardiothoracic surgeons
for decades, but prospective randomized studies comparing the rate
of ischaemic stroke with or without left appendage exclusion are pres-
ently lacking. The LAAOS (Left Atrial Appendage Occlusion Study) III
is currently randomizing cardiac surgery patients with AF to undergo
concomitant occlusion or no occlusion of the appendage.467 More
data are also needed to confirm the safety and efficacy of thoraco-
scopic exclusion, following early positive observational data.1037
15.19 Concomitant atrial fibrillation
surgery
Adequately powered randomized trials are needed, employing sys-
tematic follow-up with uniform lesion sets and energy sources, to
evaluate the benefits and risks of concomitant AF surgery in symp-
tomatic AF patients. An RCT on non-uniform lesion sets with long-
term follow-up is due to publish shortly.1038 Such trials will assist the
AF Heart Team to decide on optimal therapy for individual patients,
including the full repertoire of medical and surgical options for the
treatment of AF.
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16. To do and not to do messages from the Guidelines
Recommendations Classa Levelb
Recommendations for diagnosis and screening of AF
ECG documentation is required to establish the diagnosis of AF. I B
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm strip in patients >65 years of age. I B
In patients with TIA or ischaemic stroke, screening for AF is recommended by short-term ECG recording followed by continuous 
ECG monitoring for at least 72 hours.
I B
It is recommended to interrogate pacemakers and ICDs on a regular basis for atrial high rate episodes (AHRE). Patients with AHRE 
should undergo further ECG monitoring to document AF before initiating AF therapy.
I B
Recommendations for general management of AF
Tailored patient education is recommended in all phases of AF management to support patients’ perception of AF and to improve 
management.
I C
A full cardiovascular evaluation, including an accurate history, careful clinical examination, and assessment of concomitant conditions, 
is recommended in all AF patients.
I C
I C
Transthoracic echocardiography is recommended in all AF patients to guide management.
Use of the modified EHRA symptom scale is recommended in clinical practice and research studies to quantify AF-related symptoms.
I C
The assessment of kidney function by serum creatinine or creatinine clearance is recommended in all AF patients to detect kidney 
disease and to support correct dosing of AF therapy.
I A
Recommendations for stroke prevention in AF
The CHA2DS2-VASc score is recommended for stroke risk prediction in patients with AF. I A
Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA2DS2-VASc score of 
2 or more.
I A
Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA2DS2-VASc score of 
3 or more.
I A
When oral anticoagulation is initiated in a patient with AF who is eligible for a non vitamin-K-antagonist oral anticoagulant (apixaban, 
dabigatran, edoxaban, or rivaroxaban), a NOAC is recommended in preference to a vitamin K antagonist.
I A
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke prevention in AF patients with moderate-to-
severe mitral stenosis or mechanical heart valves.
I B
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves (Level of 




When patients are treated with a vitamin K antagonist, time in therapeutic range (TTR) should be kept as high as possible and 
closely monitored.
I A
Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk and should be avoided in AF patients without 









Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk. III
(harm)
A
After surgical occlusion or exclusion of the left atrial appendage, it is recommended to continue anticoagulation in at-risk patients 
with AF for stroke prevention.
I B
Genetic testing before the initiation of vitamin K antagonist therapy is not recommended. III(no benefit) B
In AF patients with severe active bleeding events, it is recommended to interrupt oral anticoagulation therapy until the underlying 
cause is resolved.
I C
NOACs should be avoided in pregnancy and in women planning a pregnancy.
For patients with atrial flutter, antithrombotic therapy is recommended according to the same risk profile used for AF.
Management of typical atrial flutter with ablation of the cavotricuspid isthmus is recommended for patients failing antiarrhythmic






Lifelong oral anticoagulation to prevent stroke is recommended in hypertrophic cardiomyopathy patients who develop AF. I B
Anticoagulation with heparin or low-molecular-weight heparin immediately after ischaemic stroke is not recommended in AF patients. III
(harm)
A
Systemic thrombolysis with a recombinant tissue plasminogen activator is not recommended if the INR is above 1.7 (or, for patients 















Recommendations for rate control of AF
Beta-blockers, digoxin, diltiazem, or verapamil are recommended to control heart rate in AF patients with LVEF ≥40%. I B
Beta-blockers and/or digoxin are recommended to control heart rate in AF patients with LVEF <40%. I B
In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is planned), antiarrhythmic drugs should not routinely 




Recommendations for rhythm control of AF
Rhythm control therapy is indicated for symptom improvement in patients with AF. I B
Cardioversion of AF (either electrical or pharmacological) is recommended in symptomatic patients with persistent or long-standing 
persistent AF as part of rhythm control therapy.
I B
pharmacological cardioversion of new-onset AF.
In patients with no history of ischaemic or structural heart disease, flecainide, propafenone, or vernakalant are recommended for
I A
In patients with ischaemic and/or structural heart disease, amiodarone is recommended for cardioversion of AF. I A
I B
Transoesophageal echocardiography (TOE) is recommended to exclude cardiac thrombus as an alternative to preprocedural 
For cardioversion of AF/atrial flutter, effective anticoagulation is recommended for a minimum of 3 weeks before cardioversion.
anticoagulation when early cardioversion is planned.
I B
The choice of antiarrhythmic drug needs to be carefully evaluated, taking into account the presence of comorbidities, cardiovascular 
risk and potential for serious proarrhythmia, extracardiac toxic effects, patient preferences, and symptom burden.
I A
normal left ventricular function and without pathological left ventricular hypertrophy. 
Dronedarone, flecainide, propafenone, or sotalol are recommended for prevention of recurrent symptomatic AF in patients with
I A
Dronedarone is recommended for prevention of recurrent symptomatic AF in patients with stable coronary artery disease, and 
without heart failure.
I A
Amiodarone is recommended for prevention of recurrent symptomatic AF in patients with heart failure. I B
disease or atrioventricular node dysfunction who do not have a functioning permanent pacemaker.




Catheter ablation of symptomatic paroxysmal AF is recommended to improve AF symptoms in patients who have symptomatic 
further rhythm control therapy, when performed by an electrophysiologist who has received appropriate training and is performing 
recurrences of AF on antiarrhythmic drug therapy (amiodarone, dronedarone, flecainide, propafenone, sotalol) and who prefer
the procedure in an experienced centre.
I A
ACE-Is or ARBs are not recommended for the secondary prevention of paroxysmal AF in patients with little or no underlying heart 
disease.
III B
Moderate regular physical activity is recommended to prevent AF, while athletes should be counselled that long-lasting, more intense 
sports participation can promote AF.
I A
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial fibrillation; AHRE ¼ atrial high rate episodes; ARB ¼ angiotensin receptor blocker; CHA2DS2-VASc ¼ Congestive Heart
failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); ECG ¼ electrocardiogram; EHRA ¼ European Heart
Rhythm Association; ICD ¼ implantable cardioverter defibrillator; INR ¼ international normalized ratio; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; LVH ¼ left
ventricular hypertrophy; NOAC ¼ non-vitamin K antagonist oral anticoagulant; OAC ¼ oral anticoagulation; TIA ¼ transient ischaemic attack; TOE ¼ transoesophageal
echocardiography; TTR ¼ time in therapeutic range; VKA ¼ vitamin K antagonist.
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17. A short summary of the management of atrial
fibrillation patients
Here, we provide 17 simple rules to guide the diagnosis and management
of AF patients according to the 2016 ESC Guidelines for the management
of atrial fibrillation developed in cooperation with EACTS.
(1) Use ECG screening in at-risk populations for AF, especially stroke
survivors and the elderly.
(2) Document AF by ECG before starting treatment.
(3) Evaluate all AF patients by clinical evaluation, ECG, and
echocardiogram for underlying cardiovascular conditions such as
hypertension, heart failure, valvular heart disease, and others.
(4) Provide tailored information and education to AF patients to
empower them to support AF management.
(5) Propose lifestyle changes to all suitable AF patients to make their
management more effective.
(6) Treat underlying cardiovascular conditions adequately, e.g. valve
repair or replacement in AF patients with significant valvular heart
disease, treatment of heart failure, or management of
hypertension, among others.
(7) Use oral anticoagulation in all AF patients unless they are at low
risk for stroke based on the CHA2DS2VASc score or have true
contraindications for anticoagulant therapy.
(8) Anticoagulate patients with atrial flutter similar to AF. Offer
isthmus ablation to symptomatic flutter patients.
(9) Reduce all modifiable bleeding risk factors in all AF patients on
oral anticoagulation, e.g. by treating hypertension, minimizing
the duration and intensity of concomitant antiplatelet and
non-steroidal anti-inflammatory drug therapy, treating anaemia
and eliminating causes for blood loss, maintaining stable INR
values in patients on VKAs, and moderating alcohol intake.
(10) Check ventricular rate in all AF patients and use rate control
medications to achieve lenient rate control.
(11) Evaluate AF-related symptoms in all AF patients using the
modified EHRA symptoms scale. Whenever patients have
AF-related symptoms, aim to improve symptoms by adjustment
of rate control therapy and by offering antiarrhythmic drugs,
cardioversion, or catheter or surgical ablation.
(12) Select antiarrhythmic drugs based on their safety profile and
consider catheter or surgical ablation when antiarrhythmic
drugs fail.
(13) Do not offer routine genetic testing in AF patients unless there is
suspicion of an inherited cardiac condition.
(14) Do not use antiplatelet therapy for stroke prevention in AF.
(15) Do not permanently discontinue oral anticoagulation in AF
patients at increased risk of stroke unless such a decision is taken
by a multidisciplinary team.
(16) Do not use rhythm control therapy in asymptomatic AF patients,
nor in patients with permanent AF.
(17) Do not perform cardioversion or catheter ablation without
anticoagulation, unless an atrial thrombus has been ruled out
transoesophageal echocardiogram.
18. Web addenda
Three additional Web figures and two additional Web tables can be
accessed in the Web addenda to the 2016 ESC AF Guidelines, avail-
able at European Heart Journal online and also via the ESC Website
(www.escardio.org/guidelines).
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